New Rite Aid (RADCQ) 10-K 25 Apr 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 02, 2019	Apr. 16, 2019	Sep. 01, 2018
Document and Entity Information
Entity Registrant Name	RITE AID CORP
Entity Central Index Key	0000084129
Document Type	10-K
Document Period End Date	Mar. 2, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-02
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 1,448,571,281
Entity Common Stock, Shares Outstanding		53,901,162
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Current assets:
Cash and cash equivalents	$ 144,353	$ 447,334
Accounts receivable, net	1,788,712	1,869,100
Inventories, net	1,871,941	1,799,539
Prepaid expenses and other current assets	179,132	181,181
Current assets held for sale	117,581	438,137
Total current assets	4,101,719	4,735,291
Property, plant and equipment, net	1,308,514	1,431,246
Goodwill	1,108,136	1,421,120
Other intangibles, net	448,706	590,443
Deferred tax assets	409,084	594,019
Other assets	215,208	217,208
Total assets	7,591,367	8,989,327
Current liabilities:
Current maturities of long-term debt and lease financing obligations	16,111	20,761
Accounts payable	1,618,585	1,651,363
Accrued salaries, wages and other current liabilities	808,439	1,231,736
Current liabilities held for sale		560,205
Total current liabilities	2,443,135	3,464,065
Long-term debt, less current maturities	3,454,585	3,340,099
Lease financing obligations, less current maturities	24,064	30,775
Other noncurrent liabilities	482,893	553,378
Total liabilities	6,404,677	7,388,317
Commitments and contingencies
Stockholders' equity:
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 54,016 and 53,366	54,016	53,366
Additional paid-in capital	5,876,977	5,864,664
Accumulated deficit	(4,713,244)	(4,282,471)
Accumulated other comprehensive loss	(31,059)	(34,549)
Total stockholders' equity	1,186,690	1,601,010
Total liabilities and stockholders' equity	$ 7,591,367	$ 8,989,327

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
CONDENSED CONSOLIDATED BALANCE SHEETS
Inventories, LIFO reserve (in dollars)	$ 604,444	$ 581,090
Common stock, par value (in dollars per share)	$ 1,000	$ 1,000
Common stock, shares authorized	75,000	75,000
Common stock, shares issued	54,016	53,366
Common stock, shares outstanding	54,016	53,366

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Feb. 28, 2018	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues		$ 5,379,645	$ 5,450,060	$ 5,421,362	$ 5,388,490	$ 5,394,264	$ 5,353,170	$ 5,345,011	$ 5,436,523	$ 21,639,557	$ 21,528,968	$ 22,927,540
Costs and expenses:
Cost of revenues		4,215,281	4,267,972	4,260,211	4,219,741	4,124,498	4,166,447	4,183,338	4,274,580	16,963,205	16,748,863	17,862,833
Selling, general and administrative expenses		1,143,202	1,142,555	1,153,991	1,152,627	1,181,964	1,166,514	1,141,844	1,160,940	4,592,375	4,651,262	4,776,995
Lease termination and impairment charges		55,898	2,628	39,609	9,859	47,675	3,939	3,113	4,038	107,994	58,765	45,778
Goodwill and intangible asset impairment charges				375,190						375,190	261,727
Interest expense		52,695	56,008	56,233	62,792	50,603	50,308	50,857	51,000	227,728	202,768	200,065
Loss on debt retirements, net	$ 8,180				554					554
Walgreens Boots Alliance merger termination fee								(325,000)			(325,000)
Gain on sale of assets, net		(26,806)	(382)	(4,965)	(5,859)	(5,249)	205	(14,951)	(5,877)	(38,012)	(25,872)	(6,649)
Total costs and expenses		5,440,270	5,468,781	5,880,269	5,439,714	5,661,218	5,387,413	5,039,201	5,484,681	22,229,034	21,572,513	22,879,022
(Loss) income from continuing operations before income taxes		(60,625)	(18,721)	(458,907)	(51,224)	(266,954)	(34,243)	305,810	(48,158)	(589,477)	(43,545)	48,518
Income tax expense		195,004	(1,471)	(106,559)	(9,497)	216,719	(16,061)	117,450	(12,121)	77,477	305,987	44,438
Net (loss) income from continuing operations		(255,629)	(17,250)	(352,348)	(41,727)	(483,673)	(18,182)	188,360	(36,037)	(666,954)	(349,532)	4,080
Income (loss) from discontinued operations attributable to common stockholders-basic and diluted		(17,350)	12,740	(6,792)	256,143	1,250,745	99,213	(17,644)	(39,312)	244,741	1,293,002	(27)
Net (loss) income		$ (272,979)	$ (4,510)	$ (359,140)	$ 214,416	$ 767,072	$ 81,031	$ 170,716	$ (75,349)	(422,213)	943,470	4,053
Computation of income attributable to common stockholders:
(Loss) income from continuing operations attributable to common stockholders-basic and diluted										(666,954)	(349,532)	4,080
Income (loss) from discontinued operations attributable to common stockholders-basic and diluted										244,741	1,293,002	(27)
(Loss) income attributable to common stockholders-basic and diluted										$ (422,213)	$ 943,470	$ 4,053
Basic (loss) income per share:
Continuing operations						$ (9.18)	$ (0.35)	$ 3.59	$ (0.69)	$ (12.62)	$ (6.66)	$ 0.08
Discontinued operations						23.74	1.90	(0.33)	(0.75)	4.63	24.64	0
Net basic (loss) income per share						14.56	1.55	3.26	(1.44)	(7.99)	17.98	0.08
Diluted (loss) income per share:
Continuing operations						(9.18)	(0.35)	3.53	(0.69)	(12.62)	(6.66)	0.08
Discontinued operations						23.74	1.90	(0.33)	(0.75)	4.63	24.64	0
Net diluted (loss) income per share						$ 14.56	$ 1.55	$ 3.20	$ (1.44)	$ (7.99)	$ 17.98	$ 0.08

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
Net (loss) income	$ (272,979)	$ (4,510)	$ (359,140)	$ 214,416	$ 767,072	$ 81,031	$ 170,716	$ (75,349)	$ (422,213)	$ 943,470	$ 4,053
Defined benefit pension plans:
Amortization of net actuarial losses included in net periodic pension cost, net of $1,765, $4,842 and $3,600 tax expense									3,490	7,255	5,464
Total other comprehensive income									3,490	7,255	5,464
Comprehensive (loss) income									$ (418,723)	$ 950,725	$ 9,517

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, tax expense (benefit)	$ 1,765	$ 4,842	$ 3,600

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance - beginning of period at Feb. 27, 2016	$ 52,387	$ 5,818,032	$ (5,241,210)	$ (47,781)	$ 581,428
BALANCE (in shares) at Feb. 27, 2016	52,387
Increase (Decrease) in Stockholders' Deficit
Net (loss) income			4,053		4,053
Other comprehensive income:
Changes in Defined Benefit Plans, net of $1,765, $4,842 and $3,600 tax expense at March 2, 2019, March 3, 2018 and March 4, 2017 respectively				5,464	5,464
Comprehensive (loss) income					9,517
Exchange of restricted shares for taxes	$ (40)	(6,215)			(6,255)
Exchange of restricted shares for taxes (in shares)	(40)
Issuance of restricted stock	$ 181	(181)
Issuance of restricted stock (in shares)	181
Cancellation of restricted stock	$ (21)	21
Cancellation of restricted stock (in shares)	(21)
Amortization of restricted stock balance		12,588			12,588
Stock-based compensation expense		9,989			9,989
Tax benefit from exercise of stock options and restricted stock vesting		(148)			(148)
Stock options exercised	$ 178	6,773			6,951
Stock options exercised (in shares)	178
Balance - end of period at Mar. 04, 2017	$ 52,685	5,840,859	(5,237,157)	(42,317)	614,070
BALANCE (in shares) at Mar. 04, 2017	52,685
Increase (Decrease) in Stockholders' Deficit
Net (loss) income			943,470		943,470
Other comprehensive income:
Changes in Defined Benefit Plans, net of $1,765, $4,842 and $3,600 tax expense at March 2, 2019, March 3, 2018 and March 4, 2017 respectively				7,255	7,255
Comprehensive (loss) income					950,725
Adoption of ASU | Accounting Standards Update 2016-09			11,729		11,729
Adoption of ASU | Accounting Standards Update 2018-02			(513)	513
Exchange of restricted shares for taxes	$ (73)	(4,030)			(4,103)
Exchange of restricted shares for taxes (in shares)	(73)
Issuance of restricted stock	$ 693	(693)
Issuance of restricted stock (in shares)	693
Cancellation of restricted stock	$ (180)	180
Cancellation of restricted stock (in shares)	(180)
Amortization of restricted stock balance		18,365			18,365
Stock-based compensation expense		2,761			2,761
Amortization of performance-based incentive plans		1,667			1,667
Stock options exercised	$ 241	5,555			5,796
Stock options exercised (in shares)	241
Balance - end of period at Mar. 03, 2018	$ 53,366	5,864,664	(4,282,471)	(34,549)	1,601,010
BALANCE (in shares) at Mar. 03, 2018	53,366
Increase (Decrease) in Stockholders' Deficit
Net (loss) income			(422,213)		(422,213)
Other comprehensive income:
Changes in Defined Benefit Plans, net of $1,765, $4,842 and $3,600 tax expense at March 2, 2019, March 3, 2018 and March 4, 2017 respectively				3,490	3,490
Comprehensive (loss) income					(418,723)
Adoption of ASU | Accounting Standards Update 2014-09			(8,560)		(8,560)
Exchange of restricted shares for taxes	$ (70)	(2,349)			(2,419)
Exchange of restricted shares for taxes (in shares)	(70)
Issuance of restricted stock	$ 709	(709)
Issuance of restricted stock (in shares)	709
Cancellation of restricted stock	$ (88)	88
Cancellation of restricted stock (in shares)	(88)
Amortization of restricted stock balance		14,628			14,628
Stock-based compensation expense		(1,539)			(1,539)
Stock options exercised	$ 99	2,194			2,293
Stock options exercised (in shares)	99
Balance - end of period at Mar. 02, 2019	$ 54,016	$ 5,876,977	$ (4,713,244)	$ (31,059)	$ 1,186,690
BALANCE (in shares) at Mar. 02, 2019	54,016

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Changes in defined benefit plans tax expense	$ 1,765	$ 4,842	$ 3,600

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
OPERATING ACTIVITIES:
Net (loss) income	$ (422,213)	$ 943,470	$ 4,053
Income (loss) from discontinued operations attributable to common stockholders-basic and diluted	244,741	1,293,002	(27)
Net (loss) income from continuing operations	(666,954)	(349,532)	4,080
Adjustments to reconcile to net cash (used in) provided by operating activities:
Depreciation and amortization	357,882	386,057	407,366
Lease termination and impairment charges	107,994	58,765	45,778
Goodwill and intangible asset impairment charges	375,190	261,727
LIFO charge (credit)	23,354	(28,827)	(3,721)
Gain on sale of assets, net	(38,012)	(25,872)	(6,649)
Stock-based compensation expense	12,115	25,793	23,482
Loss on debt retirements, net	554
Changes in deferred taxes	95,638	260,411	35,038
Excess tax benefit on stock options and restricted stock			(543)
Changes in operating assets and liabilities:
Accounts receivable	(75,844)	(349,481)	(159,590)
Inventories	(44,645)	18,835	(49,381)
Accounts payable	125,925	211,511	39,542
Other assets	1,000	(10,082)	(50,986)
Other liabilities	(439,906)	52,165	(101,389)
Net cash (used in) provided by operating activities of continuing operations	(165,709)	511,470	183,027
INVESTING ACTIVITIES:
Payments for property, plant and equipment	(196,778)	(185,879)	(254,149)
Intangible assets acquired	(47,911)	(28,885)	(39,648)
Proceeds from insured loss		4,239
Proceeds from sale-leaseback transactions	2,587
Proceeds from dispositions of assets and investments	43,550	27,586	16,852
Net cash used in investing activities of continuing operations	(198,552)	(182,939)	(276,945)
FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt	450,000
Net proceeds from (payments to) revolver	875,000	(265,000)	330,000
Principal payments on long-term debt	(440,370)	(9,882)	(16,588)
Change in zero balance cash accounts	(59,481)	35,605	43,080
Net proceeds from issuance of common stock	2,294	5,796	6,951
Financing fees paid for early debt redemption	(171)
Deferred financing costs paid	(21,564)
Excess tax benefit on stock options and restricted stock			543
Payments for taxes related to net share settlement of equity awards	(2,419)	(4,103)	(6,254)
Net cash provided by (used in) financing activities of continuing operations	803,289	(237,584)	357,732
Cash flows from discontinued operations:
Operating activities of discontinued operations	(62,956)	(245,126)	49,090
Investing activities of discontinued operations	664,740	3,496,222	(187,314)
Financing activities of discontinued operations	(1,343,793)	(3,140,119)	(4,651)
Net cash (used in) provided by discontinued operations	(742,009)	110,977	(142,875)
(Decrease) increase in cash and cash equivalents	(302,981)	201,924	120,939
Cash and cash equivalents, beginning of year	447,334	245,410	124,471
Cash and cash equivalents, end of year	$ 144,353	$ 447,334	$ 245,410

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 02, 2019
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Description of Business The Company is a Delaware corporation and through its 100% owned subsidiaries, operates a pharmacy retail healthcare company in the United States of America. The Company operates through its two reportable segments: the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy segment operates one of the largest retail drugstore chains in the United States, with 2,469 stores in operation as of March 2, 2019. The Retail Pharmacy segment’s drugstores’ primary business is the sale of brand and generic prescription drugs. The Retail Pharmacy segment also sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment operates both transparent and traditional pharmacy benefit management (“PBM”) businesses; mail-order and specialty pharmacy services through EnvisionPharmacies; a claims adjudication software platform through Laker Software; and a national Medicare Part D prescription drug plan through Envision Insurance Company (“EIC”). See Note 20 for additional details on the Company’s reportable segments. The discussion and presentation of the operating and financial results of our business segments have been impacted by the following event. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement (the "Amended and Restated Asset Purchase Agreement"), dated as of September 18, 2017, by and among Rite Aid, WBA and Walgreen Co., an Illinois corporation and 100% owned subsidiary of WBA ("Buyer"), Buyer agreed to purchase from Rite Aid 1,932 stores (the "Acquired Stores"), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4,375,000, on a cash free, debt free basis (the "Asset Sale" or the "Sale"). As of March 2, 2019, the Company has sold all 1,932 Acquired Stores, one distribution center, and related assets to WBA in exchange for proceeds of $4,217,937, which were used to repay outstanding debt. Based on its magnitude and because the Company has exited certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Asset Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the assets and liabilities to be sold, including the 1,932 Acquired Stores, three distribution centers, related inventory and other specified assets and liabilities related thereto (collectively the “Assets to be Sold” or “Disposal Group”) to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended March 2, 2019 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. Additionally, corporate support activities related to the Disposal Group were not reclassified to discontinued operations. See additional information as provided in Note 3 Asset Sale to WBA. Revenues for the Company are as follows: Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Retail Pharmacy segment: Pharmacy sales $ 10,391,539 $ 10,328,376 $ 11,072,480 Front-end sales 5,215,152 5,348,613 5,538,352 Other revenue 150,461 155,636 155,788 Total Retail Pharmacy segment 15,757,152 15,832,625 16,766,620 Pharmacy Services segment revenue 6,093,688 5,896,669 6,393,884 Intersegment elimination (211,283) (200,326) (232,964) Total revenue $ 21,639,557 $ 21,528,968 $ 22,927,540 Sales of prescription drugs for our Retail Pharmacy segment represented approximately 66.6%, 65.9% and 66.0% of the Company’s total drugstore sales in fiscal years 2019, 2018 and 2017, respectively. The Retail Pharmacy segment’s principal classes of products in fiscal 2019 were the following: Percentage Product Class of Sales Prescription drugs 66.6 % Over-the-counter medications and personal care 10.8 % Health and beauty aids 5.0 % General merchandise and other 17.6 % Fiscal Year The Company’s fiscal year ends on the Saturday closest to February 29 or March 1. The fiscal year ended March 2, 2019 included 52 weeks. The fiscal year ended March 3, 2018 included 52 weeks. The fiscal year ended March 4, 2017 included 53 weeks. Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its 100% owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and highly liquid investments, which are readily convertible to known amounts of cash and which have original maturities of three months or less when purchased. Allowance for Uncollectible Receivables Substantially all prescription sales are made to customers who are covered by third‑party payors, such as insurance companies, government agencies and employers. The Company recognizes receivables that represent the amount owed to the Company for sales made to customers or employees of those payors that have not yet been paid. The Company maintains a reserve for the amount of these receivables deemed to be uncollectible. This reserve is calculated based upon historical collection activity adjusted for current conditions. Inventories Inventories are stated at the lower of cost or market. Inventory balances include the capitalization of certain costs related to purchasing, freight and handling costs associated with placing inventory in its location and condition for sale. The Company uses the last‑in, first‑out (“LIFO”) cost flow assumption for substantially all of its inventories. The Company calculates its inflation index based on internal product mix and utilizes the link‑chain LIFO method. Impairment of Long‑Lived Assets Asset impairments are recorded when the carrying value of assets are not recoverable. For purposes of recognizing and measuring impairment of long‑lived assets, the Company categorizes assets of operating stores as “Assets to Be Held and Used” and “Assets to Be Disposed Of.” The Company evaluates assets at the store level because this is the lowest level of identifiable cash flows ascertainable to evaluate impairment. Assets being tested for recoverability at the store level include tangible long‑lived assets and identifiable, finite‑lived intangibles that arose in purchase business combinations. Corporate assets to be held and used are evaluated for impairment based on excess cash flows from the stores that support those assets. The Company reviews long‑lived assets to be held and used for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the undiscounted expected future cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss. Impairment losses are measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risks associated with the recovery of the asset. Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. The Company provides for depreciation using the straight‑line method over the following useful lives: buildings—30 to 45 years; equipment—3 to 15 years. Leasehold improvements are amortized on a straight‑line basis over the shorter of the estimated useful life of the asset or the term of the lease. When determining the amortization period of a leasehold improvement, the Company considers whether discretionary exercise of a lease renewal option is reasonably assured. If it is determined that the exercise of such option is reasonably assured, the Company will amortize the leasehold improvement asset over the minimum lease term, plus the option period. This determination depends on the remaining life of the minimum lease term and any economic penalties that would be incurred if the lease option is not exercised. Capitalized lease assets are recorded at the lesser of the present value of minimum lease payments or fair market value and amortized over the estimated useful life of the related property or term of the lease. The Company capitalizes direct internal and external development costs associated with internal‑use software. Neither preliminary evaluation costs nor costs associated with the software after implementation are capitalized. For fiscal years 2019, 2018 and 2017, the Company capitalized costs of approximately $13,716, $13,940 and $6,189, respectively. Goodwill The Company recognizes goodwill as the excess of the purchase price over the fair value of the assets acquired and liabilities assumed during business combinations. The Company accounts for goodwill under ASC Topic 350, “Intangibles—Goodwill and Other”, which does not permit amortization, but instead requires the Company to perform an annual impairment review, or more frequently if events or circumstances indicate that impairment may be more likely. See Note 13 for additional information on goodwill. Intangible Assets The Company has certain finite‑lived intangible assets that are amortized over their useful lives. The value of favorable and unfavorable leases on stores acquired in business combinations are amortized over the terms of the leases on a straight‑line basis. Prescription files acquired in business combinations are amortized over an estimated useful life of ten years on an accelerated basis, which approximates the anticipated prescription file retention and related cash flows. Purchased prescription files acquired in other than business combinations are amortized over their estimated useful lives of five years on a straight‑line basis. The value of finite-lived trade names are amortized over 10 years on a straight-line basis. The value of customer relationships, acquired in connection with the Company’s acquisition of EnvisionRx, are amortized over a period between 10 and 20 years on a descending percentage method which matches the pattern of expected discounted cash flows. The Pharmacy Services segment’s contract with Centers for Medicare and Medicaid Services (“CMS”) for Medicare Part D (“Part D”), which is required in order to act as a national provider of the Part D benefit, is amortized over 25 years on a straight line basis. Indefinite lifed assets The Company has a single indefinite-lived intangible asset consisting of a trade name. Intangible assets that are determined to have an indefinite life are not amortized, but are required to be evaluated at least annually for impairment. If the carrying value of an individual indefinite-lived intangible asset exceeds its fair value, such individual indefinite-lived intangible asset is impaired by the amount of the excess. Deferred Financing Costs Costs incurred to issue debt are deferred and amortized as a component of interest expense over the terms of the related debt agreements. Amortization expense of deferred financing costs was $10,761, $8,403 and $4,696 for fiscal 2019, 2018 and 2017, respectively. Revenue Recognition Retail Pharmacy Segment For front-end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front-end transactions. The Retail Pharmacy segment front-end revenue is measured based on the amount of fixed consideration that we expect to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented. For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product. Each prescription claim represents an individual arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims. The Company's revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile. The effect of adjustments between estimated and actual amounts have not been material to the Company's results of operations or financial position. Prescriptions are generally not returnable. The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program. Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front-end merchandise purchases and qualifying prescription purchases. One point is awarded for each dollar spent towards front-end merchandise and 25 points are awarded for each qualifying prescription. Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front-end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar “Silver” level with a lower threshold and benefit level. Points earned pursuant to the wellness+ program represent a performance obligation and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As members receive discounted front-end merchandise or when the benefit period expires, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $63,720 as of March 2, 2019, of which $51,042 is included in other current liabilities and $12,678 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,851 as of March 3, 2018, of which $50,036 is included in other current liabilities and $13,815 is included in noncurrent liabilities. The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness+ Rewards members have the opportunity to redeem their accumulated Bonus Cash on a future purchase with a 60 day expiration window. For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until (i) wellness + Rewards members redeem their Bonus Cash, or (ii) wellness + Rewards members allow the Bonus Cash to expire. Upon utilization or expiration of the benefit period, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires. Pharmacy Services Segment The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order prescriptions (“Mail Co-Payments”), (iii) client plan member copayments made directly to the retail pharmacy network and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type. The following revenue recognition policies have been established for the Pharmacy Services segment: · Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system. At this point the Company has performed all of its performance obligations. · Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the client plan members. The Pharmacy Services segment does not experience a significant level of returns or reshipments. · Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee. In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. In the majority of these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues. Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues. For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized. Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts. Medicare Part D—The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 9, Medicare Part D. Disaggregation of Revenue The following tables disaggregate the Company’s revenue by major source in each segment for the fiscal year ended March 2, 2019: In thousands March 2, 2019 Retail Pharmacy segment: Pharmacy sales $ 10,391,539 Front-end sales 5,215,152 Other revenue 150,461 Total Retail Pharmacy segment 15,757,152 Pharmacy Services segment 6,093,688 Intersegment elimination (211,283) Total revenue $ 21,639,557 Impact of New Revenue Recognition Standard on Financial Statement Line Items The Company adopted the new revenue standard using the modified retrospective method. The cumulative effect of applying the new standard to all contracts was recorded as an adjustment to accumulated deficit as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue standard, the following adjustments were made to accounts on the consolidated balance sheet as of March 4, 2018: Impact of Change in Accounting Policy As Reported Adjusted In thousands March 3, 2018 Adjustments March 4, 2018 Consolidated Balance Sheet: Accounts receivable, net $ 1,869,100 $ (57,897) $ 1,811,203 Inventories, net 1,799,539 51,121 1,850,660 Deferred tax assets 594,019 (1,784) 592,235 Total assets 8,989,327 (8,560) 8,980,767 Accumulated deficit (4,282,471) (8,560) (4,291,031) Total shareholders’ equity 1,601,010 (8,560) 1,592,450 See Note 20 for additional information about the revenues of the Company’s business segments. Cost of Revenues Retail Pharmacy Segment Cost of revenues for the Retail Pharmacy segment includes the following: the cost of inventory sold during the period, including related vendor rebates and allowances, LIFO credit or charges, costs incurred to return merchandise to vendors, inventory shrink, purchasing costs and warehousing costs, which include inbound freight costs from the vendor, distribution payroll and benefit costs, distribution center occupancy costs and depreciation expense and delivery expenses to the stores. Pharmacy Services Segment The Pharmacy Services segment’s cost of revenues includes the cost of prescription drugs sold during the reporting period indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The cost of prescription drugs sold component of cost of revenues includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Pharmacy Services segment’s mail service dispensing pharmacy, net of any volume-related or other discounts (see the section entitled “Vendor Rebates and Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold through the Pharmacy Services segment’s retail pharmacy network under contracts where it is the principal, net of any volume-related or other discounts. See Note 20 for additional information about the cost of revenues of the Company’s business segments. Vendor Rebates and Allowances and Purchase Discounts Retail Pharmacy Segment The Retail Pharmacy segment rebates and allowances received from vendors relate to either buying and merchandising or promoting the product. Buying and merchandising related rebates and allowances are recorded as a reduction of cost of revenue as product is sold. Buying and merchandising rebates and allowances include all types of vendor programs such as cash discounts from timely payment of invoices, purchase discounts or rebates, volume purchase allowances, price reduction allowances and slotting allowances. Certain product promotion related rebates and allowances, primarily related to advertising, are recorded as a reduction in selling, general and administrative expenses when the advertising commitment has been satisfied. Pharmacy Services Segment The Pharmacy Services segment receives purchase discounts on products purchased. The Pharmacy Services segment’s contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, or (ii) a discount (or rebate) paid subsequent to dispensing when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy). These rebates are recognized when prescriptions are dispensed and are generally billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Pharmacy Services segment’s results of operations. The Pharmacy Services segment accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts and fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of revenues. Reinsurance To minimize risk and statutory capital requirements, EIC enters into quota share reinsurance agreements with unaffiliated reinsurers whereby they assume a quota share percentage of the Company’s Medicare Part D program. The net revenue and net cost of revenue for EIC has been reduced by the amounts ceded to reinsurers under these agreements. EIC does not have a reinsurance agreement in place for its individual and most of its group prescription drug policies for calendar 2018 and calendar 2019. EIC has quota share reinsurance for certain group prescription drug policies for calendar 2018 and calendar 2019. Rent The Company records rent expense on operating leases on a straight‑line basis over the minimum lease term. The Company begins to record rent expense at the time that the Company has the right to use the property. From time to time, the Company receives incentive payments from landlords that subsidize lease improvement construction. These leasehold incentives are deferred and recognized on a straight‑line basis over the minimum lease term. Selling, General and Administrative Expenses Selling, general and administrative expenses include store and corporate administrative payroll and benefit costs, occupancy costs which include retail store and corporate rent costs, facility and leasehold improvement depreciation and utility costs, advertising, repair and maintenance, insurance, equipment depreciation and professional fees. Repairs and Maintenance Routine repairs and maintenance are charged to operations as incurred. Improvements and major repairs, which extend the useful life of an asset, are capitalized and depreciated. Advertising Advertising costs, net of specific vendor advertising allowances, are expensed in the period the advertisement first takes place. Advertising expenses, net of vendor advertising allowances, for fiscal 2019, 2018 and 2017 were $147,519, $161,826 and $181,438, respectively. Insurance The Company is self‑insured for certain general liability and workers’ compensation claims. For claims that are self‑insured, stop‑loss insurance coverage is maintained for workers’ compensation occurrences exceeding $1,000 and general liability occurrences exceeding $3,000. The Company utilizes actuarial studies as the basis for developing reported claims and estimating claims incurred but not reported relating to the Company’s self‑insurance. Workers’ compensation claims are discounted to present value using a risk‑free interest rate. Benefit Plan Accruals The Company has several defined benefit plans, under which participants earn a retirement benefit based upon a formula set forth in the plan. The Company records expense related to these plans using actuarially determined amounts that are calculated under the provisions of ASC 715, “Compensation—Retirement Benefits.” Key assumptions used in the actuarial valuations include the discount rate, the expected rate of return on plan assets and the rate of increase in future compensation levels. Stock‑Based Compensation The Company has several stock option plans, which are described in detail in Note 17. The Company accounts for stock‑based compensation under ASC 718, “Compensation—Stock Compensation.” The Company recognizes option expense over the requisite service period of the award, net of an estimate for the impact of award forfeitures. Store Pre‑opening Expenses Costs incurred prior to the opening of a new or relocated store, associated with a remodeled store or related to the opening of a distribution facility are charged against earnings when incurred. Litigation Reserves The Company is involved in litigation on an ongoing basis. The Company accrues its best estimate of the probable loss related to legal claims. Such estimates are developed in consultation with in‑house counsel, and are based upon a combination of litigation and settlement strategies. Facility Closing Costs and Lease Exit Charges When a store or distribution center is closed, the Company records an expense for unrecoverable costs and accrues a liability equal to the present value at current credit adjusted risk‑free interest rates of the remaining lease obligations and anticipated ancillary occupancy costs, net of estimated sublease income. Other store or distribution center closing and liquidation costs are expensed when incurred. Income Taxes Deferred income taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities. Deferred income tax expense (benefit) represents the change during the reporting period in the deferred tax assets and deferred tax liabilities, net of the effect of acquisitions and dispositions. Deferred tax assets include tax loss and credit carryforwards and are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion of the deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. The Company has net operating loss (“NOL”) carryforwards that can be utilized to offset future income for federal and state tax purposes. These NOLs generate a significant deferred tax asset. The Company regularly reviews the deferred tax assets for recoverability considering historical profitability, projected taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. The Company recognizes tax liabilities in accordance with ASC 740, “Income Taxes” and the Company adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities. The Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017, among other things, permanently lowered the statutory federal corporate tax rate from 35% to 21%, effective for tax years including or beginning January 1, 2018. Under the guidance of ASC 740, “Income Taxes” (“ASC 740”), the Company re-measured its net deferred tax assets on the date of enactment based on the reduction in the overall future tax benefit expected to be realized at the lower tax rate implemented by the new legislation. Sales Tax Collected Sales taxes collected from customers and remitted to various governmental agencies are presented on a net basis (excluded from revenues) in the Company’s statement of operations. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estima

Termination of the Merger Agree

Termination of the Merger Agreement with Albertsons Companies, Inc.	12 Months Ended
	Mar. 02, 2019
Termination of the Merger Agreement with Albertsons Companies, Inc.
Termination of the Merger Agreement with Albertsons Companies, Inc.	2. Termination of the Merger Agreement with Albertsons Companies, Inc. On February 18, 2018, Rite Aid entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Albertsons, Ranch Acquisition II LLC, a Delaware limited liability company and a wholly-owned direct subsidiary of Albertsons (“Merger Sub II”) and Ranch Acquisition Corp., a Delaware corporation and a wholly-owned direct subsidiary of Merger Sub II (“Merger Sub” and, together with Merger Sub II, the “Merger Subs”). On August 8, 2018, Rite Aid, Albertsons and the Merger Subs entered into a Termination Agreement (the "Merger Termination Agreement") under which the parties mutually agreed to terminate the Merger Agreement. Subject to limited customary exceptions, the Merger Termination Agreement mutually releases the parties from any claims of liability to one another relating to the contemplated merger (the "Merger"). Under the terms of the Merger Agreement, neither Rite Aid nor Albertsons is responsible for any payments to the other party as a result of the termination of the Merger Agreement and Rite Aid is no longer subject to the interim operating covenants and restrictions contained in the Merger Agreement.

Asset Sale to WBA

Asset Sale to WBA	12 Months Ended
	Mar. 02, 2019
Asset Sale to WBA
Asset Sale to WBA	3. Asset Sale to WBA On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Asset Purchase Agreement, dated as of June 28, 2017, by and among the Company, WBA and Buyer. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from the Company 1,932 Acquired Stores, three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of $4,375,000, on a cash-free, debt-free basis in the Sale. The Company announced on September 19, 2017 that the waiting period under the HSR Act, expired with respect to the Sale. The Company completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA, and the received of cash proceeds of $4,156,686. On September 13, 2018, the Company completed the sale of one of its distribution centers and related assets to WBA for proceeds of $61,251. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $14,151, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended March 2, 2019. The transfer of the remaining two distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement. The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. The Company has agreed to various covenants and agreements, including, among others, the Company’s agreement to conduct its business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. The Company has also agreed to provide transition services to Buyer for up to three years after the initial closing of the Sale. Under the terms of the TSA, the Company provides various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. The initial term of the TSA continues until October 17, 2019 and may be extended for up to two additional periods of six months each upon WBA providing written notice to Rite Aid at least 90 days prior to the expiration of the then-current term. In connection with these services, the Company purchases the related inventory and incurs cash payments for the selling, general and administrative activities, which, the Company bills on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the fifty-two week periods ended March 2, 2019 and March 3, 2018 were $6,887,092 and $725,190, respectively, of which $293,662 and $354,321 is included in Accounts receivable, net. The Company charged WBA TSA fees of $80,277 during the fifty-two week period ended March 2, 2019 and $8,422 in the fifty-two week period ended March 3, 2018, which are reflected as a reduction to selling, general and administrative expenses. Based on its magnitude and because the Company exited certain markets, the Sale represented a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05— Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended March 2, 2019 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20. The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows: March 2, March 3, 2019 2018 Inventories $ 68,233 $ 264,286 Property and equipment 49,348 158,433 Goodwill(a) — 4,629 Intangible assets — 10,789 Current assets held for sale $ 117,581 $ 438,137 Current maturities of long-term lease financing obligations $ — $ 270 Accrued salaries, wages and other current liabilities — 6,146 Long-term debt, less current maturities(b) — 549,549 Lease financing obligations, less current maturities — 838 Other noncurrent liabilities — 3,402 Current liabilities held for sale $ — $ 560,205 (a) The Company had $76,124 of goodwill in its Retail Pharmacy segment resulting from the acquisition of Health Dialog and RediClinic, which is accounted for as Retail Pharmacy segment enterprise goodwill. The Company has allocated a portion of its Retail Pharmacy segment enterprise goodwill to the discontinued operation. (b) In connection with the Sale, the Company had estimated that the Sale would generate in excess of $4.0 billion of cash proceeds, all of which was used to repay outstanding indebtedness. The operating results of the discontinued operations that are reflected on the consolidated statements of operations within net income (loss) from discontinued operations are as follows: March 2, March 3, March 4, 2019 2018 2017 (52 weeks) (52 weeks) (53 weeks) Revenues $ 34,889 $ 8,686,397 $ 10,050,049 Costs and expenses: Cost of revenues(a) 24,271 6,406,067 7,340,691 Selling, general and administrative expenses(a) 20,681 2,134,276 2,465,364 Lease termination and impairment charges — 77 9,516 Loss on debt retirements, net 22,646 8,180 — Interest expense(b) 4,616 224,300 231,926 Gain on stores sold to Walgreens Boots Alliance (374,619) (2,128,832) — Loss (gain) on sale of assets, net 1,486 (377) 2,625 (300,919) 6,643,691 10,050,122 Income (loss) from discontinued operations before income taxes 335,808 2,042,706 (73) Income tax expense 91,067 749,704 46 Net income (loss) from discontinued operations, net of tax $ 244,741 $ 1,293,002 $ (27) (a) Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations. (b) In accordance with ASC 205-20, the operating results for the fifty-two week period ended March 2, 2019, the fifty-two week period ended March 3, 2018 and the fifty-three week period ended March 4, 2017, respectively, for the discontinued operations include interest expense relating to outstanding indebtedness repaid with the estimated excess proceeds from the Sale. The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income from discontinued operations only include expenses that are directly attributable to the Disposal Group.

(Loss) Income Per Share

(Loss) Income Per Share	12 Months Ended
	Mar. 02, 2019
(Loss) Income Per Share
(Loss) Income Per Share	4. (Loss) Income Per Share Basic (loss) income per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted (loss) income per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company subject to anti- dilution limitations. March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Basic and diluted (loss) income per share: Numerator: (Loss) income from continuing operations attributable to common stockholders—basic and diluted $ (666,954) $ (349,532) $ 4,080 Income (loss) from discontinued operations attributable to common stockholders—basic and diluted 244,741 1,293,002 (27) (Loss) income attributable to common stockholders—basic and diluted $ (422,213) $ 943,470 $ 4,053 Denominator: Basic weighted average shares 52,854 52,481 52,221 Outstanding options and restricted shares, net — — 820 Diluted weighted average shares 52,854 52,481 53,041 Basic (loss) income per share: Continuing operations $ (12.62) $ (6.66) $ Discontinued operations 4.63 24.64 Net basic (loss) income per share $ (7.99) $ 17.98 $ Diluted (loss) income per share: Continuing operations $ (12.62) $ (6.66) $ Discontinued operations 4.63 24.64 Net diluted (loss) income per share $ (7.99) $ 17.98 $ Due to their antidilutive effect, 1,036, 374 and 160 potential common shares related to stock options have been excluded from the computation of diluted income per share as of March 2, 2019, March 3, 2018 and March 4, 2017, respectively. Also, excluded from the computation of diluted income per share as of March 2, 2019, March 3, 2018 and March 4, 2017 are restricted shares of 1,008, 610 and 0, respectively, which are included in shares outstanding. On April 10, 2019, the Company’s Board of Directors approved a one-for-twenty reverse stock split of the Company’s outstanding shares of common stock. The reverse stock split was effected on April 18, 2019 at 5:00 p.m. Eastern time. At the effective time, every twenty issued and outstanding shares of the Company’s common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company’s transfer agent in an amount equal to such stockholder’s respective pro rata shares of the total net proceeds from the Company’s transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of our common stock was also reduced on a one-for-twenty basis, from 1,500,000 to 75,000. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company’s 2014 Equity Incentive Plan.

Lease Termination and Impairmen

Lease Termination and Impairment Charges	12 Months Ended
	Mar. 02, 2019
Lease Termination and Impairment Charges
Lease Termination and Impairment Charges	5. Lease Termination and Impairment Charges Impairment Charges The Company evaluates long‑lived assets for impairment whenever events or changes in circumstances indicate that an asset group has a carrying value that may not be recoverable. The individual operating store is the lowest level for which cash flows are identifiable. As such, the Company evaluates individual stores for recoverability of assets. To determine if a store needs to be tested for recoverability, the Company considers items such as decreases in market prices, changes in the manner in which the store is being used or physical condition, changes in legal factors or business climate, an accumulation of losses significantly in excess of budget, a current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection of continuing losses, or an expectation that the store will be closed or sold. The Company monitors new and recently relocated stores against operational projections and other strategic factors such as regional economics, new competitive entries and other local market considerations to determine if an impairment evaluation is required. For other stores, it performs a recoverability analysis if it has experienced current‑period and historical cash flow losses. In performing the recoverability test, the Company compares the expected future cash flows of a store to the carrying amount of its assets. Significant judgment is used to estimate future cash flows. Major assumptions that contribute to its future cash flow projections include expected sales, gross profit and distribution expenses; expected costs such as payroll, occupancy costs and advertising expenses; and estimates for other significant selling, and general and administrative expenses. Many long‑term macro‑economic and industry factors are considered, both quantitatively and qualitatively, in the future cash flow assumptions. In addition to current and expected economic conditions such as inflation, interest and unemployment rates that affect customer shopping patterns, the Company considers that it operates in a highly competitive industry which includes the actions of other national and regional drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, dollar stores and internet pharmacies. Additionally, the Company takes into consideration that certain operating stores are executing specific improvement plans which are monitored quarterly to recoup recent capital investments, such as an acquisition of an independent pharmacy, which it has made to respond to specific competitive or local market conditions, or have specific programs tailored towards a specific geography or market. The Company recorded impairment charges of $63,492 in fiscal 2019, $37,873 in fiscal 2018 and $22,631 in fiscal 2017. The Company’s methodology for recording impairment charges has been consistently applied in the periods presented. At March 2, 2019, $1,093.0 million of the Company’s long‑lived assets, including intangible assets, were associated with 2,469 active operating stores. If an operating store’s estimated future undiscounted cash flows are not sufficient to cover its carrying value, its carrying value is reduced to fair value. Fair value is its estimated future discounted cash flows. The discount rate is commensurate with the risks associated with the recovery of a similar asset. An impairment charge is recorded in the period that the store does not meet its original return on investment and/or has an operating loss for the last two years and its projected cash flows do not exceed its current asset carrying value. The amount of the impairment charge is the entire difference between the current asset carrying value and its fair value which is the estimated future discounted cash flows. Most stores are fully impaired in the period that the impairment charge is originally recorded. The Company recorded impairment charges for active stores of $46,419 in fiscal 2019, $34,782 in fiscal 2018 and $20,623 in fiscal 2017. The Company reviews key performance results for active stores on a quarterly basis and approves certain stores for closure. Impairment for closed stores, if any (many stores are closed on lease expiration), are recorded in the quarter the closure decision is approved. Closure decisions are made on an individual store or regional basis considering all of the macro‑economic, industry and other factors, in addition to, the active store’s individual operating results. The Company recorded impairment charges for closed facilities of $2,788 in fiscal 2019, $3,091 in fiscal 2018 and $2,008 in fiscal 2017. The following table summarizes the impairment charges and number of locations, segregated by closed facilities and active stores that have been recorded in fiscal 2019, 2018 and 2017: March 2, 2019 March 3, 2018 March 4, 2017 (in thousands, except number of stores) Number Charge Number Charge Number Charge Active stores: Stores previously impaired(1) 288 $ 17,939 218 $ 7,313 174 $ 5,022 New, relocated and remodeled stores(2) 22 10,595 28 13,100 22 13,232 Remaining stores not meeting the recoverability test(3) 74 17,885 60 14,369 17 2,369 Total impairment charges—active stores 384 46,419 306 34,782 213 20,623 Total impairment charges—closed facilities 62 2,788 67 3,091 53 2,008 Total impairment charges—other(4) — 14,285 — — — — Total impairment charges—all locations 446 $ 63,492 373 $ 37,873 266 $ 22,631 (1) These charges are related to stores that were impaired for the first time in prior periods. Most active stores, requiring an impairment charge, are fully impaired in the first period that they do not meet their asset recoverability test. However, we do often make capital additions to certain stores to improve their operating results or to meet geographical competition, which if later are deemed to be unrecoverable, will be impaired in future periods. Of this total, 286, 215 and 173 stores for fiscal years 2019, 2018 and 2017 respectively have been fully impaired. Also included in these charges are an insignificant number of stores, which were only partially impaired in prior years based on our analysis that supported a reduced net book value greater than zero, but now require additional charges. (2) These charges are related to new stores (open at least three years) and relocated stores (relocated in the last two years) and significant strategic remodels (remodeled in the last year) that did not meet their recoverability test during the current period. These stores have not met their original return on investment projections and have a historical loss of at least two years. Their future cash flow projections do not recover their current carrying value. Of this total, 21, 23 and 18 stores for fiscal years 2019, 2018 and 2017 respectively have been fully impaired. (3) These charges are related to the remaining active stores that did not meet the recoverability test during the current period. These stores have a historical loss of at least 2 years. Their future cash flow projections do not recover their current carrying value. Of this total, 72, 58 and 16 stores for fiscal years 2019, 2018 and 2017 respectively have been fully impaired. (4) These charges are due to the impairment of assets related to the termination of a project to replace the point of sale software used in the Company’s stores. The primary drivers of its impairment charges are each store’s current and historical operating performance and the assumptions that the Company makes about each store’s operating performance in future periods. Projected cash flows are updated based on the next year’s operating budget which includes the qualitative factors noted above. The Company utilizes the three‑level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following: · Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. · Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument. · Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk. Long‑lived non‑financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long‑lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long‑lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk‑adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. The table below sets forth by level within the fair value hierarchy the long‑lived assets as of the impairment measurement date for which an impairment assessment was performed and total losses as of March 2, 2019 and March 3, 2018: Quoted Prices in Significant Fair Values Active Markets Other Significant as of Total for Identical Observable Unobservable Impairment Charges Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Date March 2, 2019 Long-lived assets held and used $ — $ — $ 8,116 $ 8,116 $ (62,115) Long-lived assets held for sale — 1,545 — 1,545 (1,377) Total $ — $ 1,545 $ 8,116 $ 9,661 $ (63,492) Quoted Prices in Significant Fair Values Active Markets Other Significant as of Total for Identical Observable Unobservable Impairment Charges Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Date March 3, 2018 Long-lived assets held and used $ — $ 2,893 $ 14,581 $ 17,474 $ (36,752) Long-lived assets held for sale — 1,029 — 1,029 (1,121) Total $ — $ 3,922 $ 14,581 $ 18,503 $ (37,873) The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and due to their immateriality, have not been reclassified to assets held for sale. Lease Termination Charges Charges to close a store, which principally consist of continuing lease obligations, are recorded at the time the store is closed and all inventory is liquidated, pursuant to the guidance set forth in ASC 420, “Exit or Disposal Cost Obligations.” The Company calculates the liability for closed stores on a store‑by‑store basis. The calculation includes the discounted effect of future minimum lease payments and related ancillary costs, from the date of closure to the end of the remaining lease term, net of estimated cost recoveries that may be achieved through subletting or favorable lease terminations. The Company evaluates these assumptions each quarter and adjusts the liability accordingly. In fiscal 2019, 2018 and 2017, the Company recorded lease termination charges of $44,502, $20,892 and $23,147, respectively. These charges related to changes in future assumptions, interest accretion and provisions for 61 stores in fiscal 2019, 11 stores in fiscal 2018 and 17 stores in fiscal 2017. As part of its ongoing business activities, the Company assesses stores and distribution centers for potential closure. Decisions to close or relocate stores or distribution centers in future periods would result in lease termination charges for lease exit costs and liquidation of inventory, as well as impairment of assets at these locations. The following table reflects the closed store and distribution center charges that relate to new closures, changes in assumptions and interest accretion: Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Balance—beginning of year $ 133,290 $ 165,138 $ 208,421 Provision for present value of noncancellable lease payments of closed stores 35,190 8,871 6,503 Changes in assumptions about future sublease income, terminations and change in interest rates 737 1,082 2,633 Interest accretion 9,741 11,439 14,186 Cash payments, net of sublease income (54,912) (53,240) (66,605) Balance—end of year $ 124,046 $ 133,290 $ 165,138 The Company’s revenues and income before income taxes for fiscal 2019, 2018 and 2017 included results from stores that have been closed or are approved for closure as of March 2, 2019. The revenue, operating expenses and income before income taxes of these stores for the periods are presented as follows: Year Ended March 2, March 3, March 4, 2019 2018 2017 Revenues $ 165,598 $ 308,005 $ 433,709 Operating expenses 182,201 342,103 471,971 Gain from sale of assets (38,113) (18,222) (1,036) Other expenses 2,183 2,417 4,590 Income (loss) before income taxes 19,327 (18,293) (41,816) Included in these stores’ loss before income taxes are: Depreciation and amortization 621 1,742 3,560 Inventory liquidation charges (5,523) (2,828) (187) The above results are not necessarily indicative of the impact that these closures will have on revenues and operating results of the Company in the future, as the Company often transfers the business of a closed store to another Company store, thereby retaining a portion of these revenues and operating expenses.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 02, 2019
Fair Value Measurements
Fair Value Measurements	6. Fair Value Measurements The Company utilizes the three‑level valuation hierarchy as described in Note 5 for the recognition and disclosure of fair value measurements. As of March 2, 2019 and March 3, 2018, the Company did not have any financial assets measured on a recurring basis. Please see Note 5 for fair value measurements of non‑financial assets measured on a non‑recurring basis. Other Financial Instruments Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature. In addition, as of March 2, 2019 and March 3, 2018, the Company has $7,191 and $7,282, respectively, of investments carried at amortized cost as these investments are being held to maturity. These investments are included as a component of prepaid expenses and other current assets as of March 2, 2019 and as a component of other assets as of March 3, 2018. The Company believes the carrying value of these investments approximates their fair value. The fair value for LIBOR‑based borrowings under the Company’s senior secured credit facility is estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long‑term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long‑term indebtedness was $3,454,585 and $3,120,335, respectively, as of March 2, 2019. The carrying amount and estimated fair value of the Company’s total long‑term indebtedness was $3,889,738 and $3,927,411, respectively, as of March 3, 2018. There were no outstanding derivative financial instruments as of March 2, 2019 and March 3, 2018.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 02, 2019
Income Taxes
Income Taxes	7. Income Taxes On December 22, 2017 (the “Enactment Date”), H.R. 1, originally known as the Tax Cuts and Jobs Act, was enacted. The new law (Public Law No.115-97 hereinafter referred to as the “Tax Act”) includes significant changes to the U.S. corporate income tax system including, but not limited to, lowering the statutory corporate tax rate from 35% to 21%, limiting or eliminating certain deductions and the repeal of Corporate AMT tax regime. The majority of the provisions are applicable to the Company for fiscal 2019. For fiscal 2018, the Company computed its income tax expense using a blended federal tax rate of 32.6%. The 21% federal tax rate applies to the fiscal year ending March 2, 2019 and each year thereafter. The provision for income tax expense (benefit) from continuing operations was as follows: Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Current tax: Federal $ (22,187) $ (210) $ — State 9,866 51,279 14,600 (12,321) 51,069 14,600 Deferred tax and other: Federal 50,151 316,451 10,355 State 39,647 (61,533) 19,483 89,798 254,918 29,838 Total income tax expense $ 77,477 $ 305,987 $ 44,438 A reconciliation of the expected statutory federal tax and the total income tax expense (benefit) from continuing operations was as follows: Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Federal statutory rate* $ (123,790) $ (14,202) $ 16,982 Federal tax rate change — 324,765 — Nondeductible expenses 2,890 1,213 2,479 State income taxes, net (12,605) (22,836) 8,225 Increase (decrease) of previously recorded liabilities (3,105) 27,295 (955) Nondeductible compensation 1,798 654 1,157 Acquisition costs — 696 4,023 Stock based compensation 3,478 8,363 — Valuation allowance 212,252 (8,853) 14,718 Other (3,441) (11,108) (2,191) Total income tax expense $ 77,477 $ 305,987 $ 44,438 * Federal statutory rate included in the above table is 21.0%, 32.6% and 35.0%, respectively, for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017. Net income for fiscal 2019 from continuing operations included income tax expense of $77,477, of which $212,252 relates to the increase in valuation allowance for federal and state net deferred tax assets that may not be realized based on the Company's future projections of taxable income. Net income for fiscal 2018 from continuing operations included income tax expense of $305,987, of which $324,765 relates to the federal income tax rate change on the re-measurement of net deferred tax assets pursuant to the Tax Act. Additionally, the Company recorded within state income taxes the net impact of the Pennsylvania tax law change which resulted in a substantial increase to the state net operating loss carryforwards and a corresponding increase to the valuation allowance. Net income from continuing operations for fiscal 2017 included income tax expense of $44,438, which included an increase in valuation allowance of $14,718 primarily related to a reduction in estimated utilization of state NOLs and for expiring carryforwards. The Company recognized tax expense of $91,067, $749,704 and $46 within Net loss (income) from discontinued operations, net of tax, in the Statement of Operations in fiscal 2019, fiscal 2018 and fiscal 2017, respectively. The Company’s effective income tax rate from discontinued operations included adjustments to the valuation allowance of $(2,417), $(32,870) and $15 for fiscal 2019, fiscal 2018 and fiscal 2017, respectively. The tax effect of temporary differences that gave rise to significant components of deferred tax assets and liabilities consisted of the following at March 2, 2019 and March 3, 2018: 2019 2018 Deferred tax assets: Accounts receivable $ 36,607 $ 39,182 Accrued expenses 107,356 113,493 Liability for lease exit costs 37,333 40,662 Pension, retirement and other benefits 87,397 104,494 Long-lived assets 320,561 246,793 Credits 48,884 85,555 Net operating losses 1,084,139 1,089,084 Total gross deferred tax assets 1,722,277 1,719,263 Valuation allowance (1,091,416) (896,800) Total deferred tax assets 630,861 822,463 Deferred tax liabilities: Outside basis difference 5,392 5,420 Inventory 215,588 223,024 Other 797 0 Total gross deferred tax liabilities 221,777 228,444 Net deferred tax assets $ 409,084 $ 594,019 A reconciliation of the beginning and ending amount of unrecognized tax benefits from continuing operations was as follows: 2019 2018 2017 Unrecognized tax benefits $ 230,210 $ 8,939 $ 10,676 Increases to prior year tax positions 155 — 16 Decreases to tax positions in prior periods (111) (1,015) (626) Increases to current year tax positions — 224,408 26 Settlements — — — Divestitures (543) (1,607) — Lapse of statute of limitations (9,872) (515) (1,153) Unrecognized tax benefits balance $ 219,839 $ 230,210 $ 8,939 The amount of the above unrecognized tax benefits at March 2, 2019, March 3, 2018 and March 4, 2017 which would impact the Company’s effective tax rate, if recognized, was $28,482, $31,377 and $892 respectively. Additionally, any impact on the effective rate may be mitigated by the valuation allowance that is remaining against the Company’s net deferred tax assets. The Company believes that it is reasonably possible that a decrease of up to $12,736 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company. The Company recognizes interest and penalties related to tax contingencies as income tax expense. The Company recognized an expense/(benefit) for interest and penalties in connection with tax matters of $(769), $7,058 and $(276) for fiscal years 2019, 2018 and 2017, respectively. As of March 2, 2019 and March 3, 2018 the total amount of accrued income tax‑related interest and penalties was $6,553 and $7,322, respectively. The Company files U.S. federal income tax returns as well as income tax returns in those states where it does business. The consolidated federal income tax returns are closed for examination through fiscal year 2015. However, any net operating losses that were generated in these prior closed years may be subject to examination by the IRS upon utilization. Tax examinations by various state taxing authorities could generally be conducted for a period of three to five years after filing of the respective return. Net Operating Losses and Tax Credits At March 2, 2019, the Company had federal net operating loss carryforwards of approximately $1,063,382. Of these, $884,627 will expire, if not utilized, between fiscal 2029 and 2031. An additional $178,246 will expire, if not utilized, between fiscal 2032 and 2037. At March 2, 2019, the Company had state net operating loss carryforwards of approximately $12,048,528, the majority of which will expire ratably through fiscal 2030; the net tax effect of these carryforwards is $1,089,656 and are reflected in the table above. At March 2, 2019, the Company had federal business tax credit carryforwards of $28,478 the majority of which will expire between 2020 and 2021. In addition to these credits, the Company had alternative minimum tax credit carryforwards of $13,497 which will be refunded to the Company between fiscal 2020 - 2022. The Company recorded a receivable for refundable AMT tax credits of $13,497 for fiscal 2019. Valuation Allowances The valuation allowances as of March 2, 2019 and March 3, 2018 apply to the net deferred tax assets of the Company. The Company maintained a valuation allowance of $1,091,416 and $896,800 at March 2, 2019 and March 3, 2018, respectively. The primary driver of the increase for fiscal 2019 is to reduce federal and state net deferred tax assets that may not be realized based on the Company's future projections of taxable income. The primary driver of the increase for fiscal 2018 resulted from the Pennsylvania tax law change which caused a substantial increase to the state net operating loss carryforwards, which required an offsetting increase in valuation allowance.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Mar. 02, 2019
Accounts Receivable
Accounts Receivable	8. Accounts Receivable The Company maintains an allowance for doubtful accounts receivable based upon the expected collectability of accounts receivable. The allowance for uncollectible accounts at March 2, 2019 and March 3, 2018 was $13,106 and $25,134 respectively. The Company’s accounts receivable are due primarily from third‑party payors (e.g., PBM companies, insurance companies or governmental agencies) and are recorded net of any allowances provided for under the respective plans. Since payments due from third‑party payors are sensitive to payment criteria changes and legislative actions, the allowance is reviewed continually and adjusted for accounts deemed uncollectible by management.

Medicare Part D

Medicare Part D	12 Months Ended
	Mar. 02, 2019
Medicare Part D
Medicare Part D	9. Medicare Part D The Company offers Medicare Part D benefits through EIC, which has contracted with CMS to be a PDP and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes. EIC is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EIC must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $15,076 as of December 31, 2018. EIC was in excess of the minimum required amounts in these states as of March 2, 2019. The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported. As of March 2, 2019, accounts receivable, net included $392,400 due from CMS relating to the calendar 2019 and 2018 plan years, respectively. Accrued salaries, wages and other current liabilities included $0 due to the Company's reinsurance carrier, relating to the 2019 and 2018 plan years, respectively. As of March 3, 2018, accounts receivable, net included $350,563 due from CMS and accrued salaries, wages and other current liabilities included $183,318 of EIC liabilities under certain reinsurance contracts. During calendar 2017, EIC limited its exposure to loss and recovered a portion of benefits paid by utilizing quota-share reinsurance with a commercial reinsurance company. EIC does not have a reinsurance agreement in place for its individual and most of its group prescription drug policies for calendar 2018 and calendar 2019. EIC has quota share reinsurance for certain group prescription drug policies for calendar 2018 and calendar 2019.

Manufacturer Rebates Receivable

Manufacturer Rebates Receivables	12 Months Ended
	Mar. 02, 2019
Manufacturer Rebates Receivables
Manufacturer Rebates Receivables.	10. Manufacturer Rebates Receivables The Pharmacy Services Segment has manufacturer rebates receivables of $445,200 and $370,861 included in Accounts receivable, net, as of March 2, 2019 and March 3, 2018, respectively.

Inventory

Inventory	12 Months Ended
	Mar. 02, 2019
Inventory
Inventory	11. Inventory At March 2, 2019 and March 3, 2018, inventories were $604,444 and $581,090, respectively, lower than the amounts that would have been reported using the first‑in, first‑out (“FIFO”) cost flow assumption. The Company calculates its FIFO inventory valuation using the retail method for store inventories and the cost method for distribution facility inventories. The Company recorded a LIFO charge for fiscal year 2019 of $23,354, compared to a LIFO credit of $28,827 for fiscal year 2018 and a LIFO credit of $3,721 for fiscal year 2017. During fiscal 2019, 2018 and 2017, a reduction in non-pharmacy inventories resulted in the liquidation of applicable LIFO inventory quantities carried at lower costs in prior years. This LIFO liquidation resulted in a $5,884, $2,707 and $2,375 cost of revenues decrease, with a corresponding reduction to the adjustment to LIFO for fiscal 2019, fiscal 2018 and fiscal 2017, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Mar. 02, 2019
Property, Plant and Equipment
Property, Plant and Equipment	12. Property, Plant and Equipment Following is a summary of property, plant and equipment, including capital lease assets, at March 2, 2019 and March 3, 2018: 2019 2018 Land $ 139,406 $ 138,768 Buildings 533,580 528,026 Leasehold improvements 1,527,371 1,567,635 Equipment 1,765,575 1,795,337 Software 38,680 25,944 Construction in progress 49,344 59,635 4,053,956 4,115,345 Accumulated depreciation (2,745,442) (2,684,099) Property, plant and equipment, net $ 1,308,514 $ 1,431,246 Depreciation expense, which included the depreciation of assets recorded under capital leases, was $232,242, $238,318 and $241,787 in fiscal 2019, 2018 and 2017, respectively. Included in property, plant and equipment was the carrying amount, which approximates fair value, of assets to be disposed of totaling $452 and $972 at March 2, 2019 and March 3, 2018, respectively.

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Mar. 02, 2019
Goodwill and Other Intangibles
Goodwill and Other Intangibles	13. Goodwill and Other Intangibles Goodwill and indefinitely-lived assets, such as certain trademarks acquired in connection with acquisition transactions, are not amortized, but are instead evaluated for impairment on an annual basis at the end of the fiscal year, or more frequently if events or circumstances indicate it may be more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, the Company performs a quantitative goodwill impairment test. The fair value estimates used in the quantitative impairment test are calculated using an average of the income and market approaches. The income approach is based on the present value of future cash flows of each reporting unit, while the market approach is based on certain multiples of selected guideline public companies or selected guideline transactions. The approaches, which qualify as Level 3 within the fair value hierarchy, incorporate a number of market participant assumptions including future growth rates, discount rates, income tax rates and market activity in assessing fair value and are reporting unit specific. If the carrying amount exceeds the reporting unit’s fair value, the Company recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. In addition, the Company considers the income tax effect of any tax deductible goodwill when measuring a goodwill impairment loss. In the fiscal second quarter of fiscal 2019 and the fourth quarter of fiscal 2018, the Company completed a qualitative goodwill impairment assessment, at which time it was determined after evaluating results, events and circumstances that a quantitative assessment was necessary for the Pharmacy Services segment. The quantitative assessment concluded that the carrying amount of the Pharmacy Services segment exceeded its fair value principally due to a decrease in Adjusted EBITDA that was driven by commercial business compression and an increase in SG&A expenses. This resulted in goodwill impairment charges of $312,985 ($235,698 net of the related income tax benefit) and $261,727 ($191,000 net of the related income tax benefit) for the fiscal years ended March 2, 2019 and March 3, 2018, respectively. As of March 2, 2019 and March 3, 2018, the accumulated impairment losses for the Pharmacy Services segment was $574,712 and $261,727, respectively. There was no impairment charge for the fiscal year ended March 4, 2017 as the Company determined that the fair value of the reporting units exceeded their carrying amounts. Below is a summary of the changes in the carrying amount of goodwill by segment for the fiscal years ended March 2, 2019 and March 3, 2018: Retail Pharmacy Pharmacy Services Total Balance, March 4, 2017 $ 43,492 $ 1,639,355 $ 1,682,847 Goodwill impairment — (261,727) (261,727) Balance, March 3, 2018 43,492 1,377,628 1,421,120 Goodwill impairment — (312,984) (312,984) Balance, March 2, 2019 $ 43,492 $ 1,064,644 $ 1,108,136 The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of March 2, 2019 and March 3, 2018. 2019 2018 Remaining Remaining Weighted Weighted Gross Average Gross Average Carrying Accumulated Amortization Carrying Accumulated Amortization Amount Amortization Net Period Amount Amortization Net Period Favorable leases and other(a) $ 370,855 $ (318,503) $ 52,352 years $ 379,355 $ (316,798) $ 62,557 years Prescription files 919,749 (827,222) 92,527 years 900,111 (801,706) 98,405 years Customer relationships(a) 388,000 (193,352) 194,648 years 465,000 (172,635) 292,365 years CMS license 57,500 (8,472) 49,028 years 57,500 (6,172) 51,328 years Claims adjudication and other developed software 58,985 (31,030) 27,955 years 58,985 (22,617) 36,368 years Trademarks 20,100 (7,404) 12,696 years 20,100 (5,394) 14,706 years Backlog 11,500 (11,500) — years 11,500 (10,286) 1,214 year Total finite $ 1,826,689 $ (1,397,483) $ 429,206 $ 1,892,551 $ (1,335,608) $ 556,943 Trademarks 19,500 — 19,500 Indefinite 33,500 — 33,500 Indefinite Total $ 1,846,189 $ (1,397,483) $ 448,706 $ 1,926,051 $ (1,335,608) $ 590,443 (a) Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows. During fiscal 2019, the Company has recorded an impairment charge to reduce the book value of customer relationships by $48,205 (gross carrying amount of $77,000 less accumulated amortization of $28,795), and indefinite lived trademarks by $14,000, both of which charges are included within goodwill and intangible asset impairment charges within the consolidated statement of operations. Also included in other non‑current liabilities as of March 2, 2019 and March 3, 2018 are unfavorable lease intangibles with a net carrying amount of $14,763 and $18,888, respectively. These intangible liabilities are amortized over their remaining lease terms at time of acquisition. Amortization expense for these intangible assets and liabilities was $125,640, $147,739 and $165,579 for fiscal 2019, 2018 and 2017, respectively. The anticipated annual amortization expense for these intangible assets and liabilities is 2020—$100,892; 2021—$77,824; 2022—$56,890; 2023—$41,344 and 2024—$28,905.

Accrued Salaries, Wages and Oth

Accrued Salaries, Wages and Other Current Liabilities	12 Months Ended
	Mar. 02, 2019
Accrued Salaries, Wages and Other Current Liabilities
Accrued Salaries, Wages and Other Current Liabilities	14. Accrued Salaries, Wages and Other Current Liabilities Accrued salaries, wages and other current liabilities consisted of the following at March 2, 2019 and March 3, 2018: 2019 2018 Accrued wages, benefits and other personnel costs $ 302,025 $ 360,179 Accrued interest 13,991 65,210 Accrued sales and other taxes payable 80,708 125,289 Accrued store expense 143,053 155,354 Accrued reinsurance — 183,418 Other 268,662 342,286 $ 808,439 $ 1,231,736

Indebtedness and Credit Agreeme

Indebtedness and Credit Agreements	12 Months Ended
	Mar. 02, 2019
Indebtedness and Credit Agreements
Indebtedness and Credit Agreements	15. Indebtedness and Credit Agreement Following is a summary of indebtedness and lease financing obligations at March 2, 2019 and March 3, 2018: 2019 2018 Secured Debt: Senior secured revolving credit facility due January 2020 ($0 face value less unamortized debt issuance costs of $0 and $13,076) $ — $ (13,076) Senior secured revolving credit facility due December 2023 ($875,000 and $0 face value less unamortized debt issuance costs of $24,069 and $0) 850,931 — FILO term loan due December 2023 ($450,000 and $0 face value less unamortized debt issuance costs of $3,918 and $0) 446,082 — Other secured — 90 1,297,013 (12,986) Guaranteed Unsecured Debt: 9.25% senior notes due March 2020 ($0 and $902,000 face value plus unamortized premium of $0 and $1,400 and less unamortized debt issuance costs of $0 and $4,924) — 898,476 6.75% senior notes due June 2021 ($0 and $810,000 face value less unamortized debt issuance costs of $0 and $4,877) — 805,123 6.125% senior notes due April 2023 ($1,753,490 and $1,800,000 face value less unamortized debt issuance costs of $16,982 and $21,708) 1,736,508 1,778,292 1,736,508 3,481,891 Unguaranteed Unsecured Debt: 7.7% notes due February 2027 ($295,000 face value less unamortized debt issuance costs of $1,295 and $1,460) 293,705 293,540 6.875% fixed-rate senior notes due December 2028 ($128,000 face value less unamortized debt issuance costs of $642 and $707) 127,358 127,293 421,063 420,833 Lease financing obligations 40,176 52,554 Total debt 3,494,760 3,942,292 Current maturities of long-term debt and lease financing obligations (16,111) (21,031) Long-term debt and lease financing obligations, less current maturities $ 3,478,649 $ 3,921,261 Reconciliation of indebtedness included in continuing operations and discontinued operations: March 3, 2018 Total Debt and Lease Financing Lease Financing Debt Obligations Obligations Balance, March 3, 2018—per above table $ 3,889,738 $ 52,554 $ 3,942,292 Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale(a) (549,549) (1,108) (550,657) Total debt and lease financing obligations 3,340,189 51,446 3,391,635 Current maturities of long-term debt and lease financing obligations—continuing operations (90) (20,671) (20,761) Long-term debt and lease financing obligations, less current maturities—continuing operations $ 3,340,099 $ 30,775 $ 3,370,874 (a) In connection with the Sale, the Company had estimated that the Sale would generate in excess of $4.0 billion of cash proceeds, all of which was used to repay outstanding indebtedness. Please see Note 3 for additional details. Credit Facility On December 20, 2018, the Company entered into a new senior secured credit agreement, consisting of a new $2,700,000 senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a new $450,000 “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan”) (collectively the “New Facilities”). Proceeds from the New Facilities were used to refinance the Company’s prior $2,700,000 Amended and Restated Senior Secured Credit Facility due January 2020 (the “Old Facility” the New Facilities and the Old Facility are collectively referred to herein as the “Facilities”). The New Facilities extend the Company’s debt maturity profile and provide additional liquidity. The New Facilities mature in December 2023, subject to an earlier maturity on December 31, 2022 if the Company has not repaid or refinanced its existing 6.125% Senior Notes due 2023 prior to such date. The Company’s new Senior Secured Revolving Credit Facility will bear interest at a rate of LIBOR plus 125 to 175 basis points (or an alternate base rate plus 25 to 75 basis points), depending on availability under the revolving facility. The Company’s new Senior Secured Term Loan will bear interest at a rate of LIBOR plus 300 basis points (or an alternate base rate plus 200 basis points). The Company’s ability to borrow under the New Facilities is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At March 2, 2019, the Company had $1,325,000 of borrowings outstanding under the New Facilities and had letters of credit outstanding against the New Facilities of $83,205 which resulted in additional borrowing capacity of $1,741,795. The New Facilities restrict the Company and the Subsidiary Guarantors (as defined herein) from accumulating cash on hand in excess of $200,000 at any time revolving loans are outstanding (not including cash located in its stores and lockbox deposit account and cash necessary to cover current liabilities.) The New Facilities allow the Company to have outstanding, at any time, up to $1,500,000 in secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock in addition to borrowings under the New Facilities and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest of (i) the fifth anniversary of the effectiveness of the New Facilities and (ii) the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the New Facilities). Subject to the limitations described in clauses (i) and (ii) of the immediately preceding sentence, the New Facilities additionally allow the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the New Facilities) is not in effect; provided, however, that certain of the Company’s other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The New Facilities also contain certain restrictions on the amount of secured first priority debt the Company is able to incur. The New Facilities also allow for the voluntary repurchase of any debt or other convertible debt, so long as the New Facilities are not in default and the Company maintains availability under its revolver of more than $365,000. The New Facilities have a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the revolver is less than $200,000 or (ii) on the third consecutive business day on which availability under the revolver is less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the New Facilities is equal to or greater than $250,000. As of March 2, 2019, the Company had availability under its New Facilities of $1,741,795, its fixed charge coverage ratio was greater than 1.00 to 1.00, and the Company was in compliance with the New Facilities’ financial covenant. The New Facilities also contain covenants which place restrictions on the incurrence of debt, the payments of dividends, sale of assets, mergers and acquisitions and the granting of liens. The New Facilities also provide for customary events of default. With the exception of EIC, substantially all of Rite Aid Corporation’s 100% owned subsidiaries guarantee the obligations under the New Facilities and unsecured guaranteed notes. The New Facilities are secured, on a senior priority basis, by a lien on, among other things, accounts receivable, inventory and prescription files of the Subsidiary Guarantors. The subsidiary guarantees related to the Company’s New Facilities and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Additionally, prior to the acquisition of EnvisionRx, the subsidiaries, including joint ventures, that did not guarantee the Old Facility and applicable notes, were minor. Accordingly, condensed consolidating financial information for the Company and subsidiaries is not presented for those periods. Subsequent to the acquisition of EnvisionRx, other than EIC, the subsidiaries, including joint ventures, that do not guarantee the New Facilities and applicable notes, are minor. As such, condensed consolidating financial information for the Company, its guaranteeing subsidiaries and non-guaranteeing subsidiaries is presented for those periods subsequent to the acquisition of EnvisionRx. See Note 24 “Guarantor and Non-Guarantor Condensed Consolidating Financial Information” for additional disclosure. Fiscal 2018 and 2019 Transactions During January 2018, the Company used proceeds from the Asset Sale to repay and retire all of its outstanding second lien $470,000 tranche 1 term loan and $500,000 tranche 2 term loan principal (the “Second Lien Term Loan Prepayment”). During February 2018, the Company reduced the borrowing capacity on its Old Facility from $3,700,000 to $3,000,000 (which was subsequently further reduced as described below). In connection with the transactions, the Company recorded a loss on debt retirement of $8,180, which included interest and unamortized debt issuance costs. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations. On February 27, 2018, the Company announced that it had commenced an offer to purchase up to $900,000 of the outstanding 9.25% senior notes due 2020 (the “9.25% Notes”), the 6.75% senior notes due 2021 (the “6.75% Notes”) and the 6.125% senior notes due 2023 (the “6.125% Notes”), pursuant to the asset sale provisions of the indentures of such notes. On March 29, 2018, the Company accepted for payment, pursuant to its offer to purchase, $3,454 principal amount of the 9.25% Notes, representing 0.38% of the outstanding principal amount of the 9.25% Notes, $3,471 principal amount of the 6.75% Notes, representing 0.43% of the outstanding principal amount of the 6.75% Notes, and $41,751 principal amount of the 6.125% Notes, representing 2.32% of the outstanding principal amount of the 6.125% Notes. In connection therewith, the Company recorded a loss on debt retirement of $49 which included unamortized debt issuance costs, partially offset by unamortized discount. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations. The debt repayment and related loss on debt retirement of $498 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations. On March 13, 2018, the Company issued a notice of redemption for all of the 9.25% Notes that were outstanding on April 12, 2018, pursuant to the terms of the indenture of the 9.25% Notes. On April 12, 2018, the Company redeemed 100% of the remaining outstanding 9.25% Notes. In connection therewith, the Company recorded a loss on debt retirement of $3,422 which included unamortized debt issuance costs, partially offset by unamortized discount. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations. On April 19, 2018, the Company announced that it had commenced an offer to purchase up to $700,000 of its outstanding 6.75% Notes and its 6.125% Notes pursuant to the asset sale provisions of such indentures. On May 21, 2018, the Company accepted for payment, pursuant to its offer to purchase, $1,360 aggregate principal amount of the 6.75% Notes and $4,759 aggregate principal amount of the 6.125% Notes. The debt repayment and related loss on debt retirement of $8 for the 6.75% Notes is included in the results of operations and cash flows of discontinued operations. The debt repayment and related loss on debt retirement of $56 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations. On April 29, 2018, the Company further reduced the borrowing capacity on its Old Facility from $3,000,000 to $2,700,000. In connection therewith, the Company recorded a loss on debt retirement of $1,091, which included unamortized debt issuance costs. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations. On June 25, 2018, the Company redeemed the remaining $805,169 of its 6.75% Notes, which resulted in a loss on debt retirement of $18,075. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations. On March 15, 2019, the Company entered into a Cap, which has been assigned to the variable interest rate payments on the first $650,000 notional amount of variable rate indebtedness. The Cap has an effective date of March 21, 2019 and expires on March 21, 2021. The Cap provides the Company with interest rate protection in the event that LIBOR increases above 2.75%. Interest Rates and Maturities The annual weighted average interest rate on the Company’s indebtedness was 5.6%, 7.1% and 5.4% for fiscal 2019, 2018 and 2017, respectively. The aggregate annual principal payments of long‑term debt for the five succeeding fiscal years are as follows: 2020—$0; 2021—$0; 2022—$0; 2023—$0 and $3,501,490 in 2024 and thereafter. These aggregate annual principal payments of long-term debt assume that the Company has not repaid or refinanced its existing 6.125% Senior Notes due 2023 prior to December 31, 2022.

Leases

Leases	12 Months Ended
	Mar. 02, 2019
Leases
Leases	16. Leases The Company leases most of its retail stores and certain distribution facilities under noncancellable operating and capital leases, most of which have initial lease terms ranging from 5 to 22 years. The Company also leases certain of its equipment and other assets under noncancellable operating leases with initial terms ranging from 3 to 10 years. In addition to minimum rental payments, certain store leases require additional payments based on sales volume, as well as reimbursements for taxes, maintenance and insurance. Most leases contain renewal options, certain of which involve rent increases. Total rental expense, net of sublease income of $4,509, $4,682 and $4,813, was $626,166, $628,511 and $634,539 in fiscal 2019, 2018 and 2017, respectively. These amounts include contingent rentals of $7,084, $8,339 and $10,229 in fiscal 2019, 2018 and 2017, respectively. During fiscal 2019, 2018 and 2017, the Company did not enter into any sale-leaseback transactions whereby the Company sold owned operating stores to independent third parties and concurrent with the sale, entered into an agreement to lease the store back from the purchasers. As a result of the Sale to WBA and the related Amended and Restated Asset Purchase Agreement, the Company has lease guarantee obligations related to 1,656 former stores. The majority of the lease guarantee obligations have a term of less than 10 years; however, 84 former stores have guarantees that exceed 10 years. The Company is only obligated to pay for the lease guarantees in the event that WBA fails to perform under the lease agreements, as WBA is the primary obligor. If WBA fails to perform under the lease agreements, the maximum lease guarantee obligations the Company would be liable for would be approximately $1,800,000 as of March 2, 2019. During fiscal 2019, WBA has performed under the lease agreements. The Company has assessed that it is highly unlikely that WBA will not perform under the leases as of March 2, 2019. The net book values of assets under capital leases and sale‑leasebacks accounted for under the financing method at March 2, 2019 and March 3, 2018 are summarized as follows: 2019 2018 Land $ 2,688 $ 3,458 Buildings 83,624 86,012 Equipment 19,595 25,225 Accumulated depreciation (77,892) (78,637) $ 28,015 $ 36,058 Following is a summary of lease finance obligations at March 2, 2019 and March 3, 2018: 2019 2018 Obligations under financing leases $ 40,176 $ 51,446 Less current obligation (16,112) (20,671) Long-term lease finance obligations $ 24,064 $ 30,775 Following are the minimum lease payments for all properties under a lease agreement that will have to be made in each of the years indicated based on non‑cancelable leases in effect as of March 2, 2019: Lease Financing Operating Fiscal year Obligations Leases 2020 $ 19,300 $ 687,412 2021 4,811 610,874 2022 4,588 545,863 2023 4,383 490,864 2024 4,042 431,714 Later years 20,470 1,541,408 Total minimum lease payments 57,594 $ 4,308,135 Amount representing interest (17,418) Present value of minimum lease payments $ 40,176

Stock Option and Stock Award Pl

Stock Option and Stock Award Plans	12 Months Ended
	Mar. 02, 2019
Stock Option and Stock Award Plans
Stock Option and Stock Awards	17. Stock Option and Stock Award Plans The Company recognizes share-based compensation expense in accordance with ASC 718, “Compensation—Stock Compensation.” Expense is recognized over the requisite service period of the award, net of an estimate for the impact of forfeitures. Operating results for fiscal 2019, 2018 and 2017 include $12,115, $25,793 and $23,482 of compensation costs related to the Company’s stock‑based compensation arrangements. In December 2000, the Company adopted the 2000 Omnibus Equity Plan (the 2000 Plan) under which 1,100 shares of common stock are reserved for granting of restricted stock, stock options, phantom stock, stock bonus awards and other stock awards at the discretion of the Board of Directors. In February 2001, the Company adopted the 2001 Stock Option Plan (the 2001 Plan) which was approved by the shareholders under which 1,000 shares of common stock are authorized for granting of stock options at the discretion of the Board of Directors. In April 2004, the Board of Directors adopted the 2004 Omnibus Equity Plan, which was approved by the shareholders. Under the plan, 1,000 shares of common stock are authorized for granting of restricted stock, stock options, phantom stock, stock bonus awards and other equity based awards at the discretion of the Board of Directors. In January 2007, the stockholders of Rite Aid Corporation approved the adoption of the Rite Aid Corporation 2006 Omnibus Equity Plan. Under the plan, 2,500 shares of Rite Aid common stock are available for granting of restricted stock, stock options, phantom stock, stock bonus awards and other equity based awards at the discretion of the Board of Directors. In June 2010, the stockholders of Rite Aid Corporation approved the adoption of the Rite Aid Corporation 2010 Omnibus Equity Plan. Under the plan, 1,750 shares of Rite Aid common stock are available for granting of restricted stock, stock options, phantom stock, stock bonus awards and other equity based awards at the discretion of the Board of Directors. The adoption of the 2010 Omnibus Equity Plan became effective on June 23, 2010. In June 2012, the stockholders of Rite Aid Corporation approved the adoption of the Rite Aid Corporation 2012 Omnibus Equity Plan. Under the plan, 1,425 shares of Rite Aid common stock are available for granting of restricted stock, stock options, phantom stock, stock bonus awards and other equity based awards at the discretion of the Board of Directors. The adoption of the 2012 Omnibus Equity Plan became effective on June 21, 2012. In June 2014, the stockholders of Rite Aid Corporation approved the adoption of the Rite Aid Corporation 2014 Omnibus Equity Plan. Under the plan, 2,900 shares of Rite Aid common stock plus any shares of common stock remaining available for grant under the Rite Aid Corporation 2010 Omnibus Equity Plan and the Rite Aid Corporation 2012 Omnibus Equity Plan as of the effective date of the 2014 Plan (provided that no more than 1,250 shares may be granted as incentive stock options) are available for granting of restricted stock, stock options, phantom stock, stock bonus awards and other equity based awards at the discretion of the Board of Directors. The adoption of the 2014 Omnibus Equity Plan became effective on June 19, 2014. All of the plans provide for the Board of Directors (or at its election, the Compensation Committee) to determine both when and in what manner options may be exercised; however, it may not be more than 10 years from the date of grant. All of the plans provide that stock options may be granted at prices that are not less than the fair market value of a share of common stock on the date of grant. The aggregate number of remaining shares authorized for issuance for all plans is 1,251 as of March 2, 2019. Stock Options The Company determines the fair value of stock options issued on the date of grant using the Black‑Scholes‑Merton option‑pricing model. The following weighted average assumptions were used for options granted in fiscal 2019, 2018 and 2017: 2019 2018 2017 Expected stock price volatility(1) N/A 58 % N/A Expected dividend yield(2) N/A 0.0 % N/A Risk-free interest rate(3) N/A 1.9 % N/A Expected option life(4) N/A 5.5 years N/A (1) The expected volatility is based on the historical volatility of the stock price over the most recent period equal to expected life of the option. (2) The dividend rate that will be paid out on the underlying shares during the expected term of the options. The Company does not currently pay dividends on its common stock, as such, the dividend rate is assumed to be 0%. (3) The risk free interest rate is equal to the rate available on United States Treasury zero‑coupon issues as of the grant date of the option with a remaining term equal to the expected term. (4) The period of time for which the option is expected to be outstanding. The Company analyzed historical exercise behavior to estimate the life. The weighted average fair value of options granted during fiscal 2019, 2018 and 2017 was $0.00, $21.60 and $0.00, respectively. Following is a summary of stock option transactions for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017: Weighted Weighted Average Average Exercise Remaining Aggregate Price Contractual Intrinsic Shares Per Share Term Value Outstanding at February 27, 2016 1,906 $ 54.53 Granted — N/A Exercised (178) 39.07 Cancelled (34) 111.99 Outstanding at March 4, 2017 1,694 $ 54.93 Granted 50 41.00 Exercised (241) 24.05 Cancelled (160) 126.61 Outstanding at March 3, 2018 1,343 $ 51.42 Granted — N/A Exercised (99) 23.07 Cancelled (208) 71.07 Outstanding at March 2, 2019 1,036 $ 50.15 $ 0 Vested or expected to vest at March 2, 2019 1,025 $ 49.07 $ 0 Exercisable at March 2, 2019 978 $ 47.87 $ 0 As of March 2, 2019, there was $1,147 of total unrecognized pre-tax compensation costs related to unvested stock options, net of forfeitures. These costs are expected to be recognized over a weighted average period of 1.57 years. Cash received from stock option exercises for fiscal 2019, 2018 and 2017 was $2,294, $5,796 and $6,951, respectively. The income tax benefit from stock options for fiscal 2019, 2018 and 2017 was $7, $10 and $421, respectively. The total intrinsic value of stock options exercised for fiscal 2019, 2018 and 2017 was $726, $3,032 and $20,475, respectively. Typically, stock options granted vest, and are subsequently exercisable in equal annual installments over a four-year period for employees. Restricted Stock The Company provides restricted stock grants to associates under plans approved by the stockholders. Shares awarded under the plans typically vest in equal annual installments over a three-year period. Unvested shares are forfeited upon termination of employment. Following is a summary of restricted stock transactions for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017: Weighted Average Grant Date Shares Fair Value Balance at February 27, 2016 243 $ 144.61 Granted 180 154.60 Vested (111) 125.55 Cancelled (21) 156.85 Balance at March 4, 2017 291 $ 157.35 Granted 693 56.44 Vested (194) 160.61 Cancelled (179) 73.95 Balance at March 3, 2018 611 $ 66.34 Granted 700 16.05 Vested (215) 76.99 Cancelled (88) 72.87 Balance at March 2, 2019 1,008 $ 28.60 At March 2, 2019, there was $21,302 of total unrecognized pre‑tax compensation costs related to unvested restricted stock grants, net of forfeitures. These costs are expected to be recognized over a weighted average period of 1.90 years. The total fair value of restricted stock vested during fiscal years 2019, 2018 and 2017 was $16,519, $31,125 and $13,951, respectively. Performance Based Incentive Plan Beginning in fiscal 2015, the Company provided certain of its associates with performance based incentive plans under which the associates will receive a certain number of shares of the Company’s common stock or cash based on the Company meeting certain financial and performance goals. If such goals are not met, no stock-based compensation expense is recognized and any recognized stock-based compensation expense is reversed. The Company incurred $(1,084), $4,122 and $(6,070) related to these performance based incentive plans for fiscal 2019, 2018 and 2017, respectively, which is recorded as a component of stock-based compensation expense.

Retirement Plans

Retirement Plans	12 Months Ended
	Mar. 02, 2019
Retirement Plans
Retirement Plans	18. Retirement Plans Defined Contribution Plans The Company and its subsidiaries sponsor several retirement plans that are primarily 401(k) defined contribution plans covering nonunion associates and certain union associates. The Company does not contribute to all of the plans. In accordance with those plan provisions, the Company matches 100% of a participant’s pretax payroll contributions, up to a maximum of 3% of such participant’s pretax annual compensation. Thereafter, the Company will match 50% of the participant’s additional pretax payroll contributions, up to a maximum of 2% of such participant’s additional pretax annual compensation. Total expense recognized for the above plans was $44,564 in fiscal 2019, $67,949 in fiscal 2018 and $68,393 in fiscal 2017. The Company sponsors a Supplemental Executive Retirement Plan (“SERP”) for its officers, based on an account-based plan design, that is subject to a five year graduated vesting schedule. The expense recognized for the SERP was $4,913 in fiscal 2019, $12,426 in fiscal 2018 and $16,921 in fiscal 2017. The Company elected on February 25, 2019 to eliminate the SERP. In conjunction with this action, all plan participants will be 100% vested in their benefits and no additional allocations will be made to participant accounts in the future. Participant benefits under this program will be paid out in full on or after February 24, 2020 in accordance with applicable government regulations regarding these programs. Defined Benefit Plans The Company and its subsidiaries also sponsor a qualified defined benefit pension plan that requires benefits to be paid to eligible associates based upon years of service and, in some cases, eligible compensation. The Company’s funding policy for The Rite Aid Pension Plan (the “Defined Benefit Pension Plan”) is to contribute the minimum amount required by the Employee Retirement Income Security Act of 1974. However, the Company may, at its sole discretion, contribute additional funds to the plan. The Company made contributions of $2,715 in fiscal 2019, $9,023 in fiscal 2018 and $0 in fiscal 2017. Net periodic pension expense and other changes recognized in other comprehensive income for the defined benefit pension plans included the following components: Defined Benefit Pension Plan 2019 2018 2017 Service cost $ 597 $ 1,212 $ 1,291 Interest cost 6,159 6,340 6,634 Expected return on plan assets (5,673) (4,525) (4,512) Amortization of unrecognized prior service cost — — — Amortization of unrecognized net loss (gain) 1,769 3,393 5,085 Net pension expense $ 2,852 $ 6,420 $ 8,498 Other changes recognized in other comprehensive loss: Unrecognized net (gain) loss arising during period $ (3,486) $ (8,704) $ (3,979) Prior service cost arising during period — — — Amortization of unrecognized prior service costs — — — Amortization of unrecognized net (loss) gain (1,769) (3,393) (5,085) Net amount recognized in other comprehensive loss (5,255) (12,097) (9,064) Net amount recognized in pension expense and other comprehensive loss $ (2,403) $ (5,677) $ (566) The table below sets forth reconciliation from the beginning of the year for both the benefit obligation and plan assets of the Company’s defined benefit plans, as well as the funded status and amounts recognized in the Company’s balance sheet as of March 2, 2019 and March 3, 2018: Defined Benefit Pension Plan 2019 2018 Change in benefit obligations: Benefit obligation at end of prior year $ 161,851 $ 164,349 Service cost 597 1,212 Interest cost 6,159 6,340 Distributions (8,816) (7,963) Change due to change in assumptions — — Actuarial loss (gain) (9,086) (2,087) Benefit obligation at end of year $ 150,705 $ 161,851 Change in plan assets: Fair value of plan assets at beginning of year $ 130,860 $ 118,658 Employer contributions 2,715 9,023 Actual return on plan assets 72 11,142 Distributions (including expenses paid by the plan) (8,815) (7,963) Fair value of plan assets at end of year $ 124,832 $ 130,860 Funded status $ (25,873) $ (30,991) Net amount recognized $ (25,873) $ (30,991) Amounts recognized in consolidated balance sheets consisted of: Prepaid pension cost $ — $ — Accrued pension liability (25,873) (30,991) Net amount recognized $ (25,873) $ (30,991) Amounts recognized in accumulated other comprehensive loss consist of: Net actuarial loss $ (27,409) $ (32,664) Prior service cost — — Amount recognized $ (27,409) $ (32,664) The estimated net actuarial loss and prior service cost amounts that will be amortized from accumulated other comprehensive loss into net periodic pension expense in fiscal 2020 are $1,661 and $0, respectively. The accumulated benefit obligation for the defined benefit pension plan was $150,705 and $161,851 as of March 2, 2019 and March 3, 2018, respectively. The significant actuarial assumptions used for all defined benefit plans to determine the benefit obligation as of March 2, 2019, March 3, 2018 and March 4, 2017 were as follows: Defined Benefit Pension Plan 2019 2018 2017 Discount rate 4.25 % 4.00 % 4.00 % Rate of increase in future compensation levels N/A N/A N/A Expected long-term rate of return on plan assets 6.25 % 6.25 % 6.50 % Weighted average assumptions used to determine net cost for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017 were: Defined Benefit Pension Plan 2019 2018 2017 Discount rate 4.00 % 4.00 % 4.25 % Rate of increase in future compensation levels N/A N/A N/A Expected long-term rate of return on plan assets 6.25 % 6.50 % 6.50 % To develop the expected long‑term rate of return on assets assumption, the Company considered the historical returns and the future expectations for returns for each asset class, as well as the target asset allocation of the pension portfolio. This resulted in the selection of the 6.25% long‑term rate of return on plan assets assumption for fiscal 2019, 2018 and 2017. The Company’s pension plan asset allocations at March 2, 2019 and March 3, 2018 by asset category were as follows: March 2, March 3, 2019 2018 Equity securities 52 % 53 % Fixed income securities 48 % 47 % Total 100 % 100 % The investment objectives of the Defined Benefit Pension Plan, the only defined benefit plan with assets, are to: · Achieve a rate of return on investments that exceeds inflation over a full market cycle and is consistent with actuarial assumptions; · Balance the correlation between assets and liabilities by diversifying the portfolio among various asset classes to address return risk and interest rate risk; · Balance the allocation of assets between the investment managers to minimize concentration risk; · Maintain liquidity in the portfolio sufficient to meet plan obligations as they come due; and · Control administrative and management costs. The asset allocation established for the pension investment program reflects the risk tolerance of the Company, as determined by: · the current and anticipated financial strength of the Company; · the funded status of the plan; and · plan liabilities. Investments in both the equity and fixed income markets will be maintained, recognizing that historical results indicate that equities (primarily common stocks) have higher expected returns than fixed income investments. It is also recognized that the correlation between assets and liabilities must be balanced to address higher volatility of equity investments (return risk) and interest rate risk. The following targets are to be applied to the allocation of plan assets. Target Category Allocation U.S. equities 39 % International equities 13 % U.S. fixed income 48 % Total 100 % The Company expects to contribute $0 to the Defined Benefit Pension Plan during fiscal 2020. Common and Collective Trusts Common collective trust funds are stated at fair value as determined by the issuer of the common collective trust funds based on the net asset value (“NAV”) of the underlying investments in accordance with ASC 820. There are generally no restrictions on redemptions from these funds and no unfunded commitments to invest. In accordance with ASC subtopic 820-10, certain investments that were measured at NAV per shared (or its equivalent) have not been classified in the fair value hierarchy. The underlying investments mainly consist of equity and fixed income securities funds that are valued based on the daily closing price as reported by the fund. The proceeding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at March 2, 2019. The following table sets forth by level within the fair value hierarchy a summary of the plan’s investments measured at fair value on a recurring basis as of March 2, 2019 and March 3, 2018: Fair Value Measurements at March 2, 2019 Quoted Prices in Active Markets Significant Significant for Identical Observable Unobservable Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Total Equity Securities International equity $ — $ — $ — $ 15,396 Large Cap — — — 34,058 Small-Mid Cap — — — 14,534 Fixed Income Long Term Credit Bond Index — — — 44,103 Long Term US Government Bonds — — — 8,383 20+ Year Treasury STRIPS — — — 847 Intermediate Fixed Income — — — 5,920 Other types of investments Short Term Investments — — — 1,591 Total $ — $ — $ — $ 124,832 Fair Value Measurements at March 3, 2018 Quoted Prices in Active Markets Significant Significant for Identical Observable Unobservable Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Total Equity Securities International equity $ — $ — $ — $ 18,043 Large Cap — — — 35,491 Small-Mid Cap — — — 15,510 Fixed Income Long Term Credit Bond Index — — — 46,222 Long Term US Government Bonds — — — 8,070 20+ Year Treasury STRIPS — — — 1,168 Intermediate Fixed Income — — — 5,617 Other types of investments Short Term Investments — — — 739 Total $ — $ — $ — $ 130,860 Following are the future benefit payments expected to be paid for the Defined Benefit Pension Plan during the years indicated: Defined Benefit Fiscal Year Pension Plan 2020 $ 8,690 2021 8,844 2022 8,999 2023 9,005 2024 9,213 2025 - 2029 45,903 Total $ 90,654 Other Plans The Company participates in various multi‑employer union pension plans that are not sponsored by the Company. Total expenses recognized for the multi‑employer plans were $23,499 in fiscal 2019, $20,979 in fiscal 2018 and $21,336 in fiscal 2017.

Multiemployer Plans that Provid

Multiemployer Plans that Provide Pension Benefits	12 Months Ended
	Mar. 02, 2019
Multiemployer Plans that Provide Pension Benefits
Multiemployer Plans that Provide Pension Benefits	19. Multiemployer Plans that Provide Pension Benefits The Company contributes to a number of multiemployer defined benefit pension plans under the terms of collective‑bargaining agreements that cover certain of its union‑represented employees. The risks of participating in these multiemployer plans are different from single‑employer plans. Assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers. If a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers. Additionally, if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the plan, referred to as a withdrawal liability. The Company’s participation in these plans for the annual period ended March 2, 2019 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employer Identification Number (EIN) and the three-digit plan number, if applicable. The most recent Pension Protection Act zone status available for fiscal 2019 and fiscal 2018 is for the plan year-ends as indicated below. The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone are generally less than 65% funded, plans in the yellow zone are less than 80% funded, and plans in the green zone are at least 80% funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (“FIP”) or a rehabilitation plan (“RP”) is either pending or has been implemented. In addition to regular plan contributions, the Company may be subject to a surcharge if the plan is in the red zone. The “Surcharge Imposed” column indicates whether a surcharge has been imposed on contributions to the plan. The last two columns list the expiration date(s) of the collective-bargaining agreement(s) to which the plans are subject and any minimum funding requirements. There have been no significant changes that affect the comparability of total employer contributions of fiscal years 2019, 2018 and 2017. Expiration FIP/ RP Date of Pension Protection Status Collective- Minimum EIN/Pension Act Zone Status Pending/ Contributions of the Company Surcharge Bargaining Funding Pension Plan Number 2019 2018 Implemented 2019 2018 2017 Imposed Agreement Requirements 1199 SEIU Health Care Employees Pension Fund 13-3604862-001 Green— Green— No $ 9,670 $ 7,372 $ 7,152 No 4/18/2019 Contribution rate of 15.80% of gross wages per associate beginning 09/30/2018. Contribution rate of 10.76% of gross wages earned per associate beginning 01/01/2016. Southern California United Food and Commercial Workers Unions and Drug Employers Pension Fund 51-6029925-001 Red— Red— Implemented 8,273 8,149 8,021 No 7/17/2021 From 01/01/2019 through 12/31/2019 contributions of $1.672 per hour for worked for pharmacists and $0.758 per hour worked for non pharmacists. From 01/01/2018 to 12/31/2018 contributions of $1.586 per hour worked. From 01/01/2017 to 12/31/2017 contributions of $1.50 per hour worked. UFCW Pharmacists, Clerks and Drug Employers Pension Trust 94-2518312-001 Green— Green— No 2,666 2,739 2,970 No 7/13/2019 Effective 09/01/2014, contribution rate frozen at $0.55 per hour worked for associates. United Food and Commercial Workers Union-Employer Pension Fund 34-6665155-001 Red— Red— Implemented 772 786 827 No 2/28/2021 Effective 02/04/2018 contribution rate of $2.03 per hour worked. Effective 02/05/2017 contribution rate of $1.89 per hour worked. Effective 02/07/2016 through 02/04/2017 contribution rate of $1.76 per hour worked. United Food and Commercial Workers Union Local 880—Mercantile Employers Joint Pension Fund 51-6031766-001 Yellow— Yellow— Implemented 470 495 504 No 2/28/2021 Effective 10/01/2018 contribution rate of $1.97 per hour worked. Effective 01/01/2017 contribution rate $1.88 per hour worked. Effective 01/01/2016 through 12/31/2016 contribution rate of $1.79 per hour worked. Other Funds 1,648 1,438 1,862 $ 23,499 $ 20,979 $ 21,336 The Company was listed in these plans Forms 5500 as providing more than 5% of the total contributions for the following plans and plan years: Year Contributions to Plan Exceeded More Than 5 % of Total Contributions (as of Pension Fund the Plan’s Year-End) UFCW Pharmacists, Clerks and Drug Employers Pension Trust 12/31/2017 and 12/31/2016 Southern California United Food and Commercial Workers Unions and Drug Employers Pension Fund 12/31/2017 and 12/31/2016 United Food & Commercial Workers Union - Employer Pension Fund 9/30/2017 and 9/30/2016 United Food & Commercial Workers Union Local 880—Mercantile Employers Joint Pension Fund 9/30/2017 and 9/30/2016 At the date the Company’s financial statements were issued, certain Forms 5500 were not available. During fiscal 2019, 2018 and 2017, the Company did not withdraw from any plans or incur any additional withdrawal liabilities.

Segment Reporting

Segment Reporting	12 Months Ended
	Mar. 02, 2019
Segment Reporting
Segment Reporting	20. Segment Reporting The Company has two reportable segments, its retail drug stores (“Retail Pharmacy”), and its pharmacy services (“Pharmacy Services”) segments, collectively the “Parent Company.” The Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of PBM services including plan design and administration, on both a transparent pass-through model and traditional model, formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, and drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program. The Parent Company’s chief operating decision makers are its Parent Company Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Operating Officer—Retail Pharmacy, and the Chief Executive Officer—Pharmacy Services (collectively the “CODM”). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit and Adjusted EBITDA. The following is balance sheet information for the Company’s reportable segments: Retail Pharmacy Pharmacy Services Eliminations(1) Consolidated March 2, 2019: Total Assets $ 5,071,055 $ 2,534,771 $ (14,459) $ 7,591,367 Goodwill 43,492 1,064,644 — 1,108,136 Additions to property and equipment and intangible assets 228,079 16,610 — 244,689 March 3, 2018: Total Assets $ 6,089,343 $ 2,954,953 $ (54,969) $ 8,989,327 Goodwill 43,492 1,377,628 — 1,421,120 Additions to property and equipment and intangible assets 199,437 15,327 — 214,764 (1) As of March 2, 2019 and March 3, 2018, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $0 and $38,713 , respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,459 and $16,256, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. The following table is a reconciliation of the Company’s business segments to the consolidated financial statements for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017: Retail Pharmacy Intersegment Pharmacy Services Eliminations(1) Consolidated March 2, 2019: Revenues $ 15,757,152 $ 6,093,688 $ (211,283) $ 21,639,557 Gross Profit 4,258,716 417,636 — 4,676,352 Adjusted EBITDA(2) 405,206 158,238 — 563,444 March 3, 2018: Revenues $ 15,832,625 $ 5,896,669 $ (200,326) $ 21,528,968 Gross Profit 4,372,373 407,732 — 4,780,105 Adjusted EBITDA(2) 388,320 171,534 — 559,854 March 4, 2017: Revenues $ 16,766,620 $ 6,393,884 $ (232,964) $ 22,927,540 Gross Profit 4,671,975 392,732 — 5,064,707 Adjusted EBITDA(2) 559,653 188,235 — 747,888 (1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis. (2) See the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details. The following is a reconciliation of net (loss) income to Adjusted EBITDA for fiscal 2019, 2018 and 2017: March 2, March 3, March 4, 2019 2018 2017 (52 weeks) (52 weeks)(a) (53 weeks)(a) Net (loss) income from continuing operations $ (666,954) $ (349,532) $ 4,080 Interest expense 227,728 202,768 200,065 Income tax expense 77,477 305,987 44,438 Depreciation and amortization 357,882 386,057 407,366 LIFO charge (credit) 23,354 (28,827) (3,721) Lease termination and impairment charges 107,994 58,765 45,778 Goodwill and intangible asset impairment charges 375,190 261,727 — Loss on debt retirements, net 554 — — Merger and Acquisition-related costs 37,821 24,283 14,066 Stock-based compensation expense 12,115 25,793 23,482 Restructuring-related costs 4,704 — — Inventory write-downs related to store closings 13,487 7,586 5,925 Litigation settlement 18,000 — — Gain on sale of assets, net (38,012) (25,872) (6,649) Walgreens Boots Alliance merger termination fee — (325,000) — Other 12,104 16,119 13,058 Adjusted EBITDA from continuing operations $ 563,444 $ 559,854 $ 747,888 (a) During fiscal 2019, the Company revised its definition of Adjusted EBITDA to no longer exclude the impact of revenue deferrals related to its customer loyalty program and further revised its disclosure by presenting certain amounts previously included within Other as separate reconciling items. Consequently, the Company revised Adjusted EBITDA for fiscal 2018 and fiscal 2017 to conform with the revised definition and present separate reconciling items previously included in Other.

Commitments, Contingencies and

Commitments, Contingencies and Guarantees	12 Months Ended
	Mar. 02, 2019
Commitments, Contingencies and Guarantees
Commitments, Contingencies and Guarantees	21. Commitments, Contingencies and Guarantees Legal Matters and Regulatory Proceedings The Company is involved in legal proceedings including litigation, arbitration, and other claims, and is subject to investigations, inspections, audits, inquiries, and similar actions by pharmacy, health care, tax and other governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss has been incurred, and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual and developments that would make a loss contingency both probable and reasonably estimable, and as a result, warrant an accrual. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters or regulatory proceedings are material individually or in the aggregate to the Company’s consolidated financial position. The Company’s contingencies are subject to significant uncertainties, many of which are beyond the Company’s control, including, among other factors: (i) proceedings are in early stages; (ii) whether class or collective action status is sought and the likelihood of a class being certified; (iii) the outcome of pending appeals or motions; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at issue; (vii) there are significant factual issues to be resolved; and/or (viii) in the case of certain government agency investigations, whether a qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation. While the Company cannot predict the outcome of any of the contingencies, the Company’s management does not believe that the outcome of any of these legal matters or regulatory proceedings will be material to the Company’s consolidated financial position. It is possible, however, the Company’s results of operations or cash flows could be materially affected by unfavorable outcomes in outstanding legal matters or regulatory proceedings. After the announcement of the then proposed merger between the Company and Walgreens Boots Alliance, Inc. (“WBA”), a putative class action lawsuit was filed in Pennsylvania in the Court of Common Pleas of Cumberland County ( Wilson v. Rite Aid Corp., et al. ) by a purported Company stockholder against the Company, its directors (the Individual Defendants, together with the Company, the Rite Aid Defendants), WBA and Victoria Merger Sub Inc. (Victoria) challenging the transactions contemplated by the merger agreement. The lawsuit was terminated on November 30, 2018. Also in connection with a proposed merger between the Company and WBA, a lawsuit was filed in the United States District Court for the Middle District of Pennsylvania (the “Pennsylvania District Court”), asserting a claim for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 against the Rite Aid Defendants, WBA and Victoria and a claim for violations of Section 20(a) of the Exchange Act against the Individual Defendants and WBA ( Hering v. Rite Aid Corp., et al. ). The complaint in the Hering action alleged, among other things, that the Rite Aid Defendants disseminated an allegedly false and materially misleading proxy and sought to enjoin the shareholder vote on the proposed merger, a declaration that the proxy was materially false and misleading in violation of federal securities laws and an award of money damages and attorneys’ and experts’ fees. On January 14 and 16, 2016, respectively, the plaintiff in the Hering action filed a motion for preliminary injunction and a motion for expedited discovery. On January 21, 2016, the Rite Aid Defendants filed a motion to dismiss the Hering complaint. At a hearing held on January 25, 2016, the Pennsylvania District Court orally denied the plaintiff’s motion for expedited discovery and subsequently denied the plaintiff’s motion for preliminary injunction on January 28, 2016. On March 14, 2016, the Pennsylvania District Court appointed Jerry Hering, Don Michael Hussey and Joanna Pauli Hussey as lead plaintiffs for the putative class and approved their selection of Robbins Geller Rudman & Dowd LLP as lead counsel. On April 14, 2016, the Pennsylvania District Court granted the lead plaintiffs’ unopposed motion to stay the Hering action for all purposes pending consummation of the merger. On August 4, 2017, the Pennsylvania District Court entered an order lifting the stay, noting that the original claims in this matter were now moot and directed the plaintiffs to file a motion for leave to amend the complaint, with brief in support thereof, which motion was subsequently filed on September 22, 2017. Also on September 22, 2017, the lead plaintiffs gave notice that plaintiffs Don Michael Hussey and Joanna Pauli Hussey were withdrawing as lead plaintiffs, and that plaintiff Jerry Hering (the “Lead Plaintiff”) would continue to represent the proposed class in the Hering action going forward. On November 27, 2017, the Pennsylvania District Court granted Lead Plaintiff’s motion to amend the complaint, and Lead Plaintiff filed the amended complaint (the “Amended Complaint”) on December 11, 2017. The Amended Complaint alleged claims for violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 against the Rite Aid Defendants, WBA, and certain WBA executives (together with WBA, the “WBA Defendants”). On February 14, 2018, the Rite Aid Defendants moved to dismiss the Amended Complaint, which the Pennsylvania District Court granted on July 11, 2018, dismissing all claims alleged against the Rite Aid Defendants. On August 24, 2018, the WBA Defendants filed a motion for judgment on the pleadings. On October 24, 2018, the Pennsylvania District Court issued a memorandum opinion and order concluding that Lead Plaintiff lacked standing to pursue his claims against the WBA Defendants, granted the WBA Defendants’ motion for judgment on the pleadings, and closed the file on this case. On November 2, 2018, a new lawsuit was filed in the Pennsylvania District Court by new plaintiffs asserting substantially similar claims against the WBA Defendants only ( Chabot, et al. v. Walgreens Boots Alliance, et al. ), and expressly adopting and incorporating allegations from the Amended Complaint previously sustained against the WBA Defendants in the Pennsylvania District Court’s July 11, 2018 memorandum opinion and order in the Hering action. The lawsuit remains pending. In connection with the then proposed merger between the Company and Albertsons Companies, Inc. (“ACI”), on April 24, 2018, a Rite Aid stockholder filed a putative class action lawsuit in the Court of Chancery of the State of Delaware (the “Delaware Court of Chancery”) against the Company, ACI, Ranch Acquisition Corp. (Merger Sub I), Ranch Acquisition II LLC (Merger Sub II, together with ACI and Merger Sub I, the ACI defendants) and each of the Rite Aid directors (the Director defendants, together with Rite Aid, the Rite Aid defendants), Del. C.A. No. 2018-0305-AGB ( Akile v. Rite Aid Corp., et al ). Plaintiff contended that Rite Aid stockholders had appraisal rights under Section 262 of the DGCL. Plaintiff alleged breach of fiduciary duty claims against the Director defendants for their alleged failure to provide alleged statutory appraisal rights under Delaware law and for allegedly falsely informing Rite Aid stockholders that they would not have appraisal rights. Plaintiff further contended that the proxy statement/prospectus related to the proposed merger, and which was filed on April 6, 2018, was deficient under Section 262(d)(1) of the DGCL for failure to inform stockholders of their alleged appraisal rights. Plaintiff sought declarations from the Court of Chancery that the action was a proper class action and that the Director defendants breached their fiduciary duties by failing to adequately inform class members of their appraisal rights under Delaware law, to enjoin the then proposed transaction from closing until such time as class members were afforded the ability to seek appraisal of their shares, or otherwise permit class members to petition the Court of Chancery for appraisal, and attorneys’ fees, expenses, and costs to plaintiff. On May 9, 2018, the Court of Chancery denied plaintiff’s motion to expedite and declined to schedule a preliminary injunction hearing, ruling that plaintiff failed to state a colorable claim. On August 13, 2018, the parties filed a Stipulation and Proposed Order of Voluntary Dismissal Pursuant to Court of Chancery Rule 41(1)(a)(ii), which the Court of Chancery entered on August 14, 2018. On June 29, July 27, and August 3, 2018, three purported stockholders of the Company each separately filed a Verified Complaint to Compel Inspection of Books and Records under 8 Del. C . §220 in the Delaware Court of Chancery against the Company, seeking to inspect books and records in order to determine whether wrongdoing or mismanagement had taken place such that it would be appropriate to file claims for breach of fiduciary duty, and to investigate the independence and disinterestedness of the Company’s directors with respect to the then proposed merger with ACI. On August 10 and September 6, 2018, respectively, two of the purported stockholders’ complaints were voluntarily dismissed. On October 18, 2018, the remaining plaintiff filed an amended complaint, Del. C.A. No. 2018-0554-AGB ( Krol v. Rite Aid Corp. ), which was substantially similar to his original complaint. On November 1, 2018, the Company answered the amended complaint, and on January 29, 2019, the remaining plaintiff filed a stipulation of voluntary dismissal with prejudice. The Company is currently a defendant in several lawsuits filed in courts in California alleging violations of California Business and Professions Code, industry wage orders, wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay for missed meals and rest periods, failure to reimburse business expenses and failure to provide employee seating (the “California Cases”). Some of the California Cases purport or may be determined to be class actions or PAGA representative actions and seek substantial damages and penalties. The single-plaintiff and multi-plaintiff California Cases regarding violations of wage-and-hour laws, failure to pay overtime and failure to pay for missed meals and rest periods, in the aggregate, seek substantial damages. The Company believes that its defenses and assertions in the California Cases, as well as other lawsuits, have merit. The Company has aggressively challenged the merits of the lawsuits and, where applicable, the allegations that the lawsuits should be certified as class or representative actions. Additionally, at this time the Company is not able to predict either the outcome of or estimate a potential range of loss with respect to the California Cases and is vigorously defending them. In the employee seating lawsuit (Hall v. Rite Aid Corporation, San Diego County Superior Court), the parties reached a class action settlement for $18 million plus institution of a two-year pilot seating program for front-end check stands. On September 14, 2018, the Court granted preliminary approval of the settlement. On November 16, 2018, the court granted final approval of the settlement. Following service of subpoenas on the Company in 2011 and 2013 by the United States Attorney’s Office for the Eastern District of Michigan (“USAO”) and the State of Indiana’s Office of the Attorney General, respectively, the Company cooperated with inquiries regarding the relationship of Rite Aid’s Rx Savings Program to the reporting of usual and customary charges to publicly funded health programs. In January 2017, the USAO, 18 states and the District of Columbia declined to intervene in a sealed False Claims Act (“FCA”) lawsuit filed by qui tam plaintiff Azam Rahimi (“Relator”) in the District Court for the Eastern District of Michigan. On January 19, 2017, the court unsealed Relator’s Second Amended Complaint against the Company; it alleges that the Company failed to report Rx Savings prices as its usual and customary charges under the Medicare Part D program and to federal and state Medicaid programs in 18 states and the District of Columbia; and that the Company is thus liable under the federal FCA and similar state statutes. In its ruling on the Company’s motion to dismiss the complaint, the Court held that Relator’s complaint was deficient, but allowed Relator the opportunity to re-plead. Relator filed a Third Amended Complaint on May 11, 2018. The Company filed a motion to dismiss the Third Amended Complaint on May 25, 2018. On March 30, 2019, the Company’s motion to dismiss the Third Amended Complaint was denied. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit. On April 26, 2012, the Company received an administrative subpoena from the U.S. Drug Enforcement Administration (“DEA”), Albany, New York District Office, requesting information regarding the Company’s sale of products containing pseudoephedrine (“PSE”). In April 2012, it also received a communication from the U.S. Attorney’s Office (“USAO”) for the Northern District of New York concerning an investigation of possible civil violations of the Combat Methamphetamine Epidemic Act of 2005 (“CMEA”). Additional subpoenas were issued in 2013, 2014, and 2015 seeking broader documentation regarding PSE sales and recordkeeping requirements. Assistant U.S. Attorneys from the Northern and Eastern Districts of New York and the Southern District of West Virginia are currently investigating, but no lawsuits have been filed. Violations of the CMEA could result in the imposition of administrative and/or civil penalties against the Company. The Company has entered into tolling agreements with the United States, and discussions have been held to attempt to resolve these matters with those USAOs and the Department of Justice, but whether any agreements can be reached and on what terms is uncertain. At this stage of the investigation, the Company is not able to predict the outcome of the investigation. In December 2017, Rite Aid executed a non-prosecution agreement with the United States Attorney’s Office for the Southern District of West Virginia (countersigned by the government in January 2018), which concluded the previous criminal investigation into Rite Aid’s PSE sales. Pursuant to that agreement, the government agreed not to bring any criminal charges against Rite Aid, and Rite Aid agreed to pay an immaterial amount of money as restitution. The civil investigation is ongoing. In June 2013, the Company was served with a Civil Investigative Demand (“CID”) by the United States Attorney’s Office for the Eastern District of California (the “USAO”) regarding (1) the Company’s Drug Utilization Review (“DUR”) and prescription dispensing protocol; and (2) the dispensing of drugs designated as “Code 1” by the State of California. The Company cooperated with the investigation, researched the government’s allegations, and refuted the government’s position. The Company produced documents including certain prescription files related to Code 1 drugs to the USAO’s office and the State of California Department of Justice’s Bureau of Medical Fraud and Elder Abuse (“CADOJ”). In August 2014, the USAO and 8 states’ attorneys general declined to intervene in a California False Claim Act (“FCA”) action (“Action”) filed under seal in the Eastern District of California by qui tam plaintiff Loyd F. Schmuckley (“Relator”) based on DUR and Code 1 allegations. In July 2016, the Commonwealth of Massachusetts and the District of Columbia also declined to intervene in the Action. On May 15, 2017, Relator and the CADOJ stipulated to dismiss all DUR-related claims and 18 other state-based claims. On September 21, 2017, the CADOJ filed a sealed complaint-in-intervention in the Action, asserting causes under the FCA, for unjust enrichment and for payment by mistake related to the Code 1 allegations. The Action was unsealed on September 26, 2017. On September 28, 2017, Relator filed a First Amended Complaint under the FCA also concerning the Code 1 allegations. The Company filed a motion to dismiss Relator’s and CADOJ’s respective complaints in January 2018, the hearing was held on March 23, 2018. On September 5, 2018, the court issued an order denying the motion to dismiss. The case is proceeding with the first stage of discovery, which focuses on plaintiffs’ proposed sampling methodology for determining liability and damages. The Company’s motion challenging plaintiffs’ proposed sampling methodology will be filed in April 2019, and is scheduled to be heard in June 2019. At this stage of the proceedings, the Company is not able to either predict the outcome of this matter or estimate a potential range of loss with respect to this matter and is vigorously defending this lawsuit. The State of Mississippi, by and through its Attorney General, filed a First Amended Complaint against the Company and various purported related entities on September 27, 2016 alleging violations of the Mississippi Medicaid Fraud Control Act, violations of the Mississippi Unfair and Deceptive Trade Practices Act, fraud and unjust enrichment. The Complaint alleges the Company failed to accurately report usual and customary prices to Mississippi’s Division of Medicaid. On November 14, 2016, the Company filed motions to dismiss based on substantive and jurisdictional grounds, as well as a motion to transfer venue, all of which were stayed pending the resolution of related litigation on appeal. In September 2018, the stay of the case was lifted. On November 28, 2018, the case was transferred to the Circuit Court of Desoto County and consolidated with related cases with similar allegations brought by Mississippi against other chain pharmacies. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit. The Company is a defendant in the consolidated multidistrict litigation proceeding, In re National Prescription Opiate Litigation (Case No. 17-md-2804), pending in the U.S. District Court for the Northern District of Ohio. Various plaintiffs (such as counties, cities, hospitals, and third-party payors) allege claims generally concerning the impacts of widespread opioid abuse against defendants along the pharmaceutical supply chain, including manufacturers, wholesale distributors, and retail pharmacy chains. Since December 2017, nearly all related cases pending in federal district courts have been transferred to this multi-district litigation. Two Ohio lawsuits (referred to as the “Track One” or “bellwether” cases) have been set for trial in the multi-district litigation: The County of Summit, Ohio v. Purdue Pharma L.P., et al ., Case No. 18-OP-45090 (N.D. Ohio); and The County of Cuyahoga v. Purdue Pharma L.P., et al ., Case No. 17-OP45004 (N.D. Ohio). On January 29, 2019, the multi-district litigation court entered an order moving the trial date from September 3, 2019 to October 21, 2019 for the two bellwether cases. On May 25, 2018, the Company and other defendants filed Motions to Dismiss the Complaints in the bellwether cases. On October 5, 2018, the magistrate judge assigned to review these Motions to Dismiss issued a report and recommendation to the district court judge on the multi-district litigation. The magistrate judge recommended granting dismissal of two claims, the common law absolute public nuisance claim and the City of Akron’s public nuisance claim. The report otherwise recommended denying all the defendants’ Motions to Dismiss. The Company filed its objections to the magistrate judge’s report on November 2, 2018 (along with other defendants). In addition, the Company (as well as most of the parties in the litigation) are engaging in intensive discovery involving the production of documents and participating in the depositions of several key individuals representing plaintiffs and defendants. New cases continue to be added each week to the multi-district litigation, which currently includes over 860 relevant federal court lawsuits that name the Company, including lawsuits filed by counties and municipalities in California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Texas, Virginia, West Virginia, and Wisconsin. There are also approximately 113 similar lawsuits that name the Company in some capacity that have been filed outside the multi-district litigation, including lawsuits filed in Georgia, Idaho, Illinois, Louisiana, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Washington, and West Virginia. At this stage of the proceedings, the Company is not able to either predict the outcome of these lawsuits or estimate a potential range of loss with respect to the lawsuits and is vigorously defending them. Additionally, the Company has received from the Attorney Generals of several states subpoenas, civil investigative demands, and/or other requests regarding opioids. The Company is involved in two putative consumer class action lawsuits in the United States District Court for the Southern District of California, alleging that it overcharged customers’ insurance companies for prescription drug purchases, resulting in overpayment of co-pays. The first lawsuit, Byron Stafford v. Rite Aid Corp ., Case No. 17-CV-01340-AJB-JLB, was filed on June 30, 2017, and the second case, Robert Josten v. Rite Aid Corp ., Case No. 18-CV-00152-AJB-JLB, was filed on January 23, 2018. Each lawsuit alleges that (1) the Company was obligated to charge the plaintiffs’ insurance companies a “usual and customary” price for their prescription drugs; and (2) the Company failed to do so properly because the prices it reported were not equal to or adjusted to account for the discount prices that Rite Aid offers to uninsured and underinsured customers through its Rx Savings Program. On December 19, 2017, the court granted the Company’s motion to dismiss Stafford’s complaint with leave to amend for failure to plead compliance with the applicable statutes of limitations. After Stafford amended the complaint on January 9, 2018, the Company filed another motion to dismiss on January 23, 2018, and a similar motion to dismiss Josten’s complaint on March 16, 2018. The court granted the motion to dismiss most of Josten’s claims for failure to plead compliance with the applicable statute of limitations but granted leave to amend. The Company’s motion to dismiss Josten’s amended complaint on the grounds that the statute of limitations expired and he failed to exhaust Medicare administrative remedies, is scheduled to be heard on April 25, 2019. The court denied the motion to dismiss Stafford’s claims, opened discovery and set a June 19, 2019 deadline for his class certification motion. At this stage of the proceedings, the Company is not able to either predict the outcome of these lawsuits or estimate a potential range of loss with respect to the lawsuit and is vigorously defending these lawsuits. In addition to the above described matters, the Company is subject from time to time to various claims and lawsuits and governmental investigations arising in the ordinary course of business. While the Company’s management cannot predict the outcome of any of the claims, the Company’s management does not believe that the outcome of any of these matters will be material to the Company’s consolidated financial position. It is possible, however, that the Company’s results of operations or cash flows could be materially affected by an unfavorable resolution of pending litigation or contingencies.

Supplementary Cash Flow Data

Supplementary Cash Flow Data	12 Months Ended
	Mar. 02, 2019
Supplementary Cash Flow Data
Supplementary Cash Flow Data	22. Supplementary Cash Flow Data Year Ended March 2, March 3, March 4, 2019 2018 2017 Cash paid for interest(a) $ 267,760 $ 405,579 $ 409,692 Cash payments for income taxes, net(a) $ 17,383 $ 87,087 $ 17,081 Equipment financed under capital leases $ 4,165 $ 13,123 $ 7,551 Equipment received for noncash consideration $ — $ 2,044 $ 746 Reduction in lease financing obligation $ — $ 4,740 — Accrued capital expenditures $ 15,298 $ 28,869 $ 27,232 Gross borrowings from revolver(a) $ 4,257,000 $ 4,221,000 $ 3,608,000 Gross repayments to revolver(a) $ 3,382,000 $ 6,651,000 $ 3,278,000 (a)–Amounts are presented on a total company basis. Significant components of cash used by Other Liabilities of $439,906 for the fifty-two week period ended March 2, 2019 includes cash used resulting from changes in accrued reinsurance of $185,761, changes in accrued wages, benefits and other personnel costs of $58,154, changes in accrued interest of $51,219 and changes in accrued sales and other taxes payable of $44,581.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 02, 2019
Related Party Transactions
Related Party Transactions	23. Related Party Transactions There were receivables from related parties of $11 and $21 at March 2, 2019 and March 3, 2018, respectively.

Guarantor and Non-Guarantor Con

Guarantor and Non-Guarantor Condensed Consolidating Financial Information	12 Months Ended
	Mar. 02, 2019
Guarantor and Non-Guarantor Condensed Consolidating Financial Information
Guarantor and Non-Guarantor Condensed Consolidating Financial Information	24. Guarantor and Non-Guarantor Condensed Consolidating Financial Information Rite Aid Corporation conducts the majority of its business through its subsidiaries. With the exception of EIC, substantially all of Rite Aid Corporation’s 100 % owned subsidiaries guarantee the obligations under the New Facilities and unsecured guaranteed notes (the “Subsidiary Guarantors”). Additionally, with the exception of EIC, the subsidiaries, including joint ventures, that do not guarantee the New Facilities and unsecured guaranteed notes, are minor. For the purposes of preparing the information below, Rite Aid Corporation uses the equity method to account for its investment in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in the non-guarantor subsidiaries. The subsidiary guarantees related to the Company’s New Facilities and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several. Presented below is condensed consolidating financial information for Rite Aid Corporation, the Subsidiary Guarantors, and the non-guarantor subsidiaries at March 2, 2019 and March 3, 2018 and for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017. Separate financial statements for Subsidiary Guarantors are not presented. Rite Aid Corporation Condensed Consolidating Balance Sheet March 2, 2019 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) ASSETS Current assets: Cash and cash equivalents $ — $ 122,134 $ 22,219 $ — $ 144,353 Accounts receivable, net — 1,377,342 411,370 — 1,788,712 Intercompany receivable — 400,526 — (400,526) (a) — Inventories, net of LIFO reserve of $0, $604,444, $0, $0, and $604,444 — 1,871,941 — — 1,871,941 Prepaid expenses and other current assets — 172,448 6,684 — 179,132 Current assets held for sale — 117,581 — — 117,581 Total current assets — 4,061,972 440,273 (400,526) 4,101,719 Property, plant and equipment, net — 1,308,514 — — 1,308,514 Goodwill — 1,108,136 — — 1,108,136 Other intangibles, net — 399,678 49,028 — 448,706 Deferred tax assets — 419,122 (10,038) — 409,084 Investment in subsidiaries 8,294,315 55,109 — (8,349,424) (b) — Intercompany receivable — 3,639,035 — (3,639,035) (a) — Other assets — 208,018 7,190 — 215,208 Noncurrent assets held for sale — — — — — Total assets $ 8,294,315 $ 11,199,584 $ 486,453 $ (12,388,985) $ 7,591,367 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ — $ 16,111 $ — $ — $ 16,111 Accounts payable — 1,612,181 6,404 — 1,618,585 Intercompany payable — — 400,526 (400,526) (a) — Accrued salaries, wages and other current liabilities 14,005 778,020 16,414 — 808,439 Total current liabilities 14,005 2,406,312 423,344 (400,526) 2,443,135 Long-term debt, less current maturities 3,454,585 — — — 3,454,585 Lease financing obligations, less current maturities — 24,064 — — 24,064 Intercompany payable 3,639,035 — — (3,639,035) (a) — Other noncurrent liabilities — 474,893 8,000 — 482,893 Total liabilities 7,107,625 2,905,269 431,344 (4,039,561) 6,404,677 Commitments and contingencies — — — — — Total stockholders’ equity 1,186,690 8,294,315 55,109 (8,349,424) (b) 1,186,690 Total liabilities and stockholders’ equity $ 8,294,315 $ 11,199,584 $ 486,453 $ (12,388,985) $ 7,591,367 (a) Elimination of intercompany accounts receivable and accounts payable amounts. (b) Elimination of investments in consolidated subsidiaries. Rite Aid Corporation Condensed Consolidating Balance Sheet March 3, 2018 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) ASSETS Current assets: Cash and cash equivalents $ — $ 441,244 $ 6,090 $ — $ 447,334 Accounts receivable, net — 1,502,507 366,593 — 1,869,100 Intercompany receivable 223,413 — (223,413) (a) — Inventories, net of LIFO reserve of $0, $581,090, $0, $0, and $581,090 — 1,799,539 — — 1,799,539 Prepaid expenses and other current assets — 176,678 4,503 — 181,181 Current assets held for sale — 438,137 — — 438,137 Total current assets — 4,581,518 377,186 (223,413) 4,735,291 Property, plant and equipment, net — 1,431,246 — — 1,431,246 Goodwill — 1,421,120 — — 1,421,120 Other intangibles, net — 539,115 51,328 — 590,443 Deferred tax assets — 594,019 — — 594,019 Investment in subsidiaries 8,745,390 54,076 — (8,799,466) (b) — Intercompany receivable — 3,189,419 — (3,189,419) (a) — Other assets — 209,926 7,282 — 217,208 Noncurrent assets held for sale — — — — — Total assets $ 8,745,390 $ 12,020,439 $ 435,796 $ (12,212,298) $ 8,989,327 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ 90 $ 20,671 $ — $ — $ 20,761 Accounts payable — 1,641,676 9,687 — 1,651,363 Intercompany payable — — 223,413 (223,413) (a) — Accrued salaries, wages and other current liabilities 65,223 1,031,379 135,134 — 1,231,736 Current liabilities held for sale 549,549 10,656 — — 560,205 Total current liabilities 614,862 2,704,382 368,234 (223,413) 3,464,065 Long-term debt, less current maturities 3,340,099 — — — 3,340,099 Lease financing obligations, less current maturities — 30,775 — — 30,775 Intercompany payable 3,189,419 — — (3,189,419) (a) — Other noncurrent liabilities — 539,892 13,486 — 553,378 Noncurrent liabilities held for sale — — — — — Total liabilities 7,144,380 3,275,049 381,720 (3,412,832) 7,388,317 Commitments and contingencies — — — — — Total stockholders’ equity 1,601,010 8,745,390 54,076 (8,799,466) (b) 1,601,010 Total liabilities and stockholders’ equity $ 8,745,390 $ 12,020,439 $ 435,796 $ (12,212,298) $ 8,989,327 (a) Elimination of intercompany accounts receivable and accounts payable amounts. (b) Elimination of investments in consolidated subsidiaries. Rite Aid Corporation Condensed Consolidating Statement of Operations For the Year Ended March 2, 2019 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Revenues $ — $ 21,297,937 $ 397,328 $ (55,708) (a) $ 21,639,557 Costs and expenses: Cost of revenues — 16,648,099 370,413 (55,307) (a) 16,963,205 Selling, general and administrative expenses — 4,567,690 25,086 (401) (a) 4,592,375 Lease termination and impairment expenses — 107,994 — — 107,994 Goodwill and intangible asset impairment charges — 375,190 — — 375,190 Interest expense 206,862 21,704 (838) — 227,728 Loss on debt retirements — 554 — — 554 Gain on sale of assets, net — (38,012) — — (38,012) Equity in earnings of subsidiaries, net of tax 210,736 (1,033) — (209,703) (b) — 417,598 21,682,186 394,661 (265,411) 22,229,034 Income (loss) from continuing operations before income taxes (417,598) (384,249) 2,667 209,703 (589,477) Income tax expense (benefit) — 75,843 1,634 — 77,477 Net income (loss) from continuing operations (417,598) (460,092) 1,033 209,703 (666,954) Net income (loss) from discontinued operations (4,615) 249,356 — — 244,741 Net income (loss) $ (422,213) $ (210,736) $ 1,033 $ 209,703 (b) $ (422,213) Total other comprehensive income (loss) 3,490 3,490 — (3,490) 3,490 Comprehensive income (loss) $ (418,723) $ (207,246) $ 1,033 $ 206,213 $ (418,723) Rite Aid Corporation Condensed Consolidating Statement of Operations For the Year Ended March 3, 2018 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Revenues $ — $ 21,413,734 $ 209,356 $ (94,122) (a) $ 21,528,968 Costs and expenses: Cost of revenues — 16,645,136 197,084 (93,357) (a) 16,748,863 Selling, general and administrative expenses — 4,635,531 16,496 (765) (a) 4,651,262 Lease termination and impairment expenses — 58,765 — — 58,765 Goodwill and intangible asset impairment charges — 261,727 — — 261,727 Interest expense 183,825 19,261 (318) — 202,768 Walgreens Boots Alliance, Inc. termination fee (325,000) — — — (325,000) Gain on sale of assets, net — (25,872) — — (25,872) Equity in earnings of subsidiaries, net of tax (1,034,775) (4,072) — 1,038,847 (b) — (1,175,950) 21,590,476 213,262 944,725 21,572,513 Income (loss) from continuing operations before income taxes 1,175,950 (176,742) (3,906) (1,038,847) (43,545) Income tax expense (benefit) — 313,965 (7,978) — 305,987 Net income (loss) from continuing operations 1,175,950 (490,707) 4,072 (1,038,847) (349,532) Net income (loss) from discontinued operations (232,480) 1,525,482 — — 1,293,002 Net income (loss) $ 943,470 $ 1,034,775 $ 4,072 $ (1,038,847) (b) $ 943,470 Total other comprehensive income (loss) 7,255 7,255 — (7,255) 7,255 Comprehensive income (loss) $ 950,725 $ 1,042,030 $ 4,072 $ (1,046,102) $ 950,725 (a) Elimination of intercompany revenues and expenses. (b) Elimination of equity in earnings of subsidiaries. Rite Aid Corporation Condensed Consolidating Statement of Operations For the Year Ended March 4, 2017 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Revenues $ — $ 22,821,940 $ 223,077 $ (117,477) (a) $ 22,927,540 Costs and expenses: Cost of revenues — 17,767,363 213,225 (117,755) (a) 17,862,833 Selling, general and administrative expenses — 4,763,176 13,541 278 (a) 4,776,995 Lease termination and impairment expenses — 45,778 — — 45,778 Interest expense 182,282 17,796 (13) — 200,065 Gain on sale of assets, net — (6,649) — — (6,649) Equity in earnings of subsidiaries, net of tax (418,261) 5,101 — 413,160 (b) — (235,979) 22,592,565 226,753 295,683 22,879,022 Income (loss) before income taxes 235,979 229,375 (3,676) (413,160) 48,518 Income tax expense — 43,013 1,425 — 44,438 Net income (loss) from continuing operations 235,979 186,362 (5,101) (413,160) (b) 4,080 Net income (loss) from discontinued operations (231,926) 231,899 — — (27) Net income (loss) $ 4,053 $ 418,261 $ (5,101) $ (413,160) $ 4,053 Total other comprehensive income (loss) 5,464 5,464 — (5,464) 5,464 Comprehensive income (loss) $ 9,517 $ 423,725 $ (5,101) $ (418,624) $ 9,517 (a) (b) Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended March 2, 2019 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Operating activities: Net cash (used in) provided by operating activities $ (255,962) $ 74,124 $ 16,129 $ — $ (165,709) Investing activities: Payments for property, plant and equipment — (196,778) — — (196,778) Intangible assets acquired — (47,911) — — (47,911) Intercompany activity — (727,221) — 727,221 — Proceeds from sale-leaseback transactions — 2,587 — — 2,587 Proceeds from dispositions of assets and investments — 43,550 — — 43,550 Net cash (used in) provided by investing activities — (925,773) — 727,221 (198,552) Financing activities: Proceeds from issuance of long-term debt 450,000 — — — 450,000 Net proceeds from revolver 875,000 — — — 875,000 Principal payments on long-term debt (427,992) (12,378) — — (440,370) Change in zero balance cash accounts — (59,481) — — (59,481) Net proceeds from issuance of common stock 2,294 — — — 2,294 Financing fees paid for early debt redemption — (171) — — (171) Payments for taxes related to net share settlement of equity awards — (2,419) — — (2,419) Intercompany activity 727,221 — — (727,221) — Deferred financing costs paid (21,564) — — — (21,564) Net cash provided by (used in) financing activities 1,604,959 (74,449) — (727,221) 803,289 Cash flows of discontinued operations: Operating activities of discontinued operations (4,615) (58,341) — — (62,956) Investing activities of discontinued operations — 664,740 — — 664,740 Financing activities of discontinued operations (1,344,382) 589 — — (1,343,793) Net cash provided by (used in) discontinued operations (1,348,997) 606,988 — — (742,009) (Decrease) increase in cash and cash equivalents — (319,110) 16,129 — (302,981) Cash and cash equivalents, beginning of period — 441,244 6,090 — 447,334 Cash and cash equivalents, end of period $ — $ 122,134 $ 22,219 $ — $ 144,353 Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended March 3, 2018 Rite Aid Corporation (Parent Non- Company Subsidiary Guarantor Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Operating activities: Net cash provided by (used in) operating activities $ 158,247 $ 379,439 $ (26,216) $ — $ 511,470 Investing activities: Payments for property, plant and equipment — (185,879) — — (185,879) Intangible assets acquired — (28,885) — — (28,885) Intercompany activity — (3,460,291) — 3,460,291 — Proceeds from insured loss — 4,239 — — 4,239 Proceeds from dispositions of assets and investments — 27,586 — — 27,586 Net cash (used in) provided by investing activities — (3,643,230) — 3,460,291 (182,939) Financing activities: Net payments to revolver (265,000) — — — (265,000) Principal payments on long-term debt — (9,882) — — (9,882) Change in zero balance cash accounts — 35,605 — — 35,605 Net proceeds from issuance of common stock 5,796 — — — 5,796 Payments for taxes related to net share settlement of equity awards — (4,103) — — (4,103) Intercompany activity 3,460,291 — — (3,460,291) — Net cash provided by (used in) financing activities 3,201,087 21,620 — (3,460,291) (237,584) Cash flows of discontinued operations: Operating activities of discontinued operations (224,300) (20,826) — — (245,126) Investing activities of discontinued operations — 3,496,222 — — 3,496,222 Financing activities of discontinued operations (3,135,034) (5,085) — — (3,140,119) Net cash provided by (used in) discontinued operations (3,359,334) 3,470,311 — — 110,977 (Decrease) increase in cash and cash equivalents — 228,140 (26,216) — 201,924 Cash and cash equivalents, beginning of period — 213,104 32,306 — 245,410 Cash and cash equivalents, end of period $ — $ 441,244 $ 6,090 $ — $ 447,334 Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended March 4, 2017 Rite Aid Corporation (Parent Non- Company Subsidiary Guarantor Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Operating activities: Net cash (used in) provided by operating activities $ (162,842) $ 347,465 $ (1,596) $ — $ 183,027 Investing activities: Payments for property, plant and equipment — (254,149) — — (254,149) Intangible assets acquired — (39,648) — — (39,648) Intercompany activity — (57,817) — 57,817 — Proceeds from dispositions of assets and investments — 16,852 — — 16,852 Net cash (used in) provided by investing activities — (334,762) — 57,817 (276,945) Financing activities: Net proceeds from revolver 330,000 — — — 330,000 Principal payments on long-term debt — (16,588) — — (16,588) Change in zero balance cash accounts — 43,080 — — 43,080 Net proceeds from issuance of common stock 6,951 — — — 6,951 Excess tax benefit on stock options and restricted stock — 543 — — 543 Payments for taxes related to net share settlement of equity awards — (6,254) — — (6,254) Intercompany activity 57,817 — — (57,817) — Net cash provided by (used in) financing activities 394,768 20,781 — (57,817) 357,732 Cash flows of discontinued operations: Operating activities of discontinued operations (231,926) 281,016 — — 49,090 Investing activities of discontinued operations — (187,314) — — (187,314) Financing activities of discontinued operations — (4,651) — — (4,651) Net cash provided by (used in) discontinued operations (231,926) 89,051 — — (142,875) Increase (decrease) in cash and cash equivalents — 122,535 (1,596) — 120,939 Cash and cash equivalents, beginning of period — 90,569 33,902 — 124,471 Cash and cash equivalents, end of period $ — $ 213,104 $ 32,306 $ — $ 245,410

Interim Financial Results (Unau

Interim Financial Results (Unaudited)	12 Months Ended
	Mar. 02, 2019
Interim Financial Results (Unaudited)
Interim Financial Results (Unaudited)	25. Interim Financial Results (Unaudited) Fiscal Year 2019 First Second Third Fourth Quarter(a) Quarter(a) Quarter Quarter Year Revenues $ 5,388,490 $ 5,421,362 $ 5,450,060 $ 5,379,645 $ 21,639,557 Cost of revenues 4,219,741 4,260,211 4,267,972 4,215,281 16,963,205 Selling, general and administrative expenses 1,152,627 1,153,991 1,142,555 1,143,202 4,592,375 Lease termination and impairment charges 9,859 39,609 2,628 55,898 107,994 Goodwill and intangible asset impairment charges — 375,190 — — 375,190 Interest expense 62,792 56,233 56,008 52,695 227,728 Loss on debt retirements, net 554 — — — 554 Gain on sale of assets, net (5,859) (4,965) (382) (26,806) (38,012) 5,439,714 5,880,269 5,468,781 5,440,270 22,229,034 Loss from continuing operations before income taxes (51,224) (458,907) (18,721) (60,625) (589,477) Income tax (benefit) expense (9,497) (106,559) (1,471) 195,004 77,477 Loss from continuing operations (41,727) (352,348) (17,250) (255,629) (666,954) Net income (loss) from discontinued operations, net of tax 256,143 (6,792) 12,740 (17,350) 244,741 Net income (loss) 214,416 (359,140) (4,510) (272,979) (422,213) Basic and diluted income (loss) per share(a): Continuing operations $ (0.79) $ (6.67) $ (0.33) $ (4.83) $ (12.62) Discontinued operations $ 4.86 $ (0.13) $ 0.24 $ (0.32) $ 4.63 Net basic and diluted income (loss) per share $ 4.07 $ (6.80) $ (0.09) $ (5.15) $ (7.99) Fiscal Year 2018 First Second Third Fourth Quarter Quarter Quarter Quarter Year Revenues $ 5,436,523 $ 5,345,011 $ 5,353,170 $ 5,394,264 $ 21,528,968 Cost of revenues 4,274,580 4,183,338 4,166,447 4,124,498 16,748,863 Selling, general and administrative expenses 1,160,940 1,141,844 1,166,514 1,181,964 4,651,262 Lease termination and impairment charges 4,038 3,113 3,939 47,675 58,765 Goodwill impairment — — — 261,727 261,727 Interest expense 51,000 50,857 50,308 50,603 202,768 Walgreens Boots Alliance merger termination fee — (325,000) — — (325,000) Loss (gain) on sale of assets, net (5,877) (14,951) 205 (5,249) (25,872) 5,484,681 5,039,201 5,387,413 5,661,218 21,572,513 (Loss) income from continuing operations before income taxes (48,158) 305,810 (34,243) (266,954) (43,545) Income tax (benefit) expense (12,121) 117,450 (16,061) 216,719 305,987 Net (loss) income from continuing operations (36,037) 188,360 (18,182) (483,673) (349,532) Net (loss) income from discontinued operations, net of tax (39,312) (17,644) 99,213 1,250,745 1,293,002 Net (loss) income $ (75,349) $ 170,716 $ 81,031 $ 767,072 $ 943,470 Basic (loss) income per share(a): Continuing operations $ (0.69) $ 3.59 $ (0.35) $ (9.18) $ (6.66) Discontinued operations $ (0.75) $ (0.33) $ 1.90 $ 23.74 $ 24.64 Net basic (loss) income per share $ (1.44) $ 3.26 $ 1.55 $ 14.56 $ 17.98 Diluted (loss) income per share(a): Continuing operations $ (0.69) $ 3.53 $ (0.35) $ (9.18) $ (6.66) Discontinued operations $ (0.75) $ (0.33) $ 1.90 $ 23.74 $ 24.64 Net diluted (loss) income per share $ (1.44) $ 3.20 $ 1.55 $ 14.56 $ 17.98 (a) Income per share amounts for each quarter may not necessarily total to the yearly income per share due to the weighting of shares outstanding on a quarterly and year-to-date basis. During the fourth quarter of fiscal 2019, the Company recorded an income tax expense of $212,252 in connection with the revaluation of the Company’s deferred tax assets resulting from an increase in the valuation allowance as discussed in Note 7 and facilities impairment charges of $28,920. Also, during the fourth quarter of fiscal 2019, the Company recorded a LIFO charge of $4,043 due to higher inflation on pharmaceutical drugs as compared to a LIFO credit recognized at prior year end caused by deflation on pharmacy generics. During the fourth quarter of fiscal 2018, the Company recorded an income tax expense of $324,765 in connection with the revaluation of the Company’s deferred tax assets as a result of the Tax Act as discussed in Note 7, a goodwill impairment charge of $261,727 ($191,000 net of the related income tax benefit), and facilities impairment charges of $36,927. Also, during the fourth quarter of fiscal 2018, the Company recorded a LIFO credit of $49,220 due to higher deflation on pharmacy generics as compared to a LIFO credit recognized at prior year end caused by lower deflation on pharmacy generics.

Financial Instruments

Financial Instruments	12 Months Ended
	Mar. 02, 2019
Financial Instruments
Financial Instruments	26. Financial Instruments The carrying amounts and fair values of financial instruments at March 2, 2019 and March 3, 2018 are listed as follows: 2019 2018 Carrying Fair Carrying Fair Amount Value Amount Value Variable rate indebtedness $ 1,297,013 $ 1,325,000 $ — $ — Fixed rate indebtedness $ 2,157,571 $ 1,795,335 $ 3,905,841 $ 3,927,411 Cash, trade receivables and trade payables are carried at market value, which approximates their fair values due to the short-term maturity of these instruments. In addition, as of March 2, 2019 and March 3, 2018, the Company had $7,191 and $7,282, respectively, of investments carried at amortized cost, as these investments are being held to maturity. As of March 2, 2019, these investments are included as a component of prepaid expenses and other current assets. As of March 3, 2018, these investments are included as a component of other assets. The Company believes the carrying value of these investments approximates their fair value. The following methods and assumptions were used in estimating fair value disclosures for financial instruments: LIBOR‑based borrowings under credit facilities: The carrying amounts for LIBOR‑based borrowings under the credit facilities and term notes are estimated based on the quoted market price of the financial instruments. Long‑term indebtedness: The fair values of long‑term indebtedness are estimated based on the quoted market prices of the financial instruments. If quoted market prices were not available, the Company estimated the fair value based on the quoted market price of a financial instrument with similar characteristics.

SCHEDULE II-VALUATION AND QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Mar. 02, 2019
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS For the Years Ended March 2, 2019, March 3, 2018, and March 4, 2017 (dollars in thousands) Additions Balance at Charged to Balance at Allowances deducted from accounts receivable for estimated Beginning Costs and End of uncollectible amounts: of Period Expenses Deductions Period Year ended March 2, 2019 $ 25,134 $ 48,728 $ 60,756 $ 13,106 Year ended March 3, 2018 $ 30,891 $ 94,006 $ 99,763 $ 25,134 Year ended March 4, 2017 $ 32,820 $ 72,876 $ 74,805 $ 30,891

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 02, 2019
Summary of Significant Accounting Policies
Fiscal Year	Fiscal Year The Company’s fiscal year ends on the Saturday closest to February 29 or March 1. The fiscal year ended March 2, 2019 included 52 weeks. The fiscal year ended March 3, 2018 included 52 weeks. The fiscal year ended March 4, 2017 included 53 weeks.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its 100% owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and highly liquid investments, which are readily convertible to known amounts of cash and which have original maturities of three months or less when purchased.
Allowance for Uncollectible Receivables	Allowance for Uncollectible Receivables Substantially all prescription sales are made to customers who are covered by third‑party payors, such as insurance companies, government agencies and employers. The Company recognizes receivables that represent the amount owed to the Company for sales made to customers or employees of those payors that have not yet been paid. The Company maintains a reserve for the amount of these receivables deemed to be uncollectible. This reserve is calculated based upon historical collection activity adjusted for current conditions.
Inventories	Inventories Inventories are stated at the lower of cost or market. Inventory balances include the capitalization of certain costs related to purchasing, freight and handling costs associated with placing inventory in its location and condition for sale. The Company uses the last‑in, first‑out (“LIFO”) cost flow assumption for substantially all of its inventories. The Company calculates its inflation index based on internal product mix and utilizes the link‑chain LIFO method.
Impairment of Long-Lived Assets	Impairment of Long‑Lived Assets Asset impairments are recorded when the carrying value of assets are not recoverable. For purposes of recognizing and measuring impairment of long‑lived assets, the Company categorizes assets of operating stores as “Assets to Be Held and Used” and “Assets to Be Disposed Of.” The Company evaluates assets at the store level because this is the lowest level of identifiable cash flows ascertainable to evaluate impairment. Assets being tested for recoverability at the store level include tangible long‑lived assets and identifiable, finite‑lived intangibles that arose in purchase business combinations. Corporate assets to be held and used are evaluated for impairment based on excess cash flows from the stores that support those assets. The Company reviews long‑lived assets to be held and used for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the undiscounted expected future cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss. Impairment losses are measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risks associated with the recovery of the asset.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. The Company provides for depreciation using the straight‑line method over the following useful lives: buildings—30 to 45 years; equipment—3 to 15 years. Leasehold improvements are amortized on a straight‑line basis over the shorter of the estimated useful life of the asset or the term of the lease. When determining the amortization period of a leasehold improvement, the Company considers whether discretionary exercise of a lease renewal option is reasonably assured. If it is determined that the exercise of such option is reasonably assured, the Company will amortize the leasehold improvement asset over the minimum lease term, plus the option period. This determination depends on the remaining life of the minimum lease term and any economic penalties that would be incurred if the lease option is not exercised. Capitalized lease assets are recorded at the lesser of the present value of minimum lease payments or fair market value and amortized over the estimated useful life of the related property or term of the lease. The Company capitalizes direct internal and external development costs associated with internal‑use software. Neither preliminary evaluation costs nor costs associated with the software after implementation are capitalized. For fiscal years 2019, 2018 and 2017, the Company capitalized costs of approximately $13,716, $13,940 and $6,189, respectively.
Goodwill	Goodwill The Company recognizes goodwill as the excess of the purchase price over the fair value of the assets acquired and liabilities assumed during business combinations. The Company accounts for goodwill under ASC Topic 350, “Intangibles—Goodwill and Other”, which does not permit amortization, but instead requires the Company to perform an annual impairment review, or more frequently if events or circumstances indicate that impairment may be more likely. See Note 13 for additional information on goodwill.
Intangible Assets	Intangible Assets The Company has certain finite‑lived intangible assets that are amortized over their useful lives. The value of favorable and unfavorable leases on stores acquired in business combinations are amortized over the terms of the leases on a straight‑line basis. Prescription files acquired in business combinations are amortized over an estimated useful life of ten years on an accelerated basis, which approximates the anticipated prescription file retention and related cash flows. Purchased prescription files acquired in other than business combinations are amortized over their estimated useful lives of five years on a straight‑line basis. The value of finite-lived trade names are amortized over 10 years on a straight-line basis. The value of customer relationships, acquired in connection with the Company’s acquisition of EnvisionRx, are amortized over a period between 10 and 20 years on a descending percentage method which matches the pattern of expected discounted cash flows. The Pharmacy Services segment’s contract with Centers for Medicare and Medicaid Services (“CMS”) for Medicare Part D (“Part D”), which is required in order to act as a national provider of the Part D benefit, is amortized over 25 years on a straight line basis.
Indefinite lifed assets	Indefinite lifed assets The Company has a single indefinite-lived intangible asset consisting of a trade name. Intangible assets that are determined to have an indefinite life are not amortized, but are required to be evaluated at least annually for impairment. If the carrying value of an individual indefinite-lived intangible asset exceeds its fair value, such individual indefinite-lived intangible asset is impaired by the amount of the excess.
Deferred Financing Costs	Deferred Financing Costs Costs incurred to issue debt are deferred and amortized as a component of interest expense over the terms of the related debt agreements. Amortization expense of deferred financing costs was $10,761, $8,403 and $4,696 for fiscal 2019, 2018 and 2017, respectively.
Revenue Recognition	Revenue Recognition Retail Pharmacy Segment For front-end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front-end transactions. The Retail Pharmacy segment front-end revenue is measured based on the amount of fixed consideration that we expect to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented. For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product. Each prescription claim represents an individual arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims. The Company's revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile. The effect of adjustments between estimated and actual amounts have not been material to the Company's results of operations or financial position. Prescriptions are generally not returnable. The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program. Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front-end merchandise purchases and qualifying prescription purchases. One point is awarded for each dollar spent towards front-end merchandise and 25 points are awarded for each qualifying prescription. Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front-end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar “Silver” level with a lower threshold and benefit level. Points earned pursuant to the wellness+ program represent a performance obligation and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As members receive discounted front-end merchandise or when the benefit period expires, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $63,720 as of March 2, 2019, of which $51,042 is included in other current liabilities and $12,678 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,851 as of March 3, 2018, of which $50,036 is included in other current liabilities and $13,815 is included in noncurrent liabilities. The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness+ Rewards members have the opportunity to redeem their accumulated Bonus Cash on a future purchase with a 60 day expiration window. For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until (i) wellness + Rewards members redeem their Bonus Cash, or (ii) wellness + Rewards members allow the Bonus Cash to expire. Upon utilization or expiration of the benefit period, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires. Pharmacy Services Segment The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order prescriptions (“Mail Co-Payments”), (iii) client plan member copayments made directly to the retail pharmacy network and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type. The following revenue recognition policies have been established for the Pharmacy Services segment: · Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system. At this point the Company has performed all of its performance obligations. · Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the client plan members. The Pharmacy Services segment does not experience a significant level of returns or reshipments. · Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee. In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. In the majority of these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues. Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues. For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized. Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts. Medicare Part D—The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 9, Medicare Part D. Disaggregation of Revenue The following tables disaggregate the Company’s revenue by major source in each segment for the fiscal year ended March 2, 2019: In thousands March 2, 2019 Retail Pharmacy segment: Pharmacy sales $ 10,391,539 Front-end sales 5,215,152 Other revenue 150,461 Total Retail Pharmacy segment 15,757,152 Pharmacy Services segment 6,093,688 Intersegment elimination (211,283) Total revenue $ 21,639,557 Impact of New Revenue Recognition Standard on Financial Statement Line Items The Company adopted the new revenue standard using the modified retrospective method. The cumulative effect of applying the new standard to all contracts was recorded as an adjustment to accumulated deficit as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue standard, the following adjustments were made to accounts on the consolidated balance sheet as of March 4, 2018: Impact of Change in Accounting Policy As Reported Adjusted In thousands March 3, 2018 Adjustments March 4, 2018 Consolidated Balance Sheet: Accounts receivable, net $ 1,869,100 $ (57,897) $ 1,811,203 Inventories, net 1,799,539 51,121 1,850,660 Deferred tax assets 594,019 (1,784) 592,235 Total assets 8,989,327 (8,560) 8,980,767 Accumulated deficit (4,282,471) (8,560) (4,291,031) Total shareholders’ equity 1,601,010 (8,560) 1,592,450 See Note 20 for additional information about the revenues of the Company’s business segments.
Cost of Revenues	Cost of Revenues Retail Pharmacy Segment Cost of revenues for the Retail Pharmacy segment includes the following: the cost of inventory sold during the period, including related vendor rebates and allowances, LIFO credit or charges, costs incurred to return merchandise to vendors, inventory shrink, purchasing costs and warehousing costs, which include inbound freight costs from the vendor, distribution payroll and benefit costs, distribution center occupancy costs and depreciation expense and delivery expenses to the stores. Pharmacy Services Segment The Pharmacy Services segment’s cost of revenues includes the cost of prescription drugs sold during the reporting period indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The cost of prescription drugs sold component of cost of revenues includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Pharmacy Services segment’s mail service dispensing pharmacy, net of any volume-related or other discounts (see the section entitled “Vendor Rebates and Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold through the Pharmacy Services segment’s retail pharmacy network under contracts where it is the principal, net of any volume-related or other discounts. See Note 20 for additional information about the cost of revenues of the Company’s business segments. Vendor Rebates and Allowances and Purchase Discounts Retail Pharmacy Segment The Retail Pharmacy segment rebates and allowances received from vendors relate to either buying and merchandising or promoting the product. Buying and merchandising related rebates and allowances are recorded as a reduction of cost of revenue as product is sold. Buying and merchandising rebates and allowances include all types of vendor programs such as cash discounts from timely payment of invoices, purchase discounts or rebates, volume purchase allowances, price reduction allowances and slotting allowances. Certain product promotion related rebates and allowances, primarily related to advertising, are recorded as a reduction in selling, general and administrative expenses when the advertising commitment has been satisfied. Pharmacy Services Segment The Pharmacy Services segment receives purchase discounts on products purchased. The Pharmacy Services segment’s contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, or (ii) a discount (or rebate) paid subsequent to dispensing when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy). These rebates are recognized when prescriptions are dispensed and are generally billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Pharmacy Services segment’s results of operations. The Pharmacy Services segment accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts and fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of revenues.
Reinsurance	Reinsurance To minimize risk and statutory capital requirements, EIC enters into quota share reinsurance agreements with unaffiliated reinsurers whereby they assume a quota share percentage of the Company’s Medicare Part D program. The net revenue and net cost of revenue for EIC has been reduced by the amounts ceded to reinsurers under these agreements. EIC does not have a reinsurance agreement in place for its individual and most of its group prescription drug policies for calendar 2018 and calendar 2019. EIC has quota share reinsurance for certain group prescription drug policies for calendar 2018 and calendar 2019.
Rent	Rent The Company records rent expense on operating leases on a straight‑line basis over the minimum lease term. The Company begins to record rent expense at the time that the Company has the right to use the property. From time to time, the Company receives incentive payments from landlords that subsidize lease improvement construction. These leasehold incentives are deferred and recognized on a straight‑line basis over the minimum lease term.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses Selling, general and administrative expenses include store and corporate administrative payroll and benefit costs, occupancy costs which include retail store and corporate rent costs, facility and leasehold improvement depreciation and utility costs, advertising, repair and maintenance, insurance, equipment depreciation and professional fees.
Repairs and Maintenance	Repairs and Maintenance Routine repairs and maintenance are charged to operations as incurred. Improvements and major repairs, which extend the useful life of an asset, are capitalized and depreciated.
Advertising	Advertising Advertising costs, net of specific vendor advertising allowances, are expensed in the period the advertisement first takes place. Advertising expenses, net of vendor advertising allowances, for fiscal 2019, 2018 and 2017 were $147,519, $161,826 and $181,438, respectively.
Insurance	Insurance The Company is self‑insured for certain general liability and workers’ compensation claims. For claims that are self‑insured, stop‑loss insurance coverage is maintained for workers’ compensation occurrences exceeding $1,000 and general liability occurrences exceeding $3,000. The Company utilizes actuarial studies as the basis for developing reported claims and estimating claims incurred but not reported relating to the Company’s self‑insurance. Workers’ compensation claims are discounted to present value using a risk‑free interest rate.
Benefit Plan Accruals	Benefit Plan Accruals The Company has several defined benefit plans, under which participants earn a retirement benefit based upon a formula set forth in the plan. The Company records expense related to these plans using actuarially determined amounts that are calculated under the provisions of ASC 715, “Compensation—Retirement Benefits.” Key assumptions used in the actuarial valuations include the discount rate, the expected rate of return on plan assets and the rate of increase in future compensation levels.
Stock-Based Compensation	Stock‑Based Compensation The Company has several stock option plans, which are described in detail in Note 17. The Company accounts for stock‑based compensation under ASC 718, “Compensation—Stock Compensation.” The Company recognizes option expense over the requisite service period of the award, net of an estimate for the impact of award forfeitures.
Store Pre-opening Expenses	Store Pre‑opening Expenses Costs incurred prior to the opening of a new or relocated store, associated with a remodeled store or related to the opening of a distribution facility are charged against earnings when incurred.
Litigation Reserves	Litigation Reserves The Company is involved in litigation on an ongoing basis. The Company accrues its best estimate of the probable loss related to legal claims. Such estimates are developed in consultation with in‑house counsel, and are based upon a combination of litigation and settlement strategies.
Facility Closing Costs and Lease Exit Charges	Facility Closing Costs and Lease Exit Charges When a store or distribution center is closed, the Company records an expense for unrecoverable costs and accrues a liability equal to the present value at current credit adjusted risk‑free interest rates of the remaining lease obligations and anticipated ancillary occupancy costs, net of estimated sublease income. Other store or distribution center closing and liquidation costs are expensed when incurred.
Income Taxes	Income Taxes Deferred income taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities. Deferred income tax expense (benefit) represents the change during the reporting period in the deferred tax assets and deferred tax liabilities, net of the effect of acquisitions and dispositions. Deferred tax assets include tax loss and credit carryforwards and are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion of the deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. The Company has net operating loss (“NOL”) carryforwards that can be utilized to offset future income for federal and state tax purposes. These NOLs generate a significant deferred tax asset. The Company regularly reviews the deferred tax assets for recoverability considering historical profitability, projected taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. The Company recognizes tax liabilities in accordance with ASC 740, “Income Taxes” and the Company adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities. The Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017, among other things, permanently lowered the statutory federal corporate tax rate from 35% to 21%, effective for tax years including or beginning January 1, 2018. Under the guidance of ASC 740, “Income Taxes” (“ASC 740”), the Company re-measured its net deferred tax assets on the date of enactment based on the reduction in the overall future tax benefit expected to be realized at the lower tax rate implemented by the new legislation.
Sales Tax Collected	Sales Tax Collected Sales taxes collected from customers and remitted to various governmental agencies are presented on a net basis (excluded from revenues) in the Company’s statement of operations.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Significant Concentrations	Significant Concentrations Retail Pharmacy Segment The Company’s pharmacy sales were primarily to customers covered by health plan contracts, which typically contract with a third party payor that agrees to pay for all or a portion of a customer’s eligible prescription purchases. During fiscal 2019, the top five third party payors accounted for approximately 80.4% of the Company’s pharmacy sales. The largest third party payor, Caremark, represented 28.3% and 27.2% of pharmacy sales during fiscal 2019 and fiscal 2018, respectively. The largest third party payor during fiscal 2017, Express Scripts, represented 26.0% of pharmacy sales. Third party payors are entities such as an insurance company, governmental agency, health maintenance organization or other managed care provider, and typically represent several health care contracts and customers. During fiscal 2019, state sponsored Medicaid agencies and related managed care Medicaid payors accounted for approximately 19.1% of the Company’s pharmacy sales, the largest of which was approximately 1.8% of the Company’s pharmacy sales. During fiscal 2019, approximately 35.8% of the Company’s pharmacy sales were to customers covered by Medicare Part D. Any significant loss of third- party payor business could have a material adverse effect on the Company’s business and results of operations. During fiscal 2019, the Company purchased brand and generic pharmaceuticals, which amounted to approximately 99.0% of the dollar volume of its prescription drugs from McKesson Corporation (“McKesson”) under its expanded agreement executed on February 17, 2014 and amended in fiscal 2019 for our pharmaceutical purchasing and distribution whereby McKesson assumed responsibility for purchasing essentially all of the brand and generic medications the Company dispenses as well as providing a new direct store delivery model to all of the Company’s stores. If the Company’s relationship with McKesson was disrupted, it could temporarily have difficulty filling prescriptions for brand-named and generic drugs until it executed a replacement wholesaler agreement or developed and implemented self-distribution processes. Pharmacy Services Segment The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a PDP. During fiscal 2019, fiscal 2018 and fiscal 2017, net revenues of $391,024 (1.8% of consolidated revenues), $203,361 ( 1.0% of consolidated revenues) and $223,077 ( 1.0% of consolidated revenues), respectively, include insurance premiums earned by the PDP, which are determined based on the PDP’s annual bid and related contractual arrangements with CMS. EIC had previously entered into a quota share reinsurance agreement with Swiss Re Life & Health America Inc. (“Swiss Re”) whereby they assume a quota share percentage of the Company’s Medicare Part D program. Fifty percent of the net revenue and net cost of revenue for EIC has been ceded to Swiss Re under this agreement. EIC does not have a reinsurance agreement in place for its individual and most of its group prescription drug policies for calendar 2018 and calendar 2019. EIC has quota share reinsurance for certain group prescription drug policies for calendar 2018 and calendar 2019.
Derivatives	Derivatives The Company may enter into interest rate swap agreements to hedge the exposure to increasing rates with respect to its variable rate debt, when the Company deems it prudent to do so. Upon inception of interest rate swap or cap agreements, or modifications thereto, the Company performs a comprehensive review of the interest rate swap agreements based on the criteria as provided by ASC 815, “Derivatives and Hedging.” As of March 2, 2019 and March 3, 2018, the Company had no interest rate swap arrangements or other derivatives. On March 15, 2019, the Company entered into an interest rate cap ("Cap"), which has been assigned to the variable interest rate payments on the first $650.0 million notional amount of variable rate indebtedness. The Cap has an effective date of March 21, 2019 and expires on March 21, 2021. The Cap provides the Company with interest rate protection in the event that LIBOR increases above 2.75%.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU No. 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU No. 2016-08, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net), which amends the principal-versus-agent implementation guidance and in April 2016, the FASB issued ASU No. 2016-10, Identifying Performance Obligations and Licensing, which amends the guidance in those areas in the new revenue recognition standard. These ASUs, collectively the “new revenue standard”, are effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018. The Company adopted the new revenue standard as of March 4, 2018 using the modified retrospective method and applying the new standard to all contracts with customers. Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. In connection with the adoption of the new revenue standard, the Company identified one difference in its Retail Pharmacy segment related to the timing of revenue recognition for third party prescription revenues, which was historically recognized at the time the prescription was filled. Upon adoption of ASU No. 2014-09, this revenue is recognized at the time the customer takes possession of the merchandise. In connection with its March 4, 2018 adoption of the new revenue standard on a modified retrospective basis, the Company recorded a reduction to accounts receivable of $57,897, a reduction to deferred tax assets of $1,784, an increase to inventory of $51,121, and a corresponding increase to accumulated deficit of $8,560 within its Retail Pharmacy segment. In addition, the Company identified revenues under one specific rebate administration program under which the Company’s Pharmacy Services segment was determined to be the principal and historically recognized revenues and cost of revenues on a gross basis of approximately $123,500 during fiscal 2018. Upon adoption of the new revenue standard, the Company is now recording revenue from this program on a net basis. Reclassification of the Statements of Cash Flows presentation During fiscal 2019, the Company expanded its disclosure on its Statements of Cash Flows to include changes in other assets separate from changes in other liabilities, which had historically been combined. Prior period amounts have been reclassified to conform to the current period presentation. Recasting of per-share amounts As previously announced, the Company implemented a reverse stock split of the Company’s common stock at a reverse stock split ratio of 1-for-20. The Company's common stock began trading on a split-adjusted basis on the NYSE at the market open on April 22, 2019. Accordingly, all share and per-share amounts for the current period and prior periods have been recasted to reflect the reverse stock split. Recently Issued Accounting Pronouncements Not Yet Adopted In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement benefits (Topic 715-20) . This ASU amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU eliminates the requirement to disclose the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year. The ASU also removes the disclosure requirements for the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost and the benefit obligation for postretirement health care benefits. This ASU is effective for fiscal years ending after December 15, 2020 and must be applied on a retrospective basis. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s financial position. In February 2016, the FASB issued ASU No. 2016-02, Leases, (Topic 842) (“ASU-2016-02” or the “Lease Standard”), which is intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that engage in lease transactions (both lessee and lessor) of lease assets such as real estate and equipment. This ASU will require organizations that lease assets—referred to as “lessees”—to recognize on the balance sheet a right of use asset (“ROU”) and a lease liability for the obligations created by those leases. ASU No. 2016-02 is effective for fiscal years and interim periods within those years beginning January 1, 2019. During July 2018, the FASB issued ASU 2018-11, Leases (Topic 842) : Targeted Improvements. Among other things, ASU 2018-11 provides administrative relief by allowing entities to implement the Lease Standard on the alternative transition method. Effectively, the alternative transition method permits adoption of the Lease Standard through an adjustment to its opening balance sheet for the period of adoption, with the cumulative effect accounted for as an adjustment to retained earnings, without restating prior periods. The Company will adopt this standard during the first quarter of fiscal 2020. Upon adoption, the Company currently expects to recognize ROU assets of approximately $3.1 billion and corresponding liabilities of approximately $3.3 billion for all lease obligations that are currently classified as operating leases, the majority of which are related to leases in the Company’s retail stores. The Company does not anticipate a material impact on its consolidated results of operations and cash flows. In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40) , which is intended to provide entities with additional guidance to determine which software implementation costs to capitalize and which costs to expense. The ASU will allow entities to capitalize costs for implementation activities during the application development stage. ASU No. 2018-15 is effective for fiscal years and interim periods within those years beginning after December 15, 2019 (fiscal 2020). Early adoption of ASU 2018-15 is permitted. The Company is in the process of assessing the impact of the adoption of ASU 2018-15, but does not expect adoption will have a material impact on the Company’s financial position, results of operations and cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 02, 2019
Summary of Significant Accounting Policies
Schedule of revenues from description of business	Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Retail Pharmacy segment: Pharmacy sales $ 10,391,539 $ 10,328,376 $ 11,072,480 Front-end sales 5,215,152 5,348,613 5,538,352 Other revenue 150,461 155,636 155,788 Total Retail Pharmacy segment 15,757,152 15,832,625 16,766,620 Pharmacy Services segment revenue 6,093,688 5,896,669 6,393,884 Intersegment elimination (211,283) (200,326) (232,964) Total revenue $ 21,639,557 $ 21,528,968 $ 22,927,540
Schedule of principal classes of products	Percentage Product Class of Sales Prescription drugs 66.6 % Over-the-counter medications and personal care 10.8 % Health and beauty aids 5.0 % General merchandise and other 17.6 %
Schedule of revenues	In thousands March 2, 2019 Retail Pharmacy segment: Pharmacy sales $ 10,391,539 Front-end sales 5,215,152 Other revenue 150,461 Total Retail Pharmacy segment 15,757,152 Pharmacy Services segment 6,093,688 Intersegment elimination (211,283) Total revenue $ 21,639,557
Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet	Impact of Change in Accounting Policy As Reported Adjusted In thousands March 3, 2018 Adjustments March 4, 2018 Consolidated Balance Sheet: Accounts receivable, net $ 1,869,100 $ (57,897) $ 1,811,203 Inventories, net 1,799,539 51,121 1,850,660 Deferred tax assets 594,019 (1,784) 592,235 Total assets 8,989,327 (8,560) 8,980,767 Accumulated deficit (4,282,471) (8,560) (4,291,031) Total shareholders’ equity 1,601,010 (8,560) 1,592,450

Asset Sale to WBA (Tables)

Asset Sale to WBA (Tables)	12 Months Ended
	Mar. 02, 2019
Asset Sale to WBA
Schedule of carrying amount of Assets to be Sold	March 2, March 3, 2019 2018 Inventories $ 68,233 $ 264,286 Property and equipment 49,348 158,433 Goodwill(a) — 4,629 Intangible assets — 10,789 Current assets held for sale $ 117,581 $ 438,137 Current maturities of long-term lease financing obligations $ — $ 270 Accrued salaries, wages and other current liabilities — 6,146 Long-term debt, less current maturities(b) — 549,549 Lease financing obligations, less current maturities — 838 Other noncurrent liabilities — 3,402 Current liabilities held for sale $ — $ 560,205 (a) The Company had $76,124 of goodwill in its Retail Pharmacy segment resulting from the acquisition of Health Dialog and RediClinic, which is accounted for as Retail Pharmacy segment enterprise goodwill. The Company has allocated a portion of its Retail Pharmacy segment enterprise goodwill to the discontinued operation. (b) In connection with the Sale, the Company had estimated that the Sale would generate in excess of $4.0 billion of cash proceeds, all of which was used to repay outstanding indebtedness.
Schedule of operating results of the discontinued operations	March 2, March 3, March 4, 2019 2018 2017 (52 weeks) (52 weeks) (53 weeks) Revenues $ 34,889 $ 8,686,397 $ 10,050,049 Costs and expenses: Cost of revenues(a) 24,271 6,406,067 7,340,691 Selling, general and administrative expenses(a) 20,681 2,134,276 2,465,364 Lease termination and impairment charges — 77 9,516 Loss on debt retirements, net 22,646 8,180 — Interest expense(b) 4,616 224,300 231,926 Gain on stores sold to Walgreens Boots Alliance (374,619) (2,128,832) — Loss (gain) on sale of assets, net 1,486 (377) 2,625 (300,919) 6,643,691 10,050,122 Income (loss) from discontinued operations before income taxes 335,808 2,042,706 (73) Income tax expense 91,067 749,704 46 Net income (loss) from discontinued operations, net of tax $ 244,741 $ 1,293,002 $ (27) (a) Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations. (b) In accordance with ASC 205-20, the operating results for the fifty-two week period ended March 2, 2019, the fifty-two week period ended March 3, 2018 and the fifty-three week period ended March 4, 2017, respectively, for the discontinued operations include interest expense relating to outstanding indebtedness repaid with the estimated excess proceeds from the Sale.

(Loss) Income Per Share (Tables

(Loss) Income Per Share (Tables)	12 Months Ended
	Mar. 02, 2019
(Loss) Income Per Share
Schedule of calculation of basic and diluted (loss) income per share	March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Basic and diluted (loss) income per share: Numerator: (Loss) income from continuing operations attributable to common stockholders—basic and diluted $ (666,954) $ (349,532) $ 4,080 Income (loss) from discontinued operations attributable to common stockholders—basic and diluted 244,741 1,293,002 (27) (Loss) income attributable to common stockholders—basic and diluted $ (422,213) $ 943,470 $ 4,053 Denominator: Basic weighted average shares 52,854 52,481 52,221 Outstanding options and restricted shares, net — — 820 Diluted weighted average shares 52,854 52,481 53,041 Basic (loss) income per share: Continuing operations $ (12.62) $ (6.66) $ Discontinued operations 4.63 24.64 Net basic (loss) income per share $ (7.99) $ 17.98 $ Diluted (loss) income per share: Continuing operations $ (12.62) $ (6.66) $ Discontinued operations 4.63 24.64 Net diluted (loss) income per share $ (7.99) $ 17.98 $

Lease Termination and Impairm_2

Lease Termination and Impairment Charges (Tables)	12 Months Ended
	Mar. 02, 2019
Lease Termination and Impairment Charges
Schedule of amounts relating to lease termination and impairment charges	March 2, 2019 March 3, 2018 March 4, 2017 (in thousands, except number of stores) Number Charge Number Charge Number Charge Active stores: Stores previously impaired(1) 288 $ 17,939 218 $ 7,313 174 $ 5,022 New, relocated and remodeled stores(2) 22 10,595 28 13,100 22 13,232 Remaining stores not meeting the recoverability test(3) 74 17,885 60 14,369 17 2,369 Total impairment charges—active stores 384 46,419 306 34,782 213 20,623 Total impairment charges—closed facilities 62 2,788 67 3,091 53 2,008 Total impairment charges—other(4) — 14,285 — — — — Total impairment charges—all locations 446 $ 63,492 373 $ 37,873 266 $ 22,631 (1) These charges are related to stores that were impaired for the first time in prior periods. Most active stores, requiring an impairment charge, are fully impaired in the first period that they do not meet their asset recoverability test. However, we do often make capital additions to certain stores to improve their operating results or to meet geographical competition, which if later are deemed to be unrecoverable, will be impaired in future periods. Of this total, 286, 215 and 173 stores for fiscal years 2019, 2018 and 2017 respectively have been fully impaired. Also included in these charges are an insignificant number of stores, which were only partially impaired in prior years based on our analysis that supported a reduced net book value greater than zero, but now require additional charges. (2) These charges are related to new stores (open at least three years) and relocated stores (relocated in the last two years) and significant strategic remodels (remodeled in the last year) that did not meet their recoverability test during the current period. These stores have not met their original return on investment projections and have a historical loss of at least two years. Their future cash flow projections do not recover their current carrying value. Of this total, 21, 23 and 18 stores for fiscal years 2019, 2018 and 2017 respectively have been fully impaired. (3) These charges are related to the remaining active stores that did not meet the recoverability test during the current period. These stores have a historical loss of at least 2 years. Their future cash flow projections do not recover their current carrying value. Of this total, 72, 58 and 16 stores for fiscal years 2019, 2018 and 2017 respectively have been fully impaired. (4) These charges are due to the impairment of assets related to the termination of a project to replace the point of sale software used in the Company’s stores.
Schedule of fair value of long-lived assets for which an impairment assessment was performed and total losses	Quoted Prices in Significant Fair Values Active Markets Other Significant as of Total for Identical Observable Unobservable Impairment Charges Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Date March 2, 2019 Long-lived assets held and used $ — $ — $ 8,116 $ 8,116 $ (62,115) Long-lived assets held for sale — 1,545 — 1,545 (1,377) Total $ — $ 1,545 $ 8,116 $ 9,661 $ (63,492) Quoted Prices in Significant Fair Values Active Markets Other Significant as of Total for Identical Observable Unobservable Impairment Charges Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Date March 3, 2018 Long-lived assets held and used $ — $ 2,893 $ 14,581 $ 17,474 $ (36,752) Long-lived assets held for sale — 1,029 — 1,029 (1,121) Total $ — $ 3,922 $ 14,581 $ 18,503 $ (37,873)
Schedule of closed store and distribution center charges related to new closures, changes in assumptions and interest accretion	Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Balance—beginning of year $ 133,290 $ 165,138 $ 208,421 Provision for present value of noncancellable lease payments of closed stores 35,190 8,871 6,503 Changes in assumptions about future sublease income, terminations and change in interest rates 737 1,082 2,633 Interest accretion 9,741 11,439 14,186 Cash payments, net of sublease income (54,912) (53,240) (66,605) Balance—end of year $ 124,046 $ 133,290 $ 165,138
Schedule of revenue, operating expenses, and income before income taxes of stores	Year Ended March 2, March 3, March 4, 2019 2018 2017 Revenues $ 165,598 $ 308,005 $ 433,709 Operating expenses 182,201 342,103 471,971 Gain from sale of assets (38,113) (18,222) (1,036) Other expenses 2,183 2,417 4,590 Income (loss) before income taxes 19,327 (18,293) (41,816) Included in these stores’ loss before income taxes are: Depreciation and amortization 621 1,742 3,560 Inventory liquidation charges (5,523) (2,828) (187)

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 02, 2019
Income Taxes
Schedule of provision for income tax expense (benefit) from continuing operations	Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Current tax: Federal $ (22,187) $ (210) $ — State 9,866 51,279 14,600 (12,321) 51,069 14,600 Deferred tax and other: Federal 50,151 316,451 10,355 State 39,647 (61,533) 19,483 89,798 254,918 29,838 Total income tax expense $ 77,477 $ 305,987 $ 44,438
Schedule of reconciliation of the expected statutory federal tax and the total income tax expense (benefit) from continuing operations	Year Ended March 2, March 3, March 4, 2019 2018 2017 (52 Weeks) (52 Weeks) (53 Weeks) Federal statutory rate* $ (123,790) $ (14,202) $ 16,982 Federal tax rate change — 324,765 — Nondeductible expenses 2,890 1,213 2,479 State income taxes, net (12,605) (22,836) 8,225 Increase (decrease) of previously recorded liabilities (3,105) 27,295 (955) Nondeductible compensation 1,798 654 1,157 Acquisition costs — 696 4,023 Stock based compensation 3,478 8,363 — Valuation allowance 212,252 (8,853) 14,718 Other (3,441) (11,108) (2,191) Total income tax expense $ 77,477 $ 305,987 $ 44,438 * Federal statutory rate included in the above table is 21.0%, 32.6% and 35.0%, respectively, for the fiscal years ended March 2, 2019, March 3, 2018 and March 4, 2017.
Schedule of significant components of deferred tax assets and liabilities	2019 2018 Deferred tax assets: Accounts receivable $ 36,607 $ 39,182 Accrued expenses 107,356 113,493 Liability for lease exit costs 37,333 40,662 Pension, retirement and other benefits 87,397 104,494 Long-lived assets 320,561 246,793 Credits 48,884 85,555 Net operating losses 1,084,139 1,089,084 Total gross deferred tax assets 1,722,277 1,719,263 Valuation allowance (1,091,416) (896,800) Total deferred tax assets 630,861 822,463 Deferred tax liabilities: Outside basis difference 5,392 5,420 Inventory 215,588 223,024 Other 797 0 Total gross deferred tax liabilities 221,777 228,444 Net deferred tax assets $ 409,084 $ 594,019
Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits from continuing operations	2019 2018 2017 Unrecognized tax benefits $ 230,210 $ 8,939 $ 10,676 Increases to prior year tax positions 155 — 16 Decreases to tax positions in prior periods (111) (1,015) (626) Increases to current year tax positions — 224,408 26 Settlements — — — Divestitures (543) (1,607) — Lapse of statute of limitations (9,872) (515) (1,153) Unrecognized tax benefits balance $ 219,839 $ 230,210 $ 8,939

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Mar. 02, 2019
Property, Plant and Equipment
Schedule of property, plant and equipment, including capital lease assets	2019 2018 Land $ 139,406 $ 138,768 Buildings 533,580 528,026 Leasehold improvements 1,527,371 1,567,635 Equipment 1,765,575 1,795,337 Software 38,680 25,944 Construction in progress 49,344 59,635 4,053,956 4,115,345 Accumulated depreciation (2,745,442) (2,684,099) Property, plant and equipment, net $ 1,308,514 $ 1,431,246

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Mar. 02, 2019
Goodwill and Other Intangibles
Summary of the changes in the carrying amount of goodwill	Retail Pharmacy Pharmacy Services Total Balance, March 4, 2017 $ 43,492 $ 1,639,355 $ 1,682,847 Goodwill impairment — (261,727) (261,727) Balance, March 3, 2018 43,492 1,377,628 1,421,120 Goodwill impairment — (312,984) (312,984) Balance, March 2, 2019 $ 43,492 $ 1,064,644 $ 1,108,136
Summary of the company's finite-lived and indefinite-lived intangible assets	2019 2018 Remaining Remaining Weighted Weighted Gross Average Gross Average Carrying Accumulated Amortization Carrying Accumulated Amortization Amount Amortization Net Period Amount Amortization Net Period Favorable leases and other(a) $ 370,855 $ (318,503) $ 52,352 years $ 379,355 $ (316,798) $ 62,557 years Prescription files 919,749 (827,222) 92,527 years 900,111 (801,706) 98,405 years Customer relationships(a) 388,000 (193,352) 194,648 years 465,000 (172,635) 292,365 years CMS license 57,500 (8,472) 49,028 years 57,500 (6,172) 51,328 years Claims adjudication and other developed software 58,985 (31,030) 27,955 years 58,985 (22,617) 36,368 years Trademarks 20,100 (7,404) 12,696 years 20,100 (5,394) 14,706 years Backlog 11,500 (11,500) — years 11,500 (10,286) 1,214 year Total finite $ 1,826,689 $ (1,397,483) $ 429,206 $ 1,892,551 $ (1,335,608) $ 556,943 Trademarks 19,500 — 19,500 Indefinite 33,500 — 33,500 Indefinite Total $ 1,846,189 $ (1,397,483) $ 448,706 $ 1,926,051 $ (1,335,608) $ 590,443 (a) Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

Accrued Salaries, Wages and O_2

Accrued Salaries, Wages and Other Current Liabilities (Tables)	12 Months Ended
	Mar. 02, 2019
Accrued Salaries, Wages and Other Current Liabilities
Schedule of accrued salaries, wages and other current liabilities	2019 2018 Accrued wages, benefits and other personnel costs $ 302,025 $ 360,179 Accrued interest 13,991 65,210 Accrued sales and other taxes payable 80,708 125,289 Accrued store expense 143,053 155,354 Accrued reinsurance — 183,418 Other 268,662 342,286 $ 808,439 $ 1,231,736

Indebtedness and Credit Agree_2

Indebtedness and Credit Agreements (Tables)	12 Months Ended
	Mar. 02, 2019
Indebtedness and Credit Agreements
Summary of indebtedness and lease financing obligations	2019 2018 Secured Debt: Senior secured revolving credit facility due January 2020 ($0 face value less unamortized debt issuance costs of $0 and $13,076) $ — $ (13,076) Senior secured revolving credit facility due December 2023 ($875,000 and $0 face value less unamortized debt issuance costs of $24,069 and $0) 850,931 — FILO term loan due December 2023 ($450,000 and $0 face value less unamortized debt issuance costs of $3,918 and $0) 446,082 — Other secured — 90 1,297,013 (12,986) Guaranteed Unsecured Debt: 9.25% senior notes due March 2020 ($0 and $902,000 face value plus unamortized premium of $0 and $1,400 and less unamortized debt issuance costs of $0 and $4,924) — 898,476 6.75% senior notes due June 2021 ($0 and $810,000 face value less unamortized debt issuance costs of $0 and $4,877) — 805,123 6.125% senior notes due April 2023 ($1,753,490 and $1,800,000 face value less unamortized debt issuance costs of $16,982 and $21,708) 1,736,508 1,778,292 1,736,508 3,481,891 Unguaranteed Unsecured Debt: 7.7% notes due February 2027 ($295,000 face value less unamortized debt issuance costs of $1,295 and $1,460) 293,705 293,540 6.875% fixed-rate senior notes due December 2028 ($128,000 face value less unamortized debt issuance costs of $642 and $707) 127,358 127,293 421,063 420,833 Lease financing obligations 40,176 52,554 Total debt 3,494,760 3,942,292 Current maturities of long-term debt and lease financing obligations (16,111) (21,031) Long-term debt and lease financing obligations, less current maturities $ 3,478,649 $ 3,921,261
Schedule of reconciliation of indebtedness included in continuing operations and discontinued operations	March 3, 2018 Total Debt and Lease Financing Lease Financing Debt Obligations Obligations Balance, March 3, 2018—per above table $ 3,889,738 $ 52,554 $ 3,942,292 Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale(a) (549,549) (1,108) (550,657) Total debt and lease financing obligations 3,340,189 51,446 3,391,635 Current maturities of long-term debt and lease financing obligations—continuing operations (90) (20,671) (20,761) Long-term debt and lease financing obligations, less current maturities—continuing operations $ 3,340,099 $ 30,775 $ 3,370,874 (a) In connection with the Sale, the Company had estimated that the Sale would generate in excess of $4.0 billion of cash proceeds, all of which was used to repay outstanding indebtedness. Please see Note 3 for additional details.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 02, 2019
Leases
Schedule of net book values of assets under capital leases and sale-leasebacks accounted for under the financing method	2019 2018 Land $ 2,688 $ 3,458 Buildings 83,624 86,012 Equipment 19,595 25,225 Accumulated depreciation (77,892) (78,637) $ 28,015 $ 36,058
Schedule of lease finance obligations	2019 2018 Obligations under financing leases $ 40,176 $ 51,446 Less current obligation (16,112) (20,671) Long-term lease finance obligations $ 24,064 $ 30,775
Schedule of minimum lease payments for all properties under a lease agreement	Lease Financing Operating Fiscal year Obligations Leases 2020 $ 19,300 $ 687,412 2021 4,811 610,874 2022 4,588 545,863 2023 4,383 490,864 2024 4,042 431,714 Later years 20,470 1,541,408 Total minimum lease payments 57,594 $ 4,308,135 Amount representing interest (17,418) Present value of minimum lease payments $ 40,176

Stock Option and Stock Award _2

Stock Option and Stock Award Plans (Tables)	12 Months Ended
	Mar. 02, 2019
Stock Option and Stock Award Plans
Schedule of weighted average assumptions used for options granted	2019 2018 2017 Expected stock price volatility(1) N/A 58 % N/A Expected dividend yield(2) N/A 0.0 % N/A Risk-free interest rate(3) N/A 1.9 % N/A Expected option life(4) N/A 5.5 years N/A (1) The expected volatility is based on the historical volatility of the stock price over the most recent period equal to expected life of the option. (2) The dividend rate that will be paid out on the underlying shares during the expected term of the options. The Company does not currently pay dividends on its common stock, as such, the dividend rate is assumed to be 0%. (3) The risk free interest rate is equal to the rate available on United States Treasury zero‑coupon issues as of the grant date of the option with a remaining term equal to the expected term. (4) The period of time for which the option is expected to be outstanding. The Company analyzed historical exercise behavior to estimate the life.
Schedule of stock option transactions	Weighted Weighted Average Average Exercise Remaining Aggregate Price Contractual Intrinsic Shares Per Share Term Value Outstanding at February 27, 2016 1,906 $ 54.53 Granted — N/A Exercised (178) 39.07 Cancelled (34) 111.99 Outstanding at March 4, 2017 1,694 $ 54.93 Granted 50 41.00 Exercised (241) 24.05 Cancelled (160) 126.61 Outstanding at March 3, 2018 1,343 $ 51.42 Granted — N/A Exercised (99) 23.07 Cancelled (208) 71.07 Outstanding at March 2, 2019 1,036 $ 50.15 $ 0 Vested or expected to vest at March 2, 2019 1,025 $ 49.07 $ 0 Exercisable at March 2, 2019 978 $ 47.87 $ 0
Schedule of restricted stock transactions	Weighted Average Grant Date Shares Fair Value Balance at February 27, 2016 243 $ 144.61 Granted 180 154.60 Vested (111) 125.55 Cancelled (21) 156.85 Balance at March 4, 2017 291 $ 157.35 Granted 693 56.44 Vested (194) 160.61 Cancelled (179) 73.95 Balance at March 3, 2018 611 $ 66.34 Granted 700 16.05 Vested (215) 76.99 Cancelled (88) 72.87 Balance at March 2, 2019 1,008 $ 28.60

Retirement Plans (Tables)

Retirement Plans (Tables)	12 Months Ended
	Mar. 02, 2019
Retirement Plans
Summary of net periodic pension expense for the defined benefit plans	Defined Benefit Pension Plan 2019 2018 2017 Service cost $ 597 $ 1,212 $ 1,291 Interest cost 6,159 6,340 6,634 Expected return on plan assets (5,673) (4,525) (4,512) Amortization of unrecognized prior service cost — — — Amortization of unrecognized net loss (gain) 1,769 3,393 5,085 Net pension expense $ 2,852 $ 6,420 $ 8,498 Other changes recognized in other comprehensive loss: Unrecognized net (gain) loss arising during period $ (3,486) $ (8,704) $ (3,979) Prior service cost arising during period — — — Amortization of unrecognized prior service costs — — — Amortization of unrecognized net (loss) gain (1,769) (3,393) (5,085) Net amount recognized in other comprehensive loss (5,255) (12,097) (9,064) Net amount recognized in pension expense and other comprehensive loss $ (2,403) $ (5,677) $ (566)
Schedule of reconciliation for both benefit obligation and plan assets of defined benefit plans, as well as funded status and amounts recognized in balance sheet	Defined Benefit Pension Plan 2019 2018 Change in benefit obligations: Benefit obligation at end of prior year $ 161,851 $ 164,349 Service cost 597 1,212 Interest cost 6,159 6,340 Distributions (8,816) (7,963) Change due to change in assumptions — — Actuarial loss (gain) (9,086) (2,087) Benefit obligation at end of year $ 150,705 $ 161,851 Change in plan assets: Fair value of plan assets at beginning of year $ 130,860 $ 118,658 Employer contributions 2,715 9,023 Actual return on plan assets 72 11,142 Distributions (including expenses paid by the plan) (8,815) (7,963) Fair value of plan assets at end of year $ 124,832 $ 130,860 Funded status $ (25,873) $ (30,991) Net amount recognized $ (25,873) $ (30,991) Amounts recognized in consolidated balance sheets consisted of: Prepaid pension cost $ — $ — Accrued pension liability (25,873) (30,991) Net amount recognized $ (25,873) $ (30,991) Amounts recognized in accumulated other comprehensive loss consist of: Net actuarial loss $ (27,409) $ (32,664) Prior service cost — — Amount recognized $ (27,409) $ (32,664)
Schedule of significant actuarial assumptions used for all defined benefit plans to determine benefit obligation	Defined Benefit Pension Plan 2019 2018 2017 Discount rate 4.25 % 4.00 % 4.00 % Rate of increase in future compensation levels N/A N/A N/A Expected long-term rate of return on plan assets 6.25 % 6.25 % 6.50 %
Schedule of weighted average assumptions used to determine net benefit cost	Defined Benefit Pension Plan 2019 2018 2017 Discount rate 4.00 % 4.00 % 4.25 % Rate of increase in future compensation levels N/A N/A N/A Expected long-term rate of return on plan assets 6.25 % 6.50 % 6.50 %
Schedule of pension plan asset allocations by asset category	March 2, March 3, 2019 2018 Equity securities 52 % 53 % Fixed income securities 48 % 47 % Total 100 % 100 %
Schedule of target allocation of plan assets	Target Category Allocation U.S. equities 39 % International equities 13 % U.S. fixed income 48 % Total 100 %
Summary of the plan's investments measured at fair value on a recurring basis	Fair Value Measurements at March 2, 2019 Quoted Prices in Active Markets Significant Significant for Identical Observable Unobservable Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Total Equity Securities International equity $ — $ — $ — $ 15,396 Large Cap — — — 34,058 Small-Mid Cap — — — 14,534 Fixed Income Long Term Credit Bond Index — — — 44,103 Long Term US Government Bonds — — — 8,383 20+ Year Treasury STRIPS — — — 847 Intermediate Fixed Income — — — 5,920 Other types of investments Short Term Investments — — — 1,591 Total $ — $ — $ — $ 124,832 Fair Value Measurements at March 3, 2018 Quoted Prices in Active Markets Significant Significant for Identical Observable Unobservable Assets (Level 1) Inputs (Level 2) Inputs (Level 3) Total Equity Securities International equity $ — $ — $ — $ 18,043 Large Cap — — — 35,491 Small-Mid Cap — — — 15,510 Fixed Income Long Term Credit Bond Index — — — 46,222 Long Term US Government Bonds — — — 8,070 20+ Year Treasury STRIPS — — — 1,168 Intermediate Fixed Income — — — 5,617 Other types of investments Short Term Investments — — — 739 Total $ — $ — $ — $ 130,860
Schedule of future benefit payments expected to be paid	Defined Benefit Fiscal Year Pension Plan 2020 $ 8,690 2021 8,844 2022 8,999 2023 9,005 2024 9,213 2025 - 2029 45,903 Total $ 90,654

Multiemployer Plans that Prov_2

Multiemployer Plans that Provide Pension Benefits (Tables)	12 Months Ended
	Mar. 02, 2019
Multiemployer Plans that Provide Pension Benefits
Schedule of multiemployer defined benefit pension plans	Expiration FIP/ RP Date of Pension Protection Status Collective- Minimum EIN/Pension Act Zone Status Pending/ Contributions of the Company Surcharge Bargaining Funding Pension Plan Number 2019 2018 Implemented 2019 2018 2017 Imposed Agreement Requirements 1199 SEIU Health Care Employees Pension Fund 13-3604862-001 Green— Green— No $ 9,670 $ 7,372 $ 7,152 No 4/18/2019 Contribution rate of 15.80% of gross wages per associate beginning 09/30/2018. Contribution rate of 10.76% of gross wages earned per associate beginning 01/01/2016. Southern California United Food and Commercial Workers Unions and Drug Employers Pension Fund 51-6029925-001 Red— Red— Implemented 8,273 8,149 8,021 No 7/17/2021 From 01/01/2019 through 12/31/2019 contributions of $1.672 per hour for worked for pharmacists and $0.758 per hour worked for non pharmacists. From 01/01/2018 to 12/31/2018 contributions of $1.586 per hour worked. From 01/01/2017 to 12/31/2017 contributions of $1.50 per hour worked. UFCW Pharmacists, Clerks and Drug Employers Pension Trust 94-2518312-001 Green— Green— No 2,666 2,739 2,970 No 7/13/2019 Effective 09/01/2014, contribution rate frozen at $0.55 per hour worked for associates. United Food and Commercial Workers Union-Employer Pension Fund 34-6665155-001 Red— Red— Implemented 772 786 827 No 2/28/2021 Effective 02/04/2018 contribution rate of $2.03 per hour worked. Effective 02/05/2017 contribution rate of $1.89 per hour worked. Effective 02/07/2016 through 02/04/2017 contribution rate of $1.76 per hour worked. United Food and Commercial Workers Union Local 880—Mercantile Employers Joint Pension Fund 51-6031766-001 Yellow— Yellow— Implemented 470 495 504 No 2/28/2021 Effective 10/01/2018 contribution rate of $1.97 per hour worked. Effective 01/01/2017 contribution rate $1.88 per hour worked. Effective 01/01/2016 through 12/31/2016 contribution rate of $1.79 per hour worked. Other Funds 1,648 1,438 1,862 $ 23,499 $ 20,979 $ 21,336
Schedule of year contributions to plan that exceeded more than 5 percent of the total contributions	Year Contributions to Plan Exceeded More Than 5 % of Total Contributions (as of Pension Fund the Plan’s Year-End) UFCW Pharmacists, Clerks and Drug Employers Pension Trust 12/31/2017 and 12/31/2016 Southern California United Food and Commercial Workers Unions and Drug Employers Pension Fund 12/31/2017 and 12/31/2016 United Food & Commercial Workers Union - Employer Pension Fund 9/30/2017 and 9/30/2016 United Food & Commercial Workers Union Local 880—Mercantile Employers Joint Pension Fund 9/30/2017 and 9/30/2016

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Mar. 02, 2019
Segment Reporting
Schedule of balance sheet information for the Company's reportable segments	Retail Pharmacy Pharmacy Services Eliminations(1) Consolidated March 2, 2019: Total Assets $ 5,071,055 $ 2,534,771 $ (14,459) $ 7,591,367 Goodwill 43,492 1,064,644 — 1,108,136 Additions to property and equipment and intangible assets 228,079 16,610 — 244,689 March 3, 2018: Total Assets $ 6,089,343 $ 2,954,953 $ (54,969) $ 8,989,327 Goodwill 43,492 1,377,628 — 1,421,120 Additions to property and equipment and intangible assets 199,437 15,327 — 214,764 (1) As of March 2, 2019 and March 3, 2018, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $0 and $38,713 , respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,459 and $16,256, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.
Schedule of reconciliation of the Company's business segments to the condensed consolidated financial statements	Retail Pharmacy Intersegment Pharmacy Services Eliminations(1) Consolidated March 2, 2019: Revenues $ 15,757,152 $ 6,093,688 $ (211,283) $ 21,639,557 Gross Profit 4,258,716 417,636 — 4,676,352 Adjusted EBITDA(2) 405,206 158,238 — 563,444 March 3, 2018: Revenues $ 15,832,625 $ 5,896,669 $ (200,326) $ 21,528,968 Gross Profit 4,372,373 407,732 — 4,780,105 Adjusted EBITDA(2) 388,320 171,534 — 559,854 March 4, 2017: Revenues $ 16,766,620 $ 6,393,884 $ (232,964) $ 22,927,540 Gross Profit 4,671,975 392,732 — 5,064,707 Adjusted EBITDA(2) 559,653 188,235 — 747,888 (1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis. (2) See the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.
Schedule of reconciliation of net (loss) income to Adjusted EBITDA	March 2, March 3, March 4, 2019 2018 2017 (52 weeks) (52 weeks)(a) (53 weeks)(a) Net (loss) income from continuing operations $ (666,954) $ (349,532) $ 4,080 Interest expense 227,728 202,768 200,065 Income tax expense 77,477 305,987 44,438 Depreciation and amortization 357,882 386,057 407,366 LIFO charge (credit) 23,354 (28,827) (3,721) Lease termination and impairment charges 107,994 58,765 45,778 Goodwill and intangible asset impairment charges 375,190 261,727 — Loss on debt retirements, net 554 — — Merger and Acquisition-related costs 37,821 24,283 14,066 Stock-based compensation expense 12,115 25,793 23,482 Restructuring-related costs 4,704 — — Inventory write-downs related to store closings 13,487 7,586 5,925 Litigation settlement 18,000 — — Gain on sale of assets, net (38,012) (25,872) (6,649) Walgreens Boots Alliance merger termination fee — (325,000) — Other 12,104 16,119 13,058 Adjusted EBITDA from continuing operations $ 563,444 $ 559,854 $ 747,888 (a) During fiscal 2019, the Company revised its definition of Adjusted EBITDA to no longer exclude the impact of revenue deferrals related to its customer loyalty program and further revised its disclosure by presenting certain amounts previously included within Other as separate reconciling items. Consequently, the Company revised Adjusted EBITDA for fiscal 2018 and fiscal 2017 to conform with the revised definition and present separate reconciling items previously included in Other.

Supplementary Cash Flow Data (T

Supplementary Cash Flow Data (Tables)	12 Months Ended
	Mar. 02, 2019
Supplementary Cash Flow Data
Schedule of supplementary cash flow data	Year Ended March 2, March 3, March 4, 2019 2018 2017 Cash paid for interest(a) $ 267,760 $ 405,579 $ 409,692 Cash payments for income taxes, net(a) $ 17,383 $ 87,087 $ 17,081 Equipment financed under capital leases $ 4,165 $ 13,123 $ 7,551 Equipment received for noncash consideration $ — $ 2,044 $ 746 Reduction in lease financing obligation $ — $ 4,740 — Accrued capital expenditures $ 15,298 $ 28,869 $ 27,232 Gross borrowings from revolver(a) $ 4,257,000 $ 4,221,000 $ 3,608,000 Gross repayments to revolver(a) $ 3,382,000 $ 6,651,000 $ 3,278,000 (a)–Amounts are presented on a total company basis.

Guarantor and Non-Guarantor C_2

Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables)	12 Months Ended
	Mar. 02, 2019
Guarantor and Non-Guarantor Condensed Consolidating Financial Information
Schedule of condensed consolidating balance sheet	Rite Aid Corporation Condensed Consolidating Balance Sheet March 2, 2019 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) ASSETS Current assets: Cash and cash equivalents $ — $ 122,134 $ 22,219 $ — $ 144,353 Accounts receivable, net — 1,377,342 411,370 — 1,788,712 Intercompany receivable — 400,526 — (400,526) (a) — Inventories, net of LIFO reserve of $0, $604,444, $0, $0, and $604,444 — 1,871,941 — — 1,871,941 Prepaid expenses and other current assets — 172,448 6,684 — 179,132 Current assets held for sale — 117,581 — — 117,581 Total current assets — 4,061,972 440,273 (400,526) 4,101,719 Property, plant and equipment, net — 1,308,514 — — 1,308,514 Goodwill — 1,108,136 — — 1,108,136 Other intangibles, net — 399,678 49,028 — 448,706 Deferred tax assets — 419,122 (10,038) — 409,084 Investment in subsidiaries 8,294,315 55,109 — (8,349,424) (b) — Intercompany receivable — 3,639,035 — (3,639,035) (a) — Other assets — 208,018 7,190 — 215,208 Noncurrent assets held for sale — — — — — Total assets $ 8,294,315 $ 11,199,584 $ 486,453 $ (12,388,985) $ 7,591,367 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ — $ 16,111 $ — $ — $ 16,111 Accounts payable — 1,612,181 6,404 — 1,618,585 Intercompany payable — — 400,526 (400,526) (a) — Accrued salaries, wages and other current liabilities 14,005 778,020 16,414 — 808,439 Total current liabilities 14,005 2,406,312 423,344 (400,526) 2,443,135 Long-term debt, less current maturities 3,454,585 — — — 3,454,585 Lease financing obligations, less current maturities — 24,064 — — 24,064 Intercompany payable 3,639,035 — — (3,639,035) (a) — Other noncurrent liabilities — 474,893 8,000 — 482,893 Total liabilities 7,107,625 2,905,269 431,344 (4,039,561) 6,404,677 Commitments and contingencies — — — — — Total stockholders’ equity 1,186,690 8,294,315 55,109 (8,349,424) (b) 1,186,690 Total liabilities and stockholders’ equity $ 8,294,315 $ 11,199,584 $ 486,453 $ (12,388,985) $ 7,591,367 (a) Elimination of intercompany accounts receivable and accounts payable amounts. (b) Elimination of investments in consolidated subsidiaries. Rite Aid Corporation Condensed Consolidating Balance Sheet March 3, 2018 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) ASSETS Current assets: Cash and cash equivalents $ — $ 441,244 $ 6,090 $ — $ 447,334 Accounts receivable, net — 1,502,507 366,593 — 1,869,100 Intercompany receivable 223,413 — (223,413) (a) — Inventories, net of LIFO reserve of $0, $581,090, $0, $0, and $581,090 — 1,799,539 — — 1,799,539 Prepaid expenses and other current assets — 176,678 4,503 — 181,181 Current assets held for sale — 438,137 — — 438,137 Total current assets — 4,581,518 377,186 (223,413) 4,735,291 Property, plant and equipment, net — 1,431,246 — — 1,431,246 Goodwill — 1,421,120 — — 1,421,120 Other intangibles, net — 539,115 51,328 — 590,443 Deferred tax assets — 594,019 — — 594,019 Investment in subsidiaries 8,745,390 54,076 — (8,799,466) (b) — Intercompany receivable — 3,189,419 — (3,189,419) (a) — Other assets — 209,926 7,282 — 217,208 Noncurrent assets held for sale — — — — — Total assets $ 8,745,390 $ 12,020,439 $ 435,796 $ (12,212,298) $ 8,989,327 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ 90 $ 20,671 $ — $ — $ 20,761 Accounts payable — 1,641,676 9,687 — 1,651,363 Intercompany payable — — 223,413 (223,413) (a) — Accrued salaries, wages and other current liabilities 65,223 1,031,379 135,134 — 1,231,736 Current liabilities held for sale 549,549 10,656 — — 560,205 Total current liabilities 614,862 2,704,382 368,234 (223,413) 3,464,065 Long-term debt, less current maturities 3,340,099 — — — 3,340,099 Lease financing obligations, less current maturities — 30,775 — — 30,775 Intercompany payable 3,189,419 — — (3,189,419) (a) — Other noncurrent liabilities — 539,892 13,486 — 553,378 Noncurrent liabilities held for sale — — — — — Total liabilities 7,144,380 3,275,049 381,720 (3,412,832) 7,388,317 Commitments and contingencies — — — — — Total stockholders’ equity 1,601,010 8,745,390 54,076 (8,799,466) (b) 1,601,010 Total liabilities and stockholders’ equity $ 8,745,390 $ 12,020,439 $ 435,796 $ (12,212,298) $ 8,989,327 (a) Elimination of intercompany accounts receivable and accounts payable amounts. (b) Elimination of investments in consolidated subsidiaries.
Schedule of condensed consolidating statement of operations	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Year Ended March 2, 2019 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Revenues $ — $ 21,297,937 $ 397,328 $ (55,708) (a) $ 21,639,557 Costs and expenses: Cost of revenues — 16,648,099 370,413 (55,307) (a) 16,963,205 Selling, general and administrative expenses — 4,567,690 25,086 (401) (a) 4,592,375 Lease termination and impairment expenses — 107,994 — — 107,994 Goodwill and intangible asset impairment charges — 375,190 — — 375,190 Interest expense 206,862 21,704 (838) — 227,728 Loss on debt retirements — 554 — — 554 Gain on sale of assets, net — (38,012) — — (38,012) Equity in earnings of subsidiaries, net of tax 210,736 (1,033) — (209,703) (b) — 417,598 21,682,186 394,661 (265,411) 22,229,034 Income (loss) from continuing operations before income taxes (417,598) (384,249) 2,667 209,703 (589,477) Income tax expense (benefit) — 75,843 1,634 — 77,477 Net income (loss) from continuing operations (417,598) (460,092) 1,033 209,703 (666,954) Net income (loss) from discontinued operations (4,615) 249,356 — — 244,741 Net income (loss) $ (422,213) $ (210,736) $ 1,033 $ 209,703 (b) $ (422,213) Total other comprehensive income (loss) 3,490 3,490 — (3,490) 3,490 Comprehensive income (loss) $ (418,723) $ (207,246) $ 1,033 $ 206,213 $ (418,723) Rite Aid Corporation Condensed Consolidating Statement of Operations For the Year Ended March 3, 2018 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Revenues $ — $ 21,413,734 $ 209,356 $ (94,122) (a) $ 21,528,968 Costs and expenses: Cost of revenues — 16,645,136 197,084 (93,357) (a) 16,748,863 Selling, general and administrative expenses — 4,635,531 16,496 (765) (a) 4,651,262 Lease termination and impairment expenses — 58,765 — — 58,765 Goodwill and intangible asset impairment charges — 261,727 — — 261,727 Interest expense 183,825 19,261 (318) — 202,768 Walgreens Boots Alliance, Inc. termination fee (325,000) — — — (325,000) Gain on sale of assets, net — (25,872) — — (25,872) Equity in earnings of subsidiaries, net of tax (1,034,775) (4,072) — 1,038,847 (b) — (1,175,950) 21,590,476 213,262 944,725 21,572,513 Income (loss) from continuing operations before income taxes 1,175,950 (176,742) (3,906) (1,038,847) (43,545) Income tax expense (benefit) — 313,965 (7,978) — 305,987 Net income (loss) from continuing operations 1,175,950 (490,707) 4,072 (1,038,847) (349,532) Net income (loss) from discontinued operations (232,480) 1,525,482 — — 1,293,002 Net income (loss) $ 943,470 $ 1,034,775 $ 4,072 $ (1,038,847) (b) $ 943,470 Total other comprehensive income (loss) 7,255 7,255 — (7,255) 7,255 Comprehensive income (loss) $ 950,725 $ 1,042,030 $ 4,072 $ (1,046,102) $ 950,725 (a) Elimination of intercompany revenues and expenses. (b) Elimination of equity in earnings of subsidiaries. Rite Aid Corporation Condensed Consolidating Statement of Operations For the Year Ended March 4, 2017 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Revenues $ — $ 22,821,940 $ 223,077 $ (117,477) (a) $ 22,927,540 Costs and expenses: Cost of revenues — 17,767,363 213,225 (117,755) (a) 17,862,833 Selling, general and administrative expenses — 4,763,176 13,541 278 (a) 4,776,995 Lease termination and impairment expenses — 45,778 — — 45,778 Interest expense 182,282 17,796 (13) — 200,065 Gain on sale of assets, net — (6,649) — — (6,649) Equity in earnings of subsidiaries, net of tax (418,261) 5,101 — 413,160 (b) — (235,979) 22,592,565 226,753 295,683 22,879,022 Income (loss) before income taxes 235,979 229,375 (3,676) (413,160) 48,518 Income tax expense — 43,013 1,425 — 44,438 Net income (loss) from continuing operations 235,979 186,362 (5,101) (413,160) (b) 4,080 Net income (loss) from discontinued operations (231,926) 231,899 — — (27) Net income (loss) $ 4,053 $ 418,261 $ (5,101) $ (413,160) $ 4,053 Total other comprehensive income (loss) 5,464 5,464 — (5,464) 5,464 Comprehensive income (loss) $ 9,517 $ 423,725 $ (5,101) $ (418,624) $ 9,517 (a) (b)
Schedule of condensed consolidating statement of cash flows	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended March 2, 2019 Rite Aid Corporation Non- (Parent Subsidiary Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Operating activities: Net cash (used in) provided by operating activities $ (255,962) $ 74,124 $ 16,129 $ — $ (165,709) Investing activities: Payments for property, plant and equipment — (196,778) — — (196,778) Intangible assets acquired — (47,911) — — (47,911) Intercompany activity — (727,221) — 727,221 — Proceeds from sale-leaseback transactions — 2,587 — — 2,587 Proceeds from dispositions of assets and investments — 43,550 — — 43,550 Net cash (used in) provided by investing activities — (925,773) — 727,221 (198,552) Financing activities: Proceeds from issuance of long-term debt 450,000 — — — 450,000 Net proceeds from revolver 875,000 — — — 875,000 Principal payments on long-term debt (427,992) (12,378) — — (440,370) Change in zero balance cash accounts — (59,481) — — (59,481) Net proceeds from issuance of common stock 2,294 — — — 2,294 Financing fees paid for early debt redemption — (171) — — (171) Payments for taxes related to net share settlement of equity awards — (2,419) — — (2,419) Intercompany activity 727,221 — — (727,221) — Deferred financing costs paid (21,564) — — — (21,564) Net cash provided by (used in) financing activities 1,604,959 (74,449) — (727,221) 803,289 Cash flows of discontinued operations: Operating activities of discontinued operations (4,615) (58,341) — — (62,956) Investing activities of discontinued operations — 664,740 — — 664,740 Financing activities of discontinued operations (1,344,382) 589 — — (1,343,793) Net cash provided by (used in) discontinued operations (1,348,997) 606,988 — — (742,009) (Decrease) increase in cash and cash equivalents — (319,110) 16,129 — (302,981) Cash and cash equivalents, beginning of period — 441,244 6,090 — 447,334 Cash and cash equivalents, end of period $ — $ 122,134 $ 22,219 $ — $ 144,353 Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended March 3, 2018 Rite Aid Corporation (Parent Non- Company Subsidiary Guarantor Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Operating activities: Net cash provided by (used in) operating activities $ 158,247 $ 379,439 $ (26,216) $ — $ 511,470 Investing activities: Payments for property, plant and equipment — (185,879) — — (185,879) Intangible assets acquired — (28,885) — — (28,885) Intercompany activity — (3,460,291) — 3,460,291 — Proceeds from insured loss — 4,239 — — 4,239 Proceeds from dispositions of assets and investments — 27,586 — — 27,586 Net cash (used in) provided by investing activities — (3,643,230) — 3,460,291 (182,939) Financing activities: Net payments to revolver (265,000) — — — (265,000) Principal payments on long-term debt — (9,882) — — (9,882) Change in zero balance cash accounts — 35,605 — — 35,605 Net proceeds from issuance of common stock 5,796 — — — 5,796 Payments for taxes related to net share settlement of equity awards — (4,103) — — (4,103) Intercompany activity 3,460,291 — — (3,460,291) — Net cash provided by (used in) financing activities 3,201,087 21,620 — (3,460,291) (237,584) Cash flows of discontinued operations: Operating activities of discontinued operations (224,300) (20,826) — — (245,126) Investing activities of discontinued operations — 3,496,222 — — 3,496,222 Financing activities of discontinued operations (3,135,034) (5,085) — — (3,140,119) Net cash provided by (used in) discontinued operations (3,359,334) 3,470,311 — — 110,977 (Decrease) increase in cash and cash equivalents — 228,140 (26,216) — 201,924 Cash and cash equivalents, beginning of period — 213,104 32,306 — 245,410 Cash and cash equivalents, end of period $ — $ 441,244 $ 6,090 $ — $ 447,334 Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended March 4, 2017 Rite Aid Corporation (Parent Non- Company Subsidiary Guarantor Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) Operating activities: Net cash (used in) provided by operating activities $ (162,842) $ 347,465 $ (1,596) $ — $ 183,027 Investing activities: Payments for property, plant and equipment — (254,149) — — (254,149) Intangible assets acquired — (39,648) — — (39,648) Intercompany activity — (57,817) — 57,817 — Proceeds from dispositions of assets and investments — 16,852 — — 16,852 Net cash (used in) provided by investing activities — (334,762) — 57,817 (276,945) Financing activities: Net proceeds from revolver 330,000 — — — 330,000 Principal payments on long-term debt — (16,588) — — (16,588) Change in zero balance cash accounts — 43,080 — — 43,080 Net proceeds from issuance of common stock 6,951 — — — 6,951 Excess tax benefit on stock options and restricted stock — 543 — — 543 Payments for taxes related to net share settlement of equity awards — (6,254) — — (6,254) Intercompany activity 57,817 — — (57,817) — Net cash provided by (used in) financing activities 394,768 20,781 — (57,817) 357,732 Cash flows of discontinued operations: Operating activities of discontinued operations (231,926) 281,016 — — 49,090 Investing activities of discontinued operations — (187,314) — — (187,314) Financing activities of discontinued operations — (4,651) — — (4,651) Net cash provided by (used in) discontinued operations (231,926) 89,051 — — (142,875) Increase (decrease) in cash and cash equivalents — 122,535 (1,596) — 120,939 Cash and cash equivalents, beginning of period — 90,569 33,902 — 124,471 Cash and cash equivalents, end of period $ — $ 213,104 $ 32,306 $ — $ 245,410

Interim Financial Results (Un_2

Interim Financial Results (Unaudited) (Tables)	12 Months Ended
	Mar. 02, 2019
Interim Financial Results (Unaudited)
Schedule of interim financial results (unaudited)	Fiscal Year 2019 First Second Third Fourth Quarter(a) Quarter(a) Quarter Quarter Year Revenues $ 5,388,490 $ 5,421,362 $ 5,450,060 $ 5,379,645 $ 21,639,557 Cost of revenues 4,219,741 4,260,211 4,267,972 4,215,281 16,963,205 Selling, general and administrative expenses 1,152,627 1,153,991 1,142,555 1,143,202 4,592,375 Lease termination and impairment charges 9,859 39,609 2,628 55,898 107,994 Goodwill and intangible asset impairment charges — 375,190 — — 375,190 Interest expense 62,792 56,233 56,008 52,695 227,728 Loss on debt retirements, net 554 — — — 554 Gain on sale of assets, net (5,859) (4,965) (382) (26,806) (38,012) 5,439,714 5,880,269 5,468,781 5,440,270 22,229,034 Loss from continuing operations before income taxes (51,224) (458,907) (18,721) (60,625) (589,477) Income tax (benefit) expense (9,497) (106,559) (1,471) 195,004 77,477 Loss from continuing operations (41,727) (352,348) (17,250) (255,629) (666,954) Net income (loss) from discontinued operations, net of tax 256,143 (6,792) 12,740 (17,350) 244,741 Net income (loss) 214,416 (359,140) (4,510) (272,979) (422,213) Basic and diluted income (loss) per share(a): Continuing operations $ (0.79) $ (6.67) $ (0.33) $ (4.83) $ (12.62) Discontinued operations $ 4.86 $ (0.13) $ 0.24 $ (0.32) $ 4.63 Net basic and diluted income (loss) per share $ 4.07 $ (6.80) $ (0.09) $ (5.15) $ (7.99) Fiscal Year 2018 First Second Third Fourth Quarter Quarter Quarter Quarter Year Revenues $ 5,436,523 $ 5,345,011 $ 5,353,170 $ 5,394,264 $ 21,528,968 Cost of revenues 4,274,580 4,183,338 4,166,447 4,124,498 16,748,863 Selling, general and administrative expenses 1,160,940 1,141,844 1,166,514 1,181,964 4,651,262 Lease termination and impairment charges 4,038 3,113 3,939 47,675 58,765 Goodwill impairment — — — 261,727 261,727 Interest expense 51,000 50,857 50,308 50,603 202,768 Walgreens Boots Alliance merger termination fee — (325,000) — — (325,000) Loss (gain) on sale of assets, net (5,877) (14,951) 205 (5,249) (25,872) 5,484,681 5,039,201 5,387,413 5,661,218 21,572,513 (Loss) income from continuing operations before income taxes (48,158) 305,810 (34,243) (266,954) (43,545) Income tax (benefit) expense (12,121) 117,450 (16,061) 216,719 305,987 Net (loss) income from continuing operations (36,037) 188,360 (18,182) (483,673) (349,532) Net (loss) income from discontinued operations, net of tax (39,312) (17,644) 99,213 1,250,745 1,293,002 Net (loss) income $ (75,349) $ 170,716 $ 81,031 $ 767,072 $ 943,470 Basic (loss) income per share(a): Continuing operations $ (0.69) $ 3.59 $ (0.35) $ (9.18) $ (6.66) Discontinued operations $ (0.75) $ (0.33) $ 1.90 $ 23.74 $ 24.64 Net basic (loss) income per share $ (1.44) $ 3.26 $ 1.55 $ 14.56 $ 17.98 Diluted (loss) income per share(a): Continuing operations $ (0.69) $ 3.53 $ (0.35) $ (9.18) $ (6.66) Discontinued operations $ (0.75) $ (0.33) $ 1.90 $ 23.74 $ 24.64 Net diluted (loss) income per share $ (1.44) $ 3.20 $ 1.55 $ 14.56 $ 17.98 (a) Income per share amounts for each quarter may not necessarily total to the yearly income per share due to the weighting of shares outstanding on a quarterly and year-to-date basis.

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Mar. 02, 2019
Financial Instruments
Schedule of carrying amounts and fair values of financial instruments	2019 2018 Carrying Fair Carrying Fair Amount Value Amount Value Variable rate indebtedness $ 1,297,013 $ 1,325,000 $ — $ — Fixed rate indebtedness $ 2,157,571 $ 1,795,335 $ 3,905,841 $ 3,927,411

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Description of Business (Details) $ in Thousands	Sep. 13, 2018USD ($)store	Sep. 18, 2017USD ($)storeitem	Mar. 31, 2018USD ($)store	Mar. 02, 2019USD ($)store	Dec. 01, 2018USD ($)	Sep. 01, 2018USD ($)	Jun. 02, 2018USD ($)	Mar. 03, 2018USD ($)	Dec. 02, 2017USD ($)	Sep. 02, 2017USD ($)	Jun. 03, 2017USD ($)	Mar. 02, 2019USD ($)segmentstore	Mar. 03, 2018USD ($)	Mar. 04, 2017USD ($)	Mar. 02, 2019item	Mar. 02, 2019	Jun. 28, 2017item
Description of Business
Number of reportable segments | segment												2
Number of stores | store				2,469								2,469
Revenues				$ 5,379,645	$ 5,450,060	$ 5,421,362	$ 5,388,490	$ 5,394,264	$ 5,353,170	$ 5,345,011	$ 5,436,523	$ 21,639,557	$ 21,528,968	$ 22,927,540
Rite Aid Corporation (Parent Company Only)
Description of Business
Ownership interest (as a percent)																100.00%
WBA and Walgreen Co. | Rite Aid Corporation (Parent Company Only)
Description of Business
Proceeds from assets sold												4,217,937
Intersegment elimination
Description of Business
Revenues												$ (211,283)	(200,326)	(232,964)
Asset Sale | WBA and Walgreen Co. | Rite Aid
Description of Business
Number of stores | store		1,932		1,932								1,932
Purchase price		$ 4,375,000
Proceeds from assets sold	$ 61,251		$ 4,156,686
Number of stores Rite Aid agreed to sell | store		1,932	1,932
Number of distribution centers agreed to sell	2	3		1								1			1		3
Asset Sale | WBA and Walgreen Co. | Rite Aid Corporation (Parent Company Only) | Rite Aid
Description of Business
Ownership interest (as a percent)		100.00%
Retail Pharmacy
Description of Business
Revenues												$ 15,757,152	15,832,625	16,766,620
Retail Pharmacy | Other
Description of Business
Revenues												150,461	155,636	155,788
Pharmacy sales
Description of Business
Revenues												10,391,539	10,328,376	11,072,480
Front end sales
Description of Business
Revenues												5,215,152	5,348,613	5,538,352
Pharmacy Services
Description of Business
Revenues												$ 6,093,688	$ 5,896,669	$ 6,393,884

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Sales by Product (Details)	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Fiscal Year
Length of reporting period	364 days	364 days	371 days
Finite-Lived Intangible Asset, Useful Life	5 years
Prescription drugs | Pharmacy sales | Retail Pharmacy
Product Class
Percentage of sales	66.60%	65.90%	66.00%
Over-the-counter medications and personal care | Pharmacy sales | Retail Pharmacy
Product Class
Percentage of sales	10.80%
Health and beauty aids | Pharmacy sales | Retail Pharmacy
Product Class
Percentage of sales	5.00%
General merchandise and other | Pharmacy sales | Retail Pharmacy
Product Class
Percentage of sales	17.60%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Revenue Recognition (Details) $ in Thousands	2 Months Ended	3 Months Ended								10 Months Ended	12 Months Ended
	Mar. 02, 2019USD ($)	Mar. 02, 2019USD ($)	Dec. 01, 2018USD ($)	Sep. 01, 2018USD ($)	Jun. 02, 2018USD ($)	Mar. 03, 2018USD ($)	Dec. 02, 2017USD ($)	Sep. 02, 2017USD ($)	Jun. 03, 2017USD ($)	Dec. 31, 2017	Mar. 02, 2019USD ($)Point	Mar. 03, 2018USD ($)	Mar. 04, 2017USD ($)	Mar. 04, 2018USD ($)	Feb. 27, 2016USD ($)
Intangible Assets
Estimated Useful Life											10 years
Estimated useful life of purchased prescription files acquired in other than business combinations											5 years
Deferred Financing Costs
Amortization expenses of deferred financing costs											$ 10,761	$ 8,403	$ 4,696
Revenue Recognition
Revenues		$ 5,379,645	$ 5,450,060	$ 5,421,362	$ 5,388,490	$ 5,394,264	$ 5,353,170	$ 5,345,011	$ 5,436,523		21,639,557	21,528,968	22,927,540
Accounts receivable, net	$ 1,788,712	1,788,712				1,869,100					1,788,712	1,869,100		$ 1,811,203
Inventories, net	1,871,941	1,871,941				1,799,539					1,871,941	1,799,539		1,850,660
Deferred tax assets	409,084	409,084				594,019					409,084	594,019		592,235
Total assets	7,591,367	7,591,367				8,989,327					7,591,367	8,989,327		8,980,767
Accumulated deficit	(4,713,244)	(4,713,244)				(4,282,471)					(4,713,244)	(4,282,471)		(4,291,031)
Total stockholders' equity	$ 1,186,690	1,186,690				1,601,010					1,186,690	1,601,010	614,070	1,592,450	$ 581,428
Advertising
Advertising expenses, net of vendor advertising allowances											$ 147,519	$ 161,826	$ 181,438
Income Taxes
Federal statutory rate (as a percent)	21.00%									35.00%	21.00%	32.60%	35.00%
Difference between Revenue Guidance in Effect before and after Topic 606
Revenue Recognition
Accounts receivable, net														(57,897)
Inventories, net														51,121
Deferred tax assets														(1,784)
Total assets														(8,560)
Accumulated deficit														(8,560)
Total stockholders' equity														(8,560)
Intersegment elimination
Revenue Recognition
Revenues											$ (211,283)	$ (200,326)	$ (232,964)
Accounts receivable, net	$ 14,459	14,459				16,256					14,459	16,256
Total assets	(14,459)	(14,459)				(54,969)					$ (14,459)	$ (54,969)
Trade names
Intangible Assets
Finite-lived intangible assets amortization period											10 years
Customer relationships
Intangible Assets
Finite-lived intangible assets amortization period											13 years	15 years
CMS license
Intangible Assets
Finite-lived intangible assets amortization period											22 years	23 years
CMS license | EnvisionRx
Intangible Assets
Finite-lived intangible assets amortization period											25 years
Minimum
Insurance
Workers compensation occurrences	1,000	1,000									$ 1,000
General liability occurrences	3,000	3,000									$ 3,000
Minimum | Customer relationships | EnvisionRx
Intangible Assets
Finite-lived intangible assets amortization period											10 years
Maximum | Customer relationships | EnvisionRx
Intangible Assets
Finite-lived intangible assets amortization period											20 years
Buildings | Minimum
Property, Plant and Equipment
Useful life											30 years
Buildings | Maximum
Property, Plant and Equipment
Useful life											45 years
Equipment | Minimum
Property, Plant and Equipment
Useful life											3 years
Equipment | Maximum
Property, Plant and Equipment
Useful life											15 years
Internal-use software
Property, Plant and Equipment
Capitalized costs											$ 13,716	$ 13,940	6,189
Retail Pharmacy
Revenue Recognition
Number of points awarded for each dollar spent towards front end merchandise | Point											1
Number of points awarded for each qualifying prescription | Point											25
Accumulated number of points in a calendar year to achieve the "Gold" tier | Point											1,000
Percentage discount on qualifying purchases of front end merchandise on achieving "Gold" tier											20.00%
Accrued contract liabilities	63,720	63,720				63,851					$ 63,720	63,851
Accrued contract liabilities included in other current liabilities	51,042	51,042				50,036					51,042	50,036
Accrued contract liabilities included in noncurrent liabilities	$ 12,678	$ 12,678				$ 13,815					$ 12,678	13,815
Expiration window to redeem accumulated Bonus Cash (in days)											60 days
Revenues											$ 15,757,152	15,832,625	16,766,620
Retail Pharmacy | Other
Revenue Recognition
Revenues											150,461	155,636	155,788
Pharmacy sales
Revenue Recognition
Revenues											10,391,539	10,328,376	11,072,480
Front end sales
Revenue Recognition
Revenues											5,215,152	5,348,613	5,538,352
Pharmacy Services
Revenue Recognition
Revenues											$ 6,093,688	$ 5,896,669	$ 6,393,884
Vendor Rebates and Allowances and Purchase Discounts
Period for rebates are dispensed to manufacturers											30 days
Accounting Standards Update 2016-09
Revenue Recognition
Accounts receivable, net														(57,897)
Inventories, net														51,121
Accumulated deficit														$ (8,560)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Significant Concentrations (Details) $ in Thousands	Mar. 15, 2019USD ($)	Mar. 15, 2018	Mar. 02, 2019USD ($)derivative	Mar. 03, 2018USD ($)derivative	Mar. 04, 2017USD ($)
Derivatives
Number of interest rate swap arrangements or other derivatives held | derivative			0	0
Interest rate cap
Derivatives
Principal amount of debt	$ 650,000
Interest rate cap | LIBOR
Derivatives
Interest rate	2.75%	2.75%
Retail Pharmacy | Pharmacy sales | Customers | Top five third party payors
Significant Concentrations
Percentage of concentration risk			80.40%
Retail Pharmacy | Pharmacy sales | Customers | Largest third party payor | Express Scripts
Significant Concentrations
Percentage of concentration risk					26.00%
Retail Pharmacy | Pharmacy sales | Customers | Largest third party payor | Caremark
Significant Concentrations
Percentage of concentration risk			28.30%	27.20%
Retail Pharmacy | Pharmacy sales | Customers | Medicaid agencies and related managed care Medicaid payors
Significant Concentrations
Percentage of concentration risk			19.10%
Retail Pharmacy | Pharmacy sales | Customers | Largest Medicaid agency
Significant Concentrations
Percentage of concentration risk			1.80%
Retail Pharmacy | Pharmacy sales | Customers | Medicare Part D
Significant Concentrations
Percentage of concentration risk			35.80%
Retail Pharmacy | Purchases | Suppliers | McKesson Corp.
Significant Concentrations
Percentage of concentration risk			99.00%
Pharmacy Services | Medicare Part D
Significant Concentrations
Percentage of revenues			1.80%	1.00%	1.00%
Derivatives
Net revenues			$ 391,024	$ 203,361	$ 223,077
Pharmacy Services | Medicare Part D | Swiss Re
Significant Concentrations
Percentage of revenues			50.00%
Percentage of cost of revenue			50.00%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details) $ in Thousands	12 Months Ended
	Mar. 02, 2019USD ($)	Mar. 03, 2018USD ($)	Mar. 04, 2018USD ($)
New accounting pronouncements
Accounts receivable, net	$ 1,788,712	$ 1,869,100	$ 1,811,203
Inventories, net	1,871,941	1,799,539	1,850,660
Deferred tax assets	221,777	228,444
Accumulated deficit	$ (4,713,244)	(4,282,471)	(4,291,031)
Reverse stock split ratio	1
Accounting Standards Update 2016-09
New accounting pronouncements
Accounts receivable, net			(57,897)
Inventories, net			51,121
Deferred tax assets			1,784
Accumulated deficit			$ (8,560)
Revenues reported under this contract		$ 123,500
Accounting Standards Update 2018-11 | Adjustments
New accounting pronouncements
Operating right-of-use assets	$ 3,100,000
Operating liabilities	$ 3,300,000

Asset Sale to WBA (Details)

Asset Sale to WBA (Details) $ in Thousands	Sep. 13, 2018USD ($)store	Sep. 18, 2017USD ($)storeitem	Mar. 31, 2018USD ($)store	Mar. 02, 2019USD ($)store	Dec. 01, 2018USD ($)	Sep. 01, 2018USD ($)	Jun. 02, 2018USD ($)	Mar. 03, 2018USD ($)	Dec. 02, 2017USD ($)	Sep. 02, 2017USD ($)	Jun. 03, 2017USD ($)	Mar. 02, 2019USD ($)store	Mar. 03, 2018USD ($)	Mar. 04, 2017USD ($)	Mar. 02, 2019item	Jun. 28, 2017item
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Total billings for purchase of inventory												$ 196,778	$ 185,879	$ 254,149
Payments incurred but not yet been paid												15,298	28,869	27,232
TSA fees from initial closing												(37,821)	(24,283)	(14,066)
Gain (Loss) on Disposition of Assets				$ 26,806	$ 382	$ 4,965	$ 5,859	$ 5,249	$ (205)	$ 14,951	$ 5,877	38,012	25,872	$ 6,649
Walgreens Boots Alliance merger termination fee										$ 325,000			325,000
Asset Sale
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Pre-tax gain on sale of the distribution center and related assets	$ 14,151
WBA and Walgreen Co.
Termination of the Merger Agreement with WBA and Asset Sale to WBA
TSA fees from initial closing												$ 80,277	8,422
WBA and Walgreen Co. | Rite Aid | Asset Sale
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Number of stores Rite Aid agreed to sell | store		1,932	1,932
Number of distribution centers agreed to sell	2	3		1								1			1	3
Purchase price		$ 4,375,000
Proceeds from assets sold	$ 61,251		$ 4,156,686
Maximum period for transition services (in years)												3 years
WBA | Selling, general and administrative expenses
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Total billings for purchase of inventory												$ 6,887,092	725,190
Payments incurred but not yet been paid												$ 293,662	$ 354,321

Asset Sale to WBA - Carrying am

Asset Sale to WBA - Carrying amount of assets sold (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Current assets held for sale
Current assets held for sale	$ 117,581	$ 438,137
Current liabilities held for sale
Current liabilities held for sale		560,205
Noncurrent liabilities held for sale
Goodwill	1,108,136	1,421,120	$ 1,682,847
Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale, Debt		549,549
Assets under Retail Pharmacy to be Sold | WBA | Assets held for sale
Current assets held for sale
Inventories	68,233	264,286
Property and equipment	49,348	158,433
Goodwill		4,629
Intangible assets		10,789
Current assets held for sale	117,581	438,137
Current liabilities held for sale
Current maturities of long-term lease financing obligations		270
Accrued salaries, wages and other current liabilities		6,146
Long-term debt, less current maturities		549,549
Lease financing obligations, less current maturities		838
Other noncurrent liabilities		3,402
Current liabilities held for sale		$ 560,205
Noncurrent liabilities held for sale
Goodwill	$ 76,124
Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale, Debt			$ 4,000,000

Asset Sale to WBA - Operating r

Asset Sale to WBA - Operating results of discontinued operations (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Income statement disclosures
Revenues									$ 34,889	$ 8,686,397	$ 10,050,049
Costs and expenses:
Cost of revenues									24,271	6,406,067	7,340,691
Selling, general and administrative expenses									20,681	2,134,276	2,465,364
Lease termination and impairment charges										77	9,516
Loss on debt retirements, net									22,646	8,180
Interest expense									4,616	224,300	231,926
Gain on assets sold to Walgreens Boots Alliance									(374,619)	(2,128,832)
Loss (gain) on sale of assets, net									1,486	(377)	2,625
Cost and expenses									(300,919)	6,643,691	10,050,122
Income from discontinued operations before income taxes									335,808	2,042,706	(73)
Income tax expense									91,067	749,704	46
Net income from discontinued operations, net of tax	$ (17,350)	$ 12,740	$ (6,792)	$ 256,143	$ 1,250,745	$ 99,213	$ (17,644)	$ (39,312)	$ 244,741	$ 1,293,002	$ (27)

(Loss) Income Per Share (Detail

(Loss) Income Per Share (Details) $ / shares in Units, $ in Thousands	Apr. 18, 2019shares	Apr. 10, 2019shares	Mar. 03, 2018$ / shares	Dec. 02, 2017$ / shares	Sep. 02, 2017$ / shares	Jun. 03, 2017$ / shares	Mar. 02, 2019USD ($)$ / sharesshares	Mar. 03, 2018USD ($)$ / sharesshares	Mar. 04, 2017USD ($)$ / sharesshares
Numerator:
(Loss) income from continuing operations attributable to common stockholders-basic and diluted | $							$ (666,954)	$ (349,532)	$ 4,080
Income (loss) from discontinued operations attributable to common stockholders-basic and diluted | $							244,741	1,293,002	(27)
(Loss) income attributable to common stockholders-basic and diluted | $							$ (422,213)	$ 943,470	$ 4,053
Denominator:
Basic weighted average shares | shares							52,854,000	52,481,000	52,221,000
Outstanding options and restricted shares, net (in shares) | shares									820,000
Diluted weighted-average shares | shares							52,854,000	52,481,000	53,041,000
Basic (loss) income per share:
Continuing operations | $ / shares			$ (9.18)	$ (0.35)	$ 3.59	$ (0.69)	$ (12.62)	$ (6.66)	$ 0.08
Discontinued operations | $ / shares			23.74	1.90	(0.33)	(0.75)	4.63	24.64	0
Net basic (loss) income per share | $ / shares			14.56	1.55	3.26	(1.44)	(7.99)	17.98	0.08
Diluted (loss) income per share:
Continuing operations | $ / shares			(9.18)	(0.35)	3.53	(0.69)	(12.62)	(6.66)	0.08
Discontinued operations | $ / shares			23.74	1.90	(0.33)	(0.75)	4.63	24.64	0
Net diluted (loss) income per share | $ / shares			$ 14.56	$ 1.55	$ 3.20	$ (1.44)	$ (7.99)	$ 17.98	$ 0.08
Reverse stock split
Reverse stock split ratio							1
Reverse stock split, 1-for-20
Reverse stock split
Reverse stock split ratio		0.05
Change in authorized shares due to reverse stock split | shares	75,000	1,500,000
Stock options
Antidilutive securities excluded from computation of income per share
Shares excluded from the computation of diluted income per share | shares							1,036,000	374,000	160,000
Restricted shares
Antidilutive securities excluded from computation of income per share
Shares excluded from the computation of diluted income per share | shares							1,008,000	610,000	0

Lease Termination and Impairm_3

Lease Termination and Impairment Charges (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 02, 2019USD ($)facilitylocationstore	Dec. 01, 2018USD ($)	Sep. 01, 2018USD ($)	Jun. 02, 2018USD ($)	Mar. 03, 2018USD ($)facilitylocationstore	Dec. 02, 2017USD ($)	Sep. 02, 2017USD ($)	Jun. 03, 2017USD ($)	Mar. 02, 2019USD ($)facilitylocationstore	Mar. 03, 2018USD ($)facilitylocationstore	Mar. 04, 2017USD ($)facilitylocationstore
Lease termination and impairment charges
Lease termination and impairment charges	$ 55,898	$ 2,628	$ 39,609	$ 9,859	$ 47,675	$ 3,939	$ 3,113	$ 4,038	$ 107,994	$ 58,765	$ 45,778
Number of stores | store	2,469								2,469
Revenues and operating losses of closed stores or stores approved for closure
Revenues	$ 5,379,645	5,450,060	5,421,362	5,388,490	5,394,264	5,353,170	5,345,011	5,436,523	$ 21,639,557	21,528,968	22,927,540
Income (loss) before income taxes	$ (60,625)	$ (18,721)	$ (458,907)	(51,224)	$ (266,954)	$ (34,243)	$ 305,810	(48,158)	(589,477)	(43,545)	48,518
Depreciation and amortization									$ 357,882	386,057	407,366
Active stores
Lease termination and impairment charges
Number of stores | store	2,469								2,469
Long-Lived Assets	$ 1,093,000								$ 1,093,000
Impairment charges
Lease termination and impairment charges
Lease termination and impairment charges									$ 63,492	$ 37,873	$ 22,631
Number of stores | location	446				373				446	373	266
Impairment charges | Active stores
Lease termination and impairment charges
Lease termination and impairment charges									$ 46,419	$ 34,782	$ 20,623
Number of stores | store	384				306				384	306	213
Period considered for recording impairment charges on the basis of operating loss									2 years
Impairment charges | Closed facilities
Lease termination and impairment charges
Lease termination and impairment charges									$ 2,788	$ 3,091	$ 2,008
Number of stores | facility	62				67				62	67	53
Lease termination charges									$ 2,788	$ 3,091	$ 2,008
Impairment charges | Other
Lease termination and impairment charges
Lease termination and impairment charges									14,285
Additional current period charges for stores previously impaired in prior periods | Active stores
Lease termination and impairment charges
Lease termination and impairment charges									$ 17,939	$ 7,313	$ 5,022
Number of stores | store	288				218				288	218	174
Number of stores fully impaired | store									286	215	173
Charges for new, relocated and remodeled stores that did not meet their asset recoverability test in the current period | Active stores
Lease termination and impairment charges
Lease termination and impairment charges									$ 10,595	$ 13,100	$ 13,232
Number of stores | store	22				28				22	28	22
Number of stores fully impaired | store									21	23	18
Period considered for impairment of relocated stores									2 years
Charges for the remaining stores that did not meet their asset recoverability test in the current period | Active stores
Lease termination and impairment charges
Lease termination and impairment charges									$ 17,885	$ 14,369	$ 2,369
Number of stores | store	74				60				74	60	17
Number of stores fully impaired | store									72	58	16
Lease termination charges
Lease termination and impairment charges
Number of stores | store	61				11				61	11	17
Lease termination charges									$ 44,502	$ 20,892	$ 23,147
Closed store and distribution center charges
Balance-beginning of period				$ 133,290				$ 165,138	133,290	165,138	208,421
Provision for present value of noncancellable lease payments of closed stores									35,190	8,871	6,503
Changes in assumptions about future sublease income, terminations and changes in interest rates									737	1,082	2,633
Interest accretion									9,741	11,439	14,186
Cash payments, net of sublease income									(54,912)	(53,240)	(66,605)
Balance-end of period	$ 124,046				$ 133,290				124,046	133,290	165,138
Closed stores or stores approved for closure
Revenues and operating losses of closed stores or stores approved for closure
Revenues									165,598	308,005	433,709
Operating expenses									182,201	342,103	471,971
Gain from sale of assets									(38,113)	(18,222)	(1,036)
Other expenses									2,183	2,417	4,590
Income (loss) before income taxes									19,327	(18,293)	(41,816)
Depreciation and amortization									621	1,742	3,560
Inventory liquidation charges									$ (5,523)	(2,828)	$ (187)
Minimum | Charges for new, relocated and remodeled stores that did not meet their asset recoverability test in the current period | Active stores
Lease termination and impairment charges
Period considered for recording impairment charges on the basis of operating loss									2 years
Period considered for impairment of new stores									3 years
Minimum | Charges for the remaining stores that did not meet their asset recoverability test in the current period | Active stores
Lease termination and impairment charges
Period considered for recording impairment charges on the basis of operating loss									2 years
Nonrecurring basis
Lease termination and impairment charges
Lease termination and impairment charges									$ 63,492	$ 37,873

Lease Termination and Impairm_4

Lease Termination and Impairment Charges - Fair value (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Non Financial Assets Measured on a Non Recurring Basis
Total Charges	$ (55,898)	$ (2,628)	$ (39,609)	$ (9,859)	$ (47,675)	$ (3,939)	$ (3,113)	$ (4,038)	$ (107,994)	$ (58,765)	$ (45,778)
Nonrecurring basis
Non Financial Assets Measured on a Non Recurring Basis
Long-lived assets held and used, impairment charges									(62,115)	(36,752)
Long-lived assets held for sale, impairment charges									(1,377)	(1,121)
Total Charges									(63,492)	(37,873)
Nonrecurring basis | Fair Value
Non Financial Assets Measured on a Non Recurring Basis
Long-lived assets held and used	8,116				17,474				8,116	17,474
Fair value of Long-lived assets held for sale	1,545				1,029				1,545	1,029
Fair value of Total	9,661				18,503				9,661	18,503
Nonrecurring basis | Level 2
Non Financial Assets Measured on a Non Recurring Basis
Long-lived assets held and used					2,893					2,893
Fair value of Long-lived assets held for sale	1,545				1,029				1,545	1,029
Fair value of Total	1,545				3,922				1,545	3,922
Nonrecurring basis | Level 3
Non Financial Assets Measured on a Non Recurring Basis
Long-lived assets held and used	8,116				14,581				8,116	14,581
Fair value of Total	$ 8,116				$ 14,581				$ 8,116	$ 14,581

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Other Financial Instruments
Outstanding derivative financial instruments	$ 0	$ 0
Prepaid expenses and other current assets
Other Financial Instruments
Investment at amortized cost	7,191	7,282
Nonrecurring basis | Level 1
Other Financial Instruments
Carrying value of total long-term indebtedness	3,454,585	3,889,738
Estimated fair value of total long-term indebtedness	$ 3,120,335	$ 3,927,411

Income Taxes (Details)

Income Taxes (Details) - USD ($)	2 Months Ended	3 Months Ended								10 Months Ended	12 Months Ended
	Mar. 02, 2019	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Dec. 31, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Federal statutory rate (as a percent)	21.00%									35.00%	21.00%	32.60%	35.00%
Current tax:
Federal											$ (22,187,000)	$ (210,000)
State											9,866,000	51,279,000	$ 14,600,000
Total current tax expense (benefit)											(12,321,000)	51,069,000	14,600,000
Deferred tax and other:
Federal											50,151,000	316,451,000	10,355,000
State											39,647,000	(61,533,000)	19,483,000
Total deferred tax expense (benefit)											89,798,000	254,918,000	29,838,000
Total income tax expense (benefit)		$ 195,004,000	$ (1,471,000)	$ (106,559,000)	$ (9,497,000)	$ 216,719,000	$ (16,061,000)	$ 117,450,000	$ (12,121,000)		77,477,000	305,987,000	44,438,000
Reconciliation of the expected statutory federal tax and the total income tax expense (benefit)
Federal statutory rate											(123,790,000)	(14,202,000)	16,982,000
Federal tax rate change		212,252,000				324,765,000						324,765,000
Nondeductible expenses											2,890,000	1,213,000	2,479,000
State income taxes, net											(12,605,000)	(22,836,000)	8,225,000
Increase/(decrease) of previously recorded liabilities											(3,105,000)	27,295,000	(955,000)
Nondeductible compensation											1,798,000	654,000	1,157,000
Acquisition costs												696,000	4,023,000
Stock based compensation											3,478,000	8,363,000
Valuation allowance											212,252,000	(8,853,000)	14,718,000
Other											(3,441,000)	(11,108,000)	(2,191,000)
Total income tax expense (benefit)		195,004,000	$ (1,471,000)	$ (106,559,000)	(9,497,000)	216,719,000	$ (16,061,000)	$ 117,450,000	(12,121,000)		77,477,000	305,987,000	44,438,000
Income tax (benefit) expense											91,067,000	749,704,000	46,000
Deferred tax assets:
Accounts receivable	$ 36,607,000	36,607,000				39,182,000					36,607,000	39,182,000
Accrued expenses	107,356,000	107,356,000				113,493,000					107,356,000	113,493,000
Liability for lease exit costs	37,333,000	37,333,000				40,662,000					37,333,000	40,662,000
Pension, retirement and other benefits	87,397,000	87,397,000				104,494,000					87,397,000	104,494,000
Long-lived assets	320,561,000	320,561,000				246,793,000					320,561,000	246,793,000
Credits	48,884,000	48,884,000				85,555,000					48,884,000	85,555,000
Net operating losses	1,084,139,000	1,084,139,000				1,089,084,000					1,084,139,000	1,089,084,000
Total gross deferred tax assets	1,722,277,000	1,722,277,000				1,719,263,000					1,722,277,000	1,719,263,000
Valuation allowance	(1,091,416,000)	(1,091,416,000)				(896,800,000)					(1,091,416,000)	(896,800,000)
Total deferred tax assets	630,861,000	630,861,000				822,463,000					630,861,000	822,463,000
Deferred tax liabilities:
Outside basis difference	5,392,000	5,392,000				5,420,000					5,392,000	5,420,000
Inventory	215,588,000	215,588,000				223,024,000					215,588,000	223,024,000
Other	797,000	797,000				0					797,000	0
Total gross deferred tax liabilities	221,777,000	221,777,000				228,444,000					221,777,000	228,444,000
Net deferred tax assets	409,084,000	409,084,000				594,019,000					409,084,000	594,019,000
Reconciliation of beginning and ending amount of unrecognized tax benefits
Unrecognized tax benefits at beginning of the period					$ 230,210,000				$ 8,939,000	$ 8,939,000	230,210,000	8,939,000	10,676,000
Increases to prior year tax positions											155,000		16,000
Decreases to tax positions in prior periods											(111,000)	(1,015,000)	(626,000)
Increases to current year tax positions												224,408,000	26,000
Divestitures											(543,000)	(1,607,000)
Lapse of statute of limitations											(9,872,000)	(515,000)	(1,153,000)
Unrecognized tax benefits balance at end of the period	219,839,000	219,839,000				230,210,000					219,839,000	230,210,000	8,939,000
Unrecognized tax benefits which would impact effective tax rate, if recognized	$ 28,482,000	$ 28,482,000				$ 31,377,000					28,482,000	31,377,000	892,000
Decrease in unrecognized tax benefits related to state exposures											12,736,000
Discontinued operations
Reconciliation of the expected statutory federal tax and the total income tax expense (benefit)
Valuation allowance											$ (2,417,000)	$ (32,870,000)	$ 15,000

Income Taxes - Tax Contingencie

Income Taxes - Tax Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Income Taxes
Interest and penalties related to tax contingencies recognized as income tax expense / (benefit)	$ (769)	$ 7,058	$ (276)
Accrued income tax-related interest and penalties	$ 6,553	$ 7,322
Period of state income tax returns subject to examination, low end of range	3 years
Period of state income tax returns subject to examination, high end of range	5 years

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Losses and Tax Credits (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018
Net Operating Losses and Tax Credits
Net tax effect of these carryforwards	$ 1,089,656
Alternative minimum tax credit carryforwards	13,497
Valuation Allowance
Valuation allowance	1,091,416	$ 896,800
Federal
Net Operating Losses and Tax Credits
Net operating loss carryforwards	1,063,382
Federal business tax credit carryforwards	28,478
Federal | Net Operating Loss Expiration Period 2029 and 2031
Net Operating Losses and Tax Credits
Net operating losses expiration amount	884,627
Federal | Net Operating Loss Expiration Period 2032 and 2037
Net Operating Losses and Tax Credits
Net operating losses expiration amount	178,246
State
Net Operating Losses and Tax Credits
Net operating loss carryforwards	$ 12,048,528

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Accounts Receivable
Allowance for uncollectible accounts	$ 13,106	$ 25,134

Medicare Part D (Details)

Medicare Part D (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Dec. 31, 2018	Mar. 03, 2018
Medicare Part D
Accounts receivable, net	$ 392,400		$ 350,563
Accrued salaries, wages and other current liabilities
Medicare Part D
Liabilities under reinsurance contracts	$ 0		$ 183,318
EIC
Medicare Part D
Minimum amount of capital and surplus required by regulatory requirements		$ 15,076

Manufacturer Rebates Receivab_2

Manufacturer Rebates Receivables (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Pharmacy Services
Manufacturer Rebates Receivables
Rebates receivables	$ 445,200	$ 370,861

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Inventory
Inventories, last-in, first-out (LIFO) cost flow assumption	$ 604,444	$ 581,090	$ 604,444	$ 581,090
LIFO charge (credit)	$ 4,043	$ (49,220)	23,354	(28,827)	$ (3,721)
Amount of decrease in the cost of revenues due to the effect of LIFO inventory liquidation			$ 5,884	$ 2,707	$ 2,375

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Property, Plant and Equipment
Property, plant and equipment, gross	$ 4,053,956	$ 4,115,345
Accumulated depreciation	(2,745,442)	(2,684,099)
Property, plant and equipment, net	1,308,514	1,431,246
Depreciation expense	232,242	238,318	$ 241,787
Carrying amount of assets to be disposed	452	972
Land
Property, Plant and Equipment
Property, plant and equipment, gross	139,406	138,768
Buildings
Property, Plant and Equipment
Property, plant and equipment, gross	533,580	528,026
Leasehold improvements
Property, Plant and Equipment
Property, plant and equipment, gross	1,527,371	1,567,635
Equipment
Property, Plant and Equipment
Property, plant and equipment, gross	1,765,575	1,795,337
Software
Property, Plant and Equipment
Property, plant and equipment, gross	38,680	25,944
Construction in progress
Property, Plant and Equipment
Property, plant and equipment, gross	$ 49,344	$ 59,635

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 03, 2018	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Goodwill
Goodwill impairment, net of tax	$ 191,000	$ 235,698	$ 191,000
Carrying amount of goodwill
Beginning Balance		1,421,120	1,682,847
Goodwill impairment	(261,727)	(312,984)	(261,727)	$ 0
Ending Balance	1,421,120	1,108,136	1,421,120	1,682,847
Retail Pharmacy
Carrying amount of goodwill
Beginning Balance		43,492	43,492
Ending Balance	43,492	43,492	43,492	43,492
Pharmacy Services
Goodwill
Accumulated impairment losses	261,727	574,712	261,727
Carrying amount of goodwill
Beginning Balance		1,377,628	1,639,355
Goodwill impairment		(312,984)	(261,727)
Ending Balance	$ 1,377,628	$ 1,064,644	$ 1,377,628	$ 1,639,355

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 1,826,689	$ 1,892,551
Accumulated Amortization	(1,397,483)	(1,335,608)
Net	429,206	556,943
Gross Carrying Amount, Total	1,846,189	1,926,051
Net, Total	448,706	590,443
Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Indefinite Lived	19,500	33,500
Pharmacy Services | Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Impairment charge of indefinite-lived intangible assets	14,000
Favorable leases and other
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	370,855	379,355
Accumulated Amortization	(318,503)	(316,798)
Net	$ 52,352	$ 62,557
Remaining Weighted Average Amortization Period	7 years	7 years
Prescription files
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 919,749	$ 900,111
Accumulated Amortization	(827,222)	(801,706)
Net	$ 92,527	$ 98,405
Remaining Weighted Average Amortization Period	3 years	3 years
Customer relationships
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 388,000	$ 465,000
Accumulated Amortization	(193,352)	(172,635)
Net	$ 194,648	$ 292,365
Remaining Weighted Average Amortization Period	13 years	15 years
Customer relationships | Pharmacy Services
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 77,000
Accumulated Amortization	28,795
Impairment charge of finite-lived intangible assets	48,205
CMS license
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	57,500	$ 57,500
Accumulated Amortization	(8,472)	(6,172)
Net	$ 49,028	$ 51,328
Remaining Weighted Average Amortization Period	22 years	23 years
Claims adjudication and other developed software
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 58,985	$ 58,985
Accumulated Amortization	(31,030)	(22,617)
Net	$ 27,955	$ 36,368
Remaining Weighted Average Amortization Period	4 years	5 years
Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 20,100	$ 20,100
Accumulated Amortization	(7,404)	(5,394)
Net	$ 12,696	$ 14,706
Remaining Weighted Average Amortization Period	7 years	8 years
Backlog
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 11,500	$ 11,500
Accumulated Amortization	$ (11,500)	(10,286)
Net		$ 1,214
Remaining Weighted Average Amortization Period	0 years	1 year

Goodwill and Other Intangible_4

Goodwill and Other Intangibles - Unfavourable lease intangibles and amortization expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Goodwill and Other Intangibles
Unfavorable lease intangibles	$ 14,763	$ 18,888
Amortization expense for intangible assets and liabilities	125,640	$ 147,739	$ 165,579
Anticipated annual amortization expense for intangible assets and liabilities
2020	100,892
2021	77,824
2022	56,890
2023	41,344
2024	$ 28,905

Accrued Salaries, Wages and O_3

Accrued Salaries, Wages and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Accrued Salaries, Wages and Other Current Liabilities
Accrued wages, benefits and other personnel costs	$ 302,025	$ 360,179
Accrued interest	13,991	65,210
Accrued sales and other taxes payable	80,708	125,289
Accrued store expense	143,053	155,354
Accrued reinsurance		183,418
Other	268,662	342,286
Accrued salaries, wages and other current liabilities	$ 808,439	$ 1,231,736

Indebtedness and Credit Agree_3

Indebtedness and Credit Agreements - Indebtedness and lease financing obligations (Details) - USD ($) $ in Thousands	Mar. 15, 2019	Dec. 20, 2018	Jun. 25, 2018	May 21, 2018	Apr. 29, 2018	Apr. 19, 2018	Apr. 12, 2018	Mar. 29, 2018	Mar. 15, 2018	Feb. 27, 2018	Feb. 28, 2018	Jun. 02, 2018	Mar. 02, 2019	Apr. 28, 2018	Mar. 03, 2018	Jan. 31, 2018
Indebtedness and credit agreements
Long-term debt															$ 3,889,738
Lease financing obligations													$ 40,176		52,554
Total Debt													3,494,760		3,942,292
Current maturities of long-term debt and lease financing obligations													(16,111)		(21,031)
Long-term debt and lease financing obligations, less current maturities													3,478,649		3,921,261
Loss on debt retirements, net											$ 8,180	$ 554	554
Secured Debt
Indebtedness and credit agreements
Long-term debt													1,297,013		12,986
Senior secured revolving credit facility due January 2020
Indebtedness and credit agreements
Long-term debt															13,076
Principal amount of debt													0
Unamortized debt issuance costs													0		13,076
Maximum borrowing capacity					$ 2,700,000						$ 3,000,000		2,700,000	$ 3,000,000		$ 3,700,000
Loss on debt retirements, net					$ 1,091
Senior secured revolving credit facility due January 2020 | Maximum | LIBOR
Indebtedness and credit agreements
Interest rate		1.75%
Senior secured revolving credit facility due December 2023
Indebtedness and credit agreements
Long-term debt													850,931
Principal amount of debt													875,000		0
Unamortized debt issuance costs													24,069		0
Maximum borrowing capacity		$ 2,700,000
Senior secured revolving credit facility due December 2023 | Minimum | LIBOR
Indebtedness and credit agreements
Interest rate		1.25%
FILO term loan due December 2023
Indebtedness and credit agreements
Long-term debt													446,082
Principal amount of debt		$ 450,000											450,000		0
Unamortized debt issuance costs													3,918		0
FILO term loan due December 2023 | LIBOR
Indebtedness and credit agreements
Interest rate		3.00%
Other secured
Indebtedness and credit agreements
Long-term debt															90
Tranche 1 Term Loan (second lien) due August 2020
Indebtedness and credit agreements
Principal amount of debt																470,000
Tranche 2 Term Loan (second lien) due June 2021
Indebtedness and credit agreements
Principal amount of debt																$ 500,000
Guaranteed Unsecured Debt
Indebtedness and credit agreements
Long-term debt													$ 1,736,508		3,481,891
9.25% senior notes due March 2020
Indebtedness and credit agreements
Long-term debt															$ 898,476
Debt instrument, stated interest rate (as a percent)													9.25%		9.25%
Principal amount of debt													$ 0		$ 902,000
Unamortized debt issuance costs													0		4,924
Unamortized premium													$ 0		1,400
Loss on debt retirements, net							$ 3,422
Offer to purchase of outstanding amount										$ 900,000
Principal amount of debt redeemed								$ 3,454
Percentage of outstanding principal amount redeemed							100.00%	0.38%
6.75% senior notes due June 2021
Indebtedness and credit agreements
Long-term debt															$ 805,123
Debt instrument, stated interest rate (as a percent)													6.75%		6.75%
Principal amount of debt													$ 0		$ 810,000
Unamortized debt issuance costs													0		4,877
Loss on debt retirements, net			$ 18,075	$ 8
Principal amount of debt redeemed			$ 805,169	1,360				$ 3,471
Percentage of outstanding principal amount redeemed								0.43%
6.125% senior notes due April 2023
Indebtedness and credit agreements
Long-term debt													$ 1,736,508		$ 1,778,292
Debt instrument, stated interest rate (as a percent)													6.125%		6.125%
Principal amount of debt													$ 1,753,490		$ 1,800,000
Unamortized debt issuance costs													16,982		21,708
Loss on debt retirements, net				56				$ 49					498
Principal amount of debt redeemed				$ 4,759				$ 41,751
Percentage of outstanding principal amount redeemed								2.32%
6.75% and 6.125% senior notes
Indebtedness and credit agreements
Offer to purchase of outstanding amount						$ 700,000
Unguaranteed Unsecured Debt
Indebtedness and credit agreements
Long-term debt													421,063		420,833
7.7% notes due February 2027
Indebtedness and credit agreements
Long-term debt													$ 293,705		$ 293,540
Debt instrument, stated interest rate (as a percent)													7.70%		7.70%
Principal amount of debt													$ 295,000		$ 295,000
Unamortized debt issuance costs													1,295		1,460
6.875% fixed-rate senior notes due December 2028
Indebtedness and credit agreements
Long-term debt													$ 127,358		$ 127,293
Debt instrument, stated interest rate (as a percent)													6.875%		6.875%
Principal amount of debt													$ 128,000		$ 128,000
Unamortized debt issuance costs													$ 642		$ 707
Interest rate cap
Indebtedness and credit agreements
Principal amount of debt	$ 650,000
Interest rate cap | LIBOR
Indebtedness and credit agreements
Interest rate	2.75%								2.75%

Indebtedness and Credit Agree_4

Indebtedness and Credit Agreements - Continuing operations and discontinued operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Indebtedness and Credit Agreements
Long-term Debt, Total		$ 3,889,738
Capital Lease Obligations, Total	$ 40,176	52,554
Total Debt	3,494,760	3,942,292
Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale, Debt		(549,549)
Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale, Lease Financing Obligations		(1,108)
Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale, Total Debt and Lease Financing Obligations		(550,657)
Total debt and lease financing obligations, Debt		3,340,189
Total debt and lease financing obligations, Lease financing obligations		51,446
Total debt and lease financing obligations		3,391,635
Current maturities of long-term debt - continuing operations		(90)
Current maturities of lease financing obligations - continuing operations	(16,112)	(20,671)
Current maturities of long-term debt and lease financing obligations - continuing operations		(20,761)
Long-term debt, less current maturities - continuing operations		3,340,099
Lease financing obligations, less current maturities - continuing operations		30,775
Long-term debt and lease financing obligations, less current maturities - continuing operations		3,370,874
Excess cash proceeds from sale of debt		4,000,000
Use of cash for financing purposes	$ (1,343,793)	$ (3,140,119)	$ (4,651)
Interest Rates and Maturities
Annual weighted average rate (as a percent)	5.60%	7.10%	5.40%

Indebtedness and Credit Agree_5

Indebtedness and Credit Agreement - Credit Facility (Details) $ in Thousands	Dec. 20, 2018USD ($)	Mar. 02, 2019USD ($)	Apr. 29, 2018USD ($)	Apr. 28, 2018USD ($)	Mar. 03, 2018USD ($)	Feb. 28, 2018USD ($)	Jan. 31, 2018USD ($)	Mar. 04, 2017
Interest Rates and Maturities
Annual weighted average rate (as a percent)		5.60%			7.10%			5.40%
Maturities
2020		$ 0
2021		0
2022		0
2023		0
thereafter		$ 3,501,490
Rite Aid Corporation (Parent Company Only)
Credit facility
Ownership interest (as a percent)		100.00%
Senior secured revolving credit facility due January 2020
Credit facility
Principal amount of debt		$ 0
Maximum borrowing capacity		$ 2,700,000	$ 2,700,000	$ 3,000,000		$ 3,000,000	$ 3,700,000
Maximum amount of accumulated cash on hand	$ 200,000
Number of days relating to debt threshold		90 days
Senior secured revolving credit facility due January 2020 | Minimum
Credit facility
Fixed charge coverage ratio		1
Senior secured revolving credit facility due January 2020 | LIBOR | Maximum
Credit facility
Percentage points added to the reference rate	1.75%
Senior secured revolving credit facility due December 2023
Credit facility
Principal amount of debt		$ 875,000			$ 0
Maximum borrowing capacity	$ 2,700,000
Outstanding borrowings		1,325,000
Letters of credit outstanding		83,205
Additional borrowing capacity		1,741,795
Amount of debt allowed to be outstanding		1,500,000
Threshold amount of debt		750,000
Number of days relating to debt threshold	90 days
Availability under revolving credit facility		1,741,795
Senior secured revolving credit facility due December 2023 | Minimum
Credit facility
Additional borrowing capacity		365,000
Fixed charge coverage ratio	1
Threshold availability on the third consecutive business day	$ 250,000
Senior secured revolving credit facility due December 2023 | Maximum
Credit facility
Threshold availability on revolving credit facility to trigger fixed charge coverage requirements	200,000
Threshold availability on the third consecutive business day	$ 250,000
Senior secured revolving credit facility due December 2023 | LIBOR | Minimum
Credit facility
Percentage points added to the reference rate	1.25%
Senior secured revolving credit facility due December 2023 | Alternate base rate | Minimum
Credit facility
Percentage points added to the reference rate	0.25%
Senior secured revolving credit facility due December 2023 | Alternate base rate | Maximum
Credit facility
Percentage points added to the reference rate	0.75%
FILO term loan due December 2023
Credit facility
Principal amount of debt	$ 450,000	$ 450,000			$ 0
FILO term loan due December 2023 | LIBOR
Credit facility
Percentage points added to the reference rate	3.00%
FILO term loan due December 2023 | Alternate base rate
Credit facility
Percentage points added to the reference rate	2.00%

Leases (Details)

Leases (Details) $ in Thousands	12 Months Ended
	Mar. 02, 2019USD ($)store	Mar. 03, 2018USD ($)	Mar. 04, 2017USD ($)
Leases
Sublease income	$ 4,509	$ 4,682	$ 4,813
Total rental expense, net of sublease income	626,166	628,511	634,539
Contingent rental	7,084	$ 8,339	$ 10,229
Proceeds from sale of owned properties	$ 2,587
Minimum
Leases
Initial lease terms under noncancellable operating and capital leases	5 years
Initial terms of noncancellable operating lease	3 years
Maximum
Leases
Initial lease terms under noncancellable operating and capital leases	22 years
Initial terms of noncancellable operating lease	10 years
WBA
Leases
Number of former stores related to asset sale | store	1,656
Number of former stores have guarantees that exceed 10 years | store	84
WBA | Minimum
Leases
Initial terms of noncancellable operating lease	10 years
WBA | Maximum
Leases
Initial terms of noncancellable operating lease	10 years
Lease guarantee obligations	$ 1,800,000

Leases - Net Book Value (Detail

Leases - Net Book Value (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Net book values of assets under capital leases and sale-leasebacks
Accumulated depreciation	$ (77,892)	$ (78,637)
Net value	28,015	36,058
Capital leases
Obligations under financing leases	40,176	51,446
Less current obligation	(16,112)	(20,671)
Lease financing obligations, less current maturities	24,064	30,775
Minimum payments for Lease Financing Obligations
2020	19,300
2021	4,811
2022	4,588
2023	4,383
2024	4,042
Later years	20,470
Total minimum lease payments	57,594
Amount representing interest	(17,418)
Present value of minimum lease payments	40,176
Minimum payments for Operating Leases
2020	687,412
2021	610,874
2022	545,863
2023	490,864
2024	431,714
Later years	1,541,408
Total minimum lease payments	4,308,135
Land
Net book values of assets under capital leases and sale-leasebacks
Gross value	2,688	3,458
Buildings
Net book values of assets under capital leases and sale-leasebacks
Gross value	83,624	86,012
Equipment
Net book values of assets under capital leases and sale-leasebacks
Gross value	$ 19,595	$ 25,225

Stock Option and Stock Award _3

Stock Option and Stock Award Plans (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Stock options and stock award Plans
Stock-based compensation costs	$ 12,115	$ 25,793	$ 23,482
Shares of common stock authorized under stock-based compensation plans	1,251
Maximum
Stock options and stock award Plans
Term of options	10 years
Stock options
Fair value assumptions
Expected stock price volatility (as a percent)		58.00%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%
Risk-free interest rate (as a percent)		1.90%
Expected option life (in years)		5 years 6 months
Shares
Outstanding at the beginning of the period (in shares)	1,343	1,694	1,906
Granted (in shares)		50
Exercised (in shares)	(99)	(241)	(178)
Cancelled (in shares)	(208)	(160)	(34)
Outstanding at the end of the period (in shares)	1,036	1,343	1,694
Vested or expected to vest at the end of the period (in shares)	1,025
Exercisable at the end of the period (in shares)	978
Weighted Average Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 51.42	$ 54.93	$ 54.53
Granted (in dollars per share)		41
Exercised (in dollars per share)	23.07	24.05	39.07
Cancelled (in dollars per share)	71.07	126.61	111.99
Outstanding at the end of the period (in dollars per share)	50.15	51.42	54.93
Vested or expected to vest at the end of the period (in dollars per share)	49.07
Exercisable at the end of the period (in dollars per share)	$ 47.87
Weighted Average Remaining Contractual Term
Outstanding at the end of the period	3 years 1 month 13 days
Vested or expected to vest at the end of the period	3 years 1 month 6 days
Exercisable at the end of the period	2 years 10 months 6 days
Aggregate Intrinsic Value
Outstanding at the end of the period	$ 0
Vested or expected to vest at the end of the period	0
Exercisable at the end of the period	0
Unrecognized pre-tax compensation costs related to unvested stock options and restricted stock grants
Unrecognized pre-tax costs	$ 1,147
Weighted average amortization period	1 year 6 months 26 days
Additional General Disclosures
Weighted average fair value of options granted (in dollars per share)	$ 0	$ 21.60	$ 0
Cash received from stock option exercises	$ 2,294	$ 5,796	$ 6,951
Income tax benefit from stock options	7	10	421
Total intrinsic value of options exercised	$ 726	3,032	20,475
Vesting period	4 years
Restricted shares
Unrecognized pre-tax compensation costs related to unvested stock options and restricted stock grants
Unrecognized pre-tax costs	$ 21,302
Weighted average amortization period	1 year 10 months 24 days
Additional General Disclosures
Total fair value of awards vested during the period	$ 16,519	$ 31,125	$ 13,951
Shares
Outstanding at the beginning of the period (in shares)	611	291	243
Granted (in shares)	700	693	180
Vested (in shares)	(215)	(194)	(111)
Cancelled (in shares)	(88)	(179)	(21)
Outstanding at the end of the period (in shares)	1,008	611	291
Weighted Average Grant Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 66.34	$ 157.35	$ 144.61
Granted (in dollars per share)	16.05	56.44	154.60
Vested (in dollars per share)	76.99	160.61	125.55
Cancelled (in dollars per share)	72.87	73.95	156.85
Outstanding at the end of the period (in dollars per share)	$ 28.60	$ 66.34	$ 157.35
Restricted shares | Maximum
Additional General Disclosures
Vesting period	3 years
Performance based awards
Stock options and stock award Plans
Stock-based compensation costs	$ (1,084)	$ 4,122	$ (6,070)
2000 Plan
Stock options and stock award Plans
Shares of common stock reserved for the granting of stock options and other incentive awards	1,100
2001 Plan
Stock options and stock award Plans
Shares of common stock authorized under stock-based compensation plans	1,000
2004 Omnibus Equity Plan
Stock options and stock award Plans
Shares of common stock authorized under stock-based compensation plans	1,000
2006 Omnibus Equity Plan
Stock options and stock award Plans
Shares of common stock available for grant	2,500
2010 Omnibus Equity Plan
Stock options and stock award Plans
Shares of common stock available for grant	1,750
2012 Omnibus Equity Plan
Stock options and stock award Plans
Shares of common stock available for grant	1,425
2014 Omnibus Equity Plan
Stock options and stock award Plans
Shares of common stock available for grant	2,900
2014 Omnibus Equity Plan | Stock options | Maximum
Stock options and stock award Plans
Shares of common stock available for grant	1,250

Retirement Plans (Details)

Retirement Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Defined Contribution Plans
Employer match of employee contributions up to 3% of pretax annual compensation to 401 (k) defined contribution plan (as a percent)	100.00%
Percentage of participant's pretax annual compensation matched 100% by employer	3.00%
Employer match of employee contributions of additional 2% of pretax annual compensation to 401 (k) defined contribution plan (as a percent)	50.00%
Percentage of participant's pretax annual compensation matched 50% by employer	2.00%
Total expense recognized for 401(k) defined contribution plans	$ 44,564	$ 67,949	$ 68,393
Vesting period	5 years
Expense recognized for supplemental retirement defined contribution plan	$ 4,913	$ 12,426	16,921
Vested (as a percent)	100.00%
Estimated amounts that will be amortized from accumulated other comprehensive loss into net periodic pension expense
Net actuarial loss	$ 1,661
Prior service cost	$ 0
Asset allocations
Total (as a percent)	100.00%	100.00%
Target allocation of plan assets
Total (as a percent)	100.00%
Equity securities
Asset allocations
Total (as a percent)	52.00%	53.00%
U.S. equities
Target allocation of plan assets
Total (as a percent)	39.00%
International equity
Target allocation of plan assets
Total (as a percent)	13.00%
Fixed income securities
Asset allocations
Total (as a percent)	48.00%	47.00%
Target allocation of plan assets
Total (as a percent)	48.00%
Defined Benefit Pension Plan
Net periodic pension expense
Service cost	$ 597	$ 1,212	1,291
Interest cost	6,159	6,340	6,634
Expected return on plan assets	(5,673)	(4,525)	(4,512)
Amortization of unrecognized net loss	1,769	3,393	5,085
Net periodic pension expense	2,852	6,420	8,498
Other changes recognized in other comprehensive loss:
Unrecognized net (gain) loss arising during period	(3,486)	(8,704)	(3,979)
Amortization of unrecognized net (loss) gain	(1,769)	(3,393)	(5,085)
Net amount recognized in other comprehensive loss	(5,255)	(12,097)	(9,064)
Net amount recognized in pension expense and other comprehensive loss	(2,403)	(5,677)	(566)
Change in benefit obligations:
Benefit obligation at end of prior year	161,851	164,349
Service cost	597	1,212	1,291
Interest cost	6,159	6,340	6,634
Distributions	(8,816)	(7,963)
Actuarial loss (gain)	(9,086)	(2,087)
Benefit obligation at end of year	150,705	161,851	164,349
Change in plan assets:
Fair value of plan assets at beginning of year	130,860	118,658
Employer contributions	2,715	9,023	0
Actual return on plan assets	72	11,142
Distributions (including expenses paid by the plan)	(8,815)	(7,963)
Fair value of plan assets at end of year	124,832	130,860	$ 118,658
Funded status	(25,873)	(30,991)
Amounts recognized in consolidated balance sheets consisted of:
Accrued pension liability	(25,873)	(30,991)
Net amount recognized	(25,873)	(30,991)
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial loss	(27,409)	(32,664)
Amount recognized	(27,409)	(32,664)
Estimated amounts that will be amortized from accumulated other comprehensive loss into net periodic pension expense
Accumulated benefit obligation	$ 150,705	$ 161,851
Significant actuarial assumptions used for all defined benefit plans to determine the benefit obligation
Discount rate (as a percent)	4.25%	4.00%	4.00%
Expected long-term rate of return on plan assets	6.25%	6.25%	6.50%
Weighted average assumptions used to determine net cost
Discount rate (as a percent)	4.00%	4.00%	4.25%
Expected long-term rate of return on plan assets (as a percent)	6.25%	6.50%	6.50%
Defined benefit plans estimated future employer contributions
Expected employer contribution during next fiscal year	$ 0

Retirement Plans - Fair Value (

Retirement Plans - Fair Value (Details) - Recurring - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Retirement Plans
Total assets at fair value	$ 124,832	$ 130,860
International equity
Retirement Plans
Total assets at fair value	15,396	18,043
Large Cap
Retirement Plans
Total assets at fair value	34,058	35,491
Small-Mid Cap
Retirement Plans
Total assets at fair value	14,534	15,510
Long Term Credit Bond Index
Retirement Plans
Total assets at fair value	44,103	46,222
Long Term US Government Bonds
Retirement Plans
Total assets at fair value	8,383	8,070
20+ Year Treasury STRIPS
Retirement Plans
Total assets at fair value	847	1,168
Intermediate Fixed Income
Retirement Plans
Total assets at fair value	5,920	5,617
Short Term Investments
Retirement Plans
Total assets at fair value	$ 1,591	$ 739

Retirement Plans - Future Benef

Retirement Plans - Future Benefit Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Future benefit payments expected to be paid in Fiscal Year
Multiemployer plans total expenses recognized	$ 23,499	$ 20,979	$ 21,336
Defined Benefit Pension Plan
Future benefit payments expected to be paid in Fiscal Year
2020	8,690
2021	8,844
2022	8,999
2023	9,005
2024	9,213
2025 - 2029	45,903
Total	$ 90,654

Multiemployer Plans that Prov_3

Multiemployer Plans that Provide Pension Benefits (Details) $ in Thousands	Oct. 01, 2018$ / h	Sep. 30, 2018	Feb. 04, 2018$ / h	Feb. 05, 2017$ / h	Jan. 01, 2017$ / h	Jan. 01, 2016	Sep. 01, 2014$ / h	Feb. 04, 2017$ / h	Dec. 31, 2019$ / h	Mar. 02, 2019USD ($)	Dec. 31, 2018$ / h	Mar. 03, 2018USD ($)	Dec. 31, 2017$ / h	Mar. 04, 2017USD ($)	Dec. 31, 2016$ / h
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										$ 23,499		$ 20,979		$ 21,336
Minimum
Multiemployer Plans that Provide Pension Benefits
Company listed in these plan's Forms 5500 as providing more than specified percentage of the total contributions (as a percent)										5.00%
1199 SEIU Health Care Employees Pension Fund
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										$ 9,670		7,372		7,152
Minimum funding requirements (as a percent)		15.80%				10.76%
Southern California United Food and Commercial Workers Unions and Drug Employers Pension Fund
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										8,273		8,149		8,021
Minimum funding requirements for non pharmacists (in dollars per hour) | $ / h									1.672
Minimum funding requirements (in dollars per hour) | $ / h									0.758		1.586		1.50
UFCW Pharmacists, Clerks and Drug Employers Pension Trust
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										2,666		2,739		2,970
Minimum funding requirements (in dollars per hour) | $ / h							0.55
United Food and Commercial Workers Union-Employer Pension Fund
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										772		786		827
Minimum funding requirements (in dollars per hour) | $ / h			2.03	1.89				1.76
United Food and Commercial Workers Union Local 880 - Mercantile Employers Joint Pension Fund
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										470		495		504
Minimum funding requirements (in dollars per hour) | $ / h	1.97				1.88										1.79
Other Funds
Multiemployer Plans that Provide Pension Benefits
Contributions by employer										$ 1,648		$ 1,438		$ 1,862

Segment Reporting - Balance She

Segment Reporting - Balance Sheet information (Details) $ in Thousands	12 Months Ended
	Mar. 02, 2019USD ($)segment	Mar. 03, 2018USD ($)	Mar. 04, 2018USD ($)	Mar. 04, 2017USD ($)
Segment Reporting
Number of reportable segments | segment	2
Total assets	$ 7,591,367	$ 8,989,327	$ 8,980,767
Goodwill	1,108,136	1,421,120		$ 1,682,847
Additions to property and equipment and intangible assets	244,689	214,764
Accounts receivable	1,788,712	1,869,100	$ 1,811,203
Retail Pharmacy
Segment Reporting
Goodwill	43,492	43,492		43,492
Pharmacy Services
Segment Reporting
Goodwill	1,064,644	1,377,628		$ 1,639,355
Operating segments | Retail Pharmacy
Segment Reporting
Total assets	5,071,055	6,089,343
Goodwill	43,492	43,492
Additions to property and equipment and intangible assets	228,079	199,437
Operating segments | Pharmacy Services
Segment Reporting
Total assets	2,534,771	2,954,953
Goodwill	1,064,644	1,377,628
Additions to property and equipment and intangible assets	16,610	15,327
Intersegment elimination
Segment Reporting
Total assets	(14,459)	(54,969)
Long-term deferred tax liability	0	38,713
Accounts receivable	$ 14,459	$ 16,256

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Segment Reporting
Revenues	$ 5,379,645	$ 5,450,060	$ 5,421,362	$ 5,388,490	$ 5,394,264	$ 5,353,170	$ 5,345,011	$ 5,436,523	$ 21,639,557	$ 21,528,968	$ 22,927,540
Gross Profit									4,676,352	4,780,105	5,064,707
Adjusted EBITDA									563,444	559,854	747,888
Retail Pharmacy
Segment Reporting
Revenues									15,757,152	15,832,625	16,766,620
Pharmacy Services
Segment Reporting
Revenues									6,093,688	5,896,669	6,393,884
Operating segments | Retail Pharmacy
Segment Reporting
Revenues									15,757,152	15,832,625	16,766,620
Gross Profit									4,258,716	4,372,373	4,671,975
Adjusted EBITDA									405,206	388,320	559,653
Operating segments | Pharmacy Services
Segment Reporting
Revenues									6,093,688	5,896,669	6,393,884
Gross Profit									417,636	407,732	392,732
Adjusted EBITDA									158,238	171,534	188,235
Intersegment elimination
Segment Reporting
Revenues									$ (211,283)	$ (200,326)	$ (232,964)

Segment Reporting - Adjusted EB

Segment Reporting - Adjusted EBITDA (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Feb. 28, 2018	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Segment Reporting
Net (loss) income from continuing operations		$ (255,629)	$ (17,250)	$ (352,348)	$ (41,727)	$ (483,673)	$ (18,182)	$ 188,360	$ (36,037)	$ (666,954)	$ (349,532)	$ 4,080
Interest expense		52,695	56,008	56,233	62,792	50,603	50,308	50,857	51,000	227,728	202,768	200,065
Income tax expense		195,004	(1,471)	(106,559)	(9,497)	216,719	(16,061)	117,450	(12,121)	77,477	305,987	44,438
Depreciation and amortization										357,882	386,057	407,366
LIFO charge (credit)		4,043				(49,220)				23,354	(28,827)	(3,721)
Lease termination and impairment charges		55,898	2,628	39,609	9,859	47,675	3,939	3,113	4,038	107,994	58,765	45,778
Goodwill and intangible asset impairment charges				375,190						375,190	261,727
Loss on debt retirements, net	$ 8,180				554					554
Merger and Acquisition-related costs										(37,821)	(24,283)	(14,066)
Stock-based compensation expense										12,115	25,793	23,482
Restructuring-related costs										4,704
Inventory write-downs related to store closings										13,487	7,586	5,925
Litigation settlement										18,000
Gain on sale of assets, net		$ (26,806)	$ (382)	$ (4,965)	$ (5,859)	$ (5,249)	$ 205	(14,951)	$ (5,877)	(38,012)	(25,872)	(6,649)
Walgreens Boots Alliance, Inc. termination fee								$ (325,000)			(325,000)
Other										12,104	16,119	13,058
Adjusted EBITDA from continuing operations										$ 563,444	$ 559,854	$ 747,888

Commitments, Contingencies an_2

Commitments, Contingencies and Guarantees (Details) $ in Thousands	Sep. 06, 2018	Aug. 03, 2018	Jul. 27, 2018	Jun. 29, 2018	Mar. 02, 2019USD ($)	Dec. 31, 2018	Jan. 19, 2017state
Commitments, Contingencies and Guarantees
Number of purported stockholders that filed a complaint		3	3	3
Number of purported stockholders' complaints were voluntarily dismissed	2
Settlement amount					$ 18,000
Number of states failed to report Rx savings prices | state							18
Number of lawsuits						2
Hall
Commitments, Contingencies and Guarantees
Settlement amount					$ 18,000
Pilot seating program (in years)					2 years

Supplementary Cash Flow Data (D

Supplementary Cash Flow Data (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Supplementary Cash Flow Data
Cash paid for interest	$ 267,760	$ 405,579	$ 409,692
Cash payments for income taxes, net	17,383	87,087	17,081
Equipment financed under capital leases	4,165	13,123	7,551
Equipment received for noncash consideration		2,044	746
Reduction in lease financing obligation		4,740
Accrued capital expenditures	15,298	28,869	27,232
Gross borrowings from revolver	4,257,000	4,221,000	3,608,000
Gross repayments to revolver	3,382,000	$ 6,651,000	$ 3,278,000
Significant components of cash used by Other Liabilities
Cash used by Other Liabilities	439,906
Accrued reinsurance	185,761
Accrued wages, benefits and other personnel costs	58,154
Accrued interest	51,219
Accrued sales and other taxes payable	$ 44,581

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Related Party Transactions
Receivables from related parties	$ 11	$ 21

Guarantor and Non-Guarantor C_3

Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 04, 2018	Mar. 03, 2018	Mar. 04, 2017	Feb. 27, 2016
Current assets:
Cash and cash equivalents	$ 144,353		$ 447,334	$ 245,410	$ 124,471
Accounts receivable, net	1,788,712	$ 1,811,203	1,869,100
Inventories, net of LIFO reserve of $604,444 and $581,090	1,871,941	1,850,660	1,799,539
Prepaid expenses and other current assets	179,132		181,181
Current assets held for sale	117,581		438,137
Total current assets	4,101,719		4,735,291
Property, plant and equipment, net	1,308,514		1,431,246
Goodwill	1,108,136		1,421,120	1,682,847
Other intangibles, net	448,706		590,443
Deferred tax assets	409,084	592,235	594,019
Other assets	215,208		217,208
Total assets	7,591,367	8,980,767	8,989,327
Current liabilities:
Current maturities of long-term debt and lease financing obligations	16,111		20,761
Accounts payable	1,618,585		1,651,363
Accrued salaries, wages and other current liabilities	808,439		1,231,736
Current liabilities held for sale			560,205
Total current liabilities	2,443,135		3,464,065
Long-term debt, less current maturities	3,454,585		3,340,099
Lease financing obligations, less current maturities	24,064		30,775
Other noncurrent liabilities	482,893		553,378
Total liabilities	6,404,677		7,388,317
Commitments and contingencies
Total stockholders' equity	1,186,690	$ 1,592,450	1,601,010	614,070	581,428
Total liabilities and stockholders' equity	7,591,367		8,989,327
Inventories, LIFO reserve (in dollars)	604,444		581,090
Subsidiary Guarantors
Current assets:
Cash and cash equivalents				213,104	90,569
Non-Guarantor Subsidiaries
Current assets:
Cash and cash equivalents				32,306	$ 33,902
Reportable legal entity | Rite Aid Corporation (Parent Company Only)
Current assets:
Investment in subsidiaries	8,294,315		8,745,390
Total assets	8,294,315		8,745,390
Current liabilities:
Current maturities of long-term debt and lease financing obligations			90
Accrued salaries, wages and other current liabilities	14,005		65,223
Current liabilities held for sale			549,549
Total current liabilities	14,005		614,862
Long-term debt, less current maturities	3,454,585		3,340,099
Intercompany payable	3,639,035		3,189,419
Total liabilities	7,107,625		7,144,380
Commitments and contingencies
Total stockholders' equity	1,186,690		1,601,010
Total liabilities and stockholders' equity	8,294,315		8,745,390
Inventories, LIFO reserve (in dollars)	0		0
Reportable legal entity | Subsidiary Guarantors
Current assets:
Cash and cash equivalents	122,134		441,244	213,104
Accounts receivable, net	1,377,342		1,502,507
Intercompany receivable	400,526		223,413
Inventories, net of LIFO reserve of $604,444 and $581,090	1,871,941		1,799,539
Prepaid expenses and other current assets	172,448		176,678
Current assets held for sale	117,581		438,137
Total current assets	4,061,972		4,581,518
Property, plant and equipment, net	1,308,514		1,431,246
Goodwill	1,108,136		1,421,120
Other intangibles, net	399,678		539,115
Deferred tax assets	419,122		594,019
Investment in subsidiaries	55,109		54,076
Intercompany receivable	3,639,035		3,189,419
Other assets	208,018		209,926
Total assets	11,199,584		12,020,439
Current liabilities:
Current maturities of long-term debt and lease financing obligations	16,111		20,671
Accounts payable	1,612,181		1,641,676
Accrued salaries, wages and other current liabilities	778,020		1,031,379
Current liabilities held for sale			10,656
Total current liabilities	2,406,312		2,704,382
Lease financing obligations, less current maturities	24,064		30,775
Other noncurrent liabilities	474,893		539,892
Total liabilities	2,905,269		3,275,049
Commitments and contingencies
Total stockholders' equity	8,294,315		8,745,390
Total liabilities and stockholders' equity	11,199,584		12,020,439
Inventories, LIFO reserve (in dollars)	604,444		581,090
Reportable legal entity | Non-Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	22,219		6,090	$ 32,306
Accounts receivable, net	411,370		366,593
Prepaid expenses and other current assets	6,684		4,503
Total current assets	440,273		377,186
Other intangibles, net	49,028		51,328
Deferred tax assets	(10,038)
Other assets	7,190		7,282
Total assets	486,453		435,796
Current liabilities:
Accounts payable	6,404		9,687
Intercompany payable	400,526		223,413
Accrued salaries, wages and other current liabilities	16,414		135,134
Total current liabilities	423,344		368,234
Other noncurrent liabilities	8,000		13,486
Total liabilities	431,344		381,720
Commitments and contingencies
Total stockholders' equity	55,109		54,076
Total liabilities and stockholders' equity	486,453		435,796
Inventories, LIFO reserve (in dollars)	0		0
Eliminations
Current assets:
Intercompany receivable	(400,526)		(223,413)
Total current assets	(400,526)		(223,413)
Investment in subsidiaries	(8,349,424)		(8,799,466)
Intercompany receivable	(3,639,035)		(3,189,419)
Total assets	(12,388,985)		(12,212,298)
Current liabilities:
Intercompany payable	(400,526)		(223,413)
Total current liabilities	(400,526)		(223,413)
Intercompany payable	(3,639,035)		(3,189,419)
Total liabilities	(4,039,561)		(3,412,832)
Commitments and contingencies
Total stockholders' equity	(8,349,424)		(8,799,466)
Total liabilities and stockholders' equity	(12,388,985)		(12,212,298)
Inventories, LIFO reserve (in dollars)	$ 0		$ 0
Rite Aid Corporation (Parent Company Only)
Condensed Consolidating Balance Sheet
Ownership interest (as a percent)	100.00%

Guarantor and Non-Guarantor C_4

Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Statement of Operations (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Feb. 28, 2018	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Condensed Consolidating Statement of Operations
Net revenues		$ 5,379,645	$ 5,450,060	$ 5,421,362	$ 5,388,490	$ 5,394,264	$ 5,353,170	$ 5,345,011	$ 5,436,523	$ 21,639,557	$ 21,528,968	$ 22,927,540
Costs and expenses:
Cost of revenues		4,215,281	4,267,972	4,260,211	4,219,741	4,124,498	4,166,447	4,183,338	4,274,580	16,963,205	16,748,863	17,862,833
Selling, general and administrative expenses		1,143,202	1,142,555	1,153,991	1,152,627	1,181,964	1,166,514	1,141,844	1,160,940	4,592,375	4,651,262	4,776,995
Lease termination and impairment expenses		55,898	2,628	39,609	9,859	47,675	3,939	3,113	4,038	107,994	58,765	45,778
Goodwill and intangible asset impairment charges				375,190						375,190	261,727
Interest expense		52,695	56,008	56,233	62,792	50,603	50,308	50,857	51,000	227,728	202,768	200,065
Loss on debt retirements, net	$ 8,180				554					554
Walgreens Boots Alliance, Inc. termination fee								(325,000)			(325,000)
Gain on sale of assets, net		(26,806)	(382)	(4,965)	(5,859)	(5,249)	205	(14,951)	(5,877)	(38,012)	(25,872)	(6,649)
Total costs and expenses		5,440,270	5,468,781	5,880,269	5,439,714	5,661,218	5,387,413	5,039,201	5,484,681	22,229,034	21,572,513	22,879,022
Income (loss) from continuing operations before income taxes		(60,625)	(18,721)	(458,907)	(51,224)	(266,954)	(34,243)	305,810	(48,158)	(589,477)	(43,545)	48,518
Income tax expense (benefit)		195,004	(1,471)	(106,559)	(9,497)	216,719	(16,061)	117,450	(12,121)	77,477	305,987	44,438
Net (loss) income from continuing operations		(255,629)	(17,250)	(352,348)	(41,727)	(483,673)	(18,182)	188,360	(36,037)	(666,954)	(349,532)	4,080
Net income (loss) from discontinued operations, net of tax		(17,350)	12,740	(6,792)	256,143	1,250,745	99,213	(17,644)	(39,312)	244,741	1,293,002	(27)
Net (loss) income		$ (272,979)	$ (4,510)	$ (359,140)	$ 214,416	$ 767,072	$ 81,031	$ 170,716	$ (75,349)	(422,213)	943,470	4,053
Total other comprehensive income (loss)										3,490	7,255	5,464
Comprehensive (loss) income										(418,723)	950,725	9,517
Rite Aid Corporation (Parent Company Only)
Costs and expenses:
Interest expense												182,282
Equity in earnings of subsidiaries, net of tax												(418,261)
Total costs and expenses												(235,979)
Income (loss) from continuing operations before income taxes												235,979
Net (loss) income from continuing operations												235,979
Net income (loss) from discontinued operations, net of tax												(231,926)
Net (loss) income												4,053
Total other comprehensive income (loss)												5,464
Comprehensive (loss) income												9,517
Subsidiary Guarantors
Condensed Consolidating Statement of Operations
Net revenues												22,821,940
Costs and expenses:
Cost of revenues												17,767,363
Selling, general and administrative expenses												4,763,176
Lease termination and impairment expenses												45,778
Interest expense												17,796
Gain on sale of assets, net												(6,649)
Equity in earnings of subsidiaries, net of tax												5,101
Total costs and expenses												22,592,565
Income (loss) from continuing operations before income taxes												229,375
Income tax expense (benefit)												43,013
Net (loss) income from continuing operations												186,362
Net income (loss) from discontinued operations, net of tax												231,899
Net (loss) income												418,261
Total other comprehensive income (loss)												5,464
Comprehensive (loss) income												423,725
Non-Guarantor Subsidiaries
Condensed Consolidating Statement of Operations
Net revenues												223,077
Costs and expenses:
Cost of revenues												213,225
Selling, general and administrative expenses												13,541
Interest expense												(13)
Total costs and expenses												226,753
Income (loss) from continuing operations before income taxes												(3,676)
Income tax expense (benefit)												1,425
Net (loss) income from continuing operations												(5,101)
Net (loss) income												(5,101)
Comprehensive (loss) income												(5,101)
Reportable legal entity | Rite Aid Corporation (Parent Company Only)
Costs and expenses:
Interest expense										206,862	183,825
Walgreens Boots Alliance, Inc. termination fee											(325,000)
Equity in earnings of subsidiaries, net of tax										210,736	(1,034,775)
Total costs and expenses										417,598	(1,175,950)
Income (loss) from continuing operations before income taxes										(417,598)	1,175,950
Net (loss) income from continuing operations										(417,598)	1,175,950
Net income (loss) from discontinued operations, net of tax										(4,615)	(232,480)
Net (loss) income										(422,213)	943,470
Total other comprehensive income (loss)										3,490	7,255
Comprehensive (loss) income										(418,723)	950,725
Reportable legal entity | Subsidiary Guarantors
Condensed Consolidating Statement of Operations
Net revenues										21,297,937	21,413,734
Costs and expenses:
Cost of revenues										16,648,099	16,645,136
Selling, general and administrative expenses										4,567,690	4,635,531
Lease termination and impairment expenses										107,994	58,765
Goodwill and intangible asset impairment charges										375,190	261,727
Interest expense										21,704	19,261
Loss on debt retirements, net										554
Gain on sale of assets, net										(38,012)	(25,872)
Equity in earnings of subsidiaries, net of tax										(1,033)	(4,072)
Total costs and expenses										21,682,186	21,590,476
Income (loss) from continuing operations before income taxes										(384,249)	(176,742)
Income tax expense (benefit)										75,843	313,965
Net (loss) income from continuing operations										(460,092)	(490,707)
Net income (loss) from discontinued operations, net of tax										249,356	1,525,482
Net (loss) income										(210,736)	1,034,775
Total other comprehensive income (loss)										3,490	7,255
Comprehensive (loss) income										(207,246)	1,042,030
Reportable legal entity | Non-Guarantor Subsidiaries
Condensed Consolidating Statement of Operations
Net revenues										397,328	209,356
Costs and expenses:
Cost of revenues										370,413	197,084
Selling, general and administrative expenses										25,086	16,496
Interest expense										(838)	(318)
Total costs and expenses										394,661	213,262
Income (loss) from continuing operations before income taxes										2,667	(3,906)
Income tax expense (benefit)										1,634	(7,978)
Net (loss) income from continuing operations										1,033	4,072
Net (loss) income										1,033	4,072
Comprehensive (loss) income										1,033	4,072
Eliminations
Condensed Consolidating Statement of Operations
Net revenues										(55,708)	(94,122)	(117,477)
Costs and expenses:
Cost of revenues										(55,307)	(93,357)	(117,755)
Selling, general and administrative expenses										(401)	(765)	278
Equity in earnings of subsidiaries, net of tax										(209,703)	1,038,847	413,160
Total costs and expenses										(265,411)	944,725	295,683
Income (loss) from continuing operations before income taxes										209,703	(1,038,847)	(413,160)
Net (loss) income from continuing operations										209,703	(1,038,847)	(413,160)
Net (loss) income										209,703	(1,038,847)	(413,160)
Total other comprehensive income (loss)										(3,490)	(7,255)	(5,464)
Comprehensive (loss) income										$ 206,213	$ (1,046,102)	$ (418,624)

Guarantor and Non-Guarantor C_5

Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Statement of Cash Flow (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Operating activities:
Net cash (used in) provided by operating activities	$ (165,709)	$ 511,470	$ 183,027
Investing activities:
Payments for property, plant and equipment	(196,778)	(185,879)	(254,149)
Intangible assets acquired	(47,911)	(28,885)	(39,648)
Proceeds from sale-leaseback transactions	2,587
Proceeds from insured loss		4,239
Proceeds from dispositions of assets and investments	43,550	27,586	16,852
Net cash used in investing activities of continuing operations	(198,552)	(182,939)	(276,945)
Financing activities:
Proceeds from issuance of long-term debt	450,000
Net proceeds from revolver	875,000	(265,000)	330,000
Principal payments on long-term debt	(440,370)	(9,882)	(16,588)
Change in zero balance cash accounts	(59,481)	35,605	43,080
Net proceeds from issuance of common stock	2,294	5,796	6,951
Financing fees paid for early debt redemption	(171)
Excess tax benefit on stock options and restricted stock			543
Payments for taxes related to net share settlement of equity awards	(2,419)	(4,103)	(6,254)
Deferred financing costs paid	(21,564)
Net cash provided by (used in) financing activities of continuing operations	803,289	(237,584)	357,732
Cash flows of discontinued operations:
Operating activities of discontinued operations	(62,956)	(245,126)	49,090
Investing activities of discontinued operations	664,740	3,496,222	(187,314)
Financing activities of discontinued operations	(1,343,793)	(3,140,119)	(4,651)
Net cash (used in) provided by discontinued operations	(742,009)	110,977	(142,875)
(Decrease) increase in cash and cash equivalents	(302,981)	201,924	120,939
Cash and cash equivalents, beginning of year	447,334	245,410	124,471
Cash and cash equivalents, end of year	144,353	447,334	245,410
Rite Aid Corporation (Parent Company Only)
Operating activities:
Net cash (used in) provided by operating activities		158,247	(162,842)
Financing activities:
Net proceeds from revolver		(265,000)	330,000
Net proceeds from issuance of common stock		5,796	6,951
Intercompany activity		3,460,291	57,817
Net cash provided by (used in) financing activities of continuing operations		3,201,087	394,768
Cash flows of discontinued operations:
Operating activities of discontinued operations		(224,300)	(231,926)
Financing activities of discontinued operations		(3,135,034)
Net cash (used in) provided by discontinued operations		(3,359,334)	(231,926)
Subsidiary Guarantors
Operating activities:
Net cash (used in) provided by operating activities			347,465
Investing activities:
Payments for property, plant and equipment			(254,149)
Intangible assets acquired			(39,648)
Intercompany activity			(57,817)
Proceeds from dispositions of assets and investments			16,852
Net cash used in investing activities of continuing operations			(334,762)
Financing activities:
Principal payments on long-term debt			(16,588)
Change in zero balance cash accounts			43,080
Excess tax benefit on stock options and restricted stock			543
Payments for taxes related to net share settlement of equity awards			(6,254)
Net cash provided by (used in) financing activities of continuing operations			20,781
Cash flows of discontinued operations:
Operating activities of discontinued operations			281,016
Investing activities of discontinued operations			(187,314)
Financing activities of discontinued operations			(4,651)
Net cash (used in) provided by discontinued operations			89,051
(Decrease) increase in cash and cash equivalents			122,535
Non-Guarantor Subsidiaries
Operating activities:
Net cash (used in) provided by operating activities			(1,596)
Cash flows of discontinued operations:
(Decrease) increase in cash and cash equivalents			(1,596)
Reportable legal entity | Rite Aid Corporation (Parent Company Only)
Operating activities:
Net cash (used in) provided by operating activities	(255,962)
Financing activities:
Proceeds from issuance of long-term debt	450,000
Net proceeds from revolver	875,000
Principal payments on long-term debt	(427,992)
Net proceeds from issuance of common stock	2,294
Intercompany activity	727,221
Deferred financing costs paid	(21,564)
Net cash provided by (used in) financing activities of continuing operations	1,604,959
Cash flows of discontinued operations:
Operating activities of discontinued operations	(4,615)
Financing activities of discontinued operations	(1,344,382)
Net cash (used in) provided by discontinued operations	(1,348,997)
Reportable legal entity | Subsidiary Guarantors
Operating activities:
Net cash (used in) provided by operating activities	74,124	379,439
Investing activities:
Payments for property, plant and equipment	(196,778)	(185,879)
Intangible assets acquired	(47,911)	(28,885)
Intercompany activity	(727,221)	(3,460,291)
Proceeds from sale-leaseback transactions	2,587
Proceeds from insured loss		4,239
Proceeds from dispositions of assets and investments	43,550	27,586
Net cash used in investing activities of continuing operations	(925,773)	(3,643,230)
Financing activities:
Principal payments on long-term debt	(12,378)	(9,882)
Change in zero balance cash accounts	(59,481)	35,605
Financing fees paid for early debt redemption	(171)
Payments for taxes related to net share settlement of equity awards	(2,419)	(4,103)
Net cash provided by (used in) financing activities of continuing operations	(74,449)	21,620
Cash flows of discontinued operations:
Operating activities of discontinued operations	(58,341)	(20,826)
Investing activities of discontinued operations	664,740	3,496,222
Financing activities of discontinued operations	589	(5,085)
Net cash (used in) provided by discontinued operations	606,988	3,470,311
(Decrease) increase in cash and cash equivalents	(319,110)	228,140
Cash and cash equivalents, beginning of year	441,244
Cash and cash equivalents, end of year		441,244
Reportable legal entity | Non-Guarantor Subsidiaries
Operating activities:
Net cash (used in) provided by operating activities	16,129	(26,216)
Cash flows of discontinued operations:
(Decrease) increase in cash and cash equivalents	16,129	(26,216)
Cash and cash equivalents, beginning of year	6,090
Cash and cash equivalents, end of year		6,090
Eliminations
Investing activities:
Intercompany activity	727,221	3,460,291	57,817
Net cash used in investing activities of continuing operations	727,221	3,460,291	57,817
Financing activities:
Intercompany activity	(727,221)	(3,460,291)	(57,817)
Net cash provided by (used in) financing activities of continuing operations	$ (727,221)	$ (3,460,291)	$ (57,817)

Interim Financial Results (Un_3

Interim Financial Results (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Feb. 28, 2018	Mar. 02, 2019	Dec. 01, 2018	Sep. 01, 2018	Jun. 02, 2018	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Interim Financial Results (Unaudited)
Revenues		$ 5,379,645	$ 5,450,060	$ 5,421,362	$ 5,388,490	$ 5,394,264	$ 5,353,170	$ 5,345,011	$ 5,436,523	$ 21,639,557	$ 21,528,968	$ 22,927,540
Cost of revenues		4,215,281	4,267,972	4,260,211	4,219,741	4,124,498	4,166,447	4,183,338	4,274,580	16,963,205	16,748,863	17,862,833
Selling, general and administrative expenses		1,143,202	1,142,555	1,153,991	1,152,627	1,181,964	1,166,514	1,141,844	1,160,940	4,592,375	4,651,262	4,776,995
Lease termination and impairment charges		55,898	2,628	39,609	9,859	47,675	3,939	3,113	4,038	107,994	58,765	45,778
Goodwill and intangible asset impairment charges				375,190						375,190	261,727
Goodwill impairment						261,727				312,984	261,727	0
Interest expense		52,695	56,008	56,233	62,792	50,603	50,308	50,857	51,000	227,728	202,768	200,065
Loss on debt retirements, net	$ 8,180				554					554
Walgreens Boots Alliance merger termination fee								(325,000)			(325,000)
Loss (gain) on sale of assets, net		(26,806)	(382)	(4,965)	(5,859)	(5,249)	205	(14,951)	(5,877)	(38,012)	(25,872)	(6,649)
Total costs and expenses		5,440,270	5,468,781	5,880,269	5,439,714	5,661,218	5,387,413	5,039,201	5,484,681	22,229,034	21,572,513	22,879,022
(Loss) income from continuing operations before income taxes		(60,625)	(18,721)	(458,907)	(51,224)	(266,954)	(34,243)	305,810	(48,158)	(589,477)	(43,545)	48,518
Income tax expense (benefit)		195,004	(1,471)	(106,559)	(9,497)	216,719	(16,061)	117,450	(12,121)	77,477	305,987	44,438
Net (loss) income from continuing operations		(255,629)	(17,250)	(352,348)	(41,727)	(483,673)	(18,182)	188,360	(36,037)	(666,954)	(349,532)	4,080
Net income (loss) from discontinued operations, net of tax		(17,350)	12,740	(6,792)	256,143	1,250,745	99,213	(17,644)	(39,312)	244,741	1,293,002	(27)
Net (loss) income		$ (272,979)	$ (4,510)	$ (359,140)	$ 214,416	$ 767,072	$ 81,031	$ 170,716	$ (75,349)	$ (422,213)	$ 943,470	$ 4,053
Basic (loss) income per share:
Continuing operations						$ (9.18)	$ (0.35)	$ 3.59	$ (0.69)	$ (12.62)	$ (6.66)	$ 0.08
Discontinued operations						23.74	1.90	(0.33)	(0.75)	4.63	24.64	0
Net basic (loss) income per share						14.56	1.55	3.26	(1.44)	(7.99)	17.98	0.08
Diluted (loss) income per share:
Continuing operations						(9.18)	(0.35)	3.53	(0.69)	(12.62)	(6.66)	0.08
Discontinued operations						23.74	1.90	(0.33)	(0.75)	4.63	24.64	0
Net diluted (loss) income per share						$ 14.56	$ 1.55	$ 3.20	$ (1.44)	(7.99)	$ 17.98	$ 0.08
Basic and diluted (loss) income per share:
Continuing operations		$ (4.83)	$ (0.33)	$ (6.67)	$ (0.79)					(12.62)
Discontinued operations		(0.32)	0.24	(0.13)	4.86					4.63
Net basic and diluted income (loss) per share		$ (5.15)	$ (0.09)	$ (6.80)	$ 4.07					$ (7.99)
Income tax expense recorded in connection with revaluation of deferred tax assets		$ 212,252				$ 324,765					$ 324,765
Goodwill impairment, net of tax						191,000				$ 235,698	191,000
Facilities impairment charges		28,920				36,927
LIFO charge (credit)		$ 4,043				$ (49,220)				$ 23,354	$ (28,827)	$ (3,721)

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 02, 2019	Mar. 03, 2018
Carrying Amount
Financial instruments
Variable rate indebtedness	$ 1,297,013
Fixed rate indebtedness	2,157,571	$ 3,905,841
Fair Value
Financial instruments
Variable rate indebtedness	1,325,000
Fixed rate indebtedness	1,795,335	3,927,411
Other assets
Financial instruments
Investment at amortized cost	$ 7,191	$ 7,282

SCHEDULE II-VALUATION AND QUA_2

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowances deducted from accounts receivable for estimated uncollectible amounts: - USD ($) $ in Thousands	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Allowances deducted from accounts receivable for estimated uncollectible amounts:
Balance at Beginning of Period	$ 25,134	$ 30,891	$ 32,820
Additions Charged to Costs and Expenses	48,728	94,006	72,876
Deductions	60,756	99,763	74,805
Balance at End of Period	$ 13,106	$ 25,134	$ 30,891